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Abstract
Chlamydia (C.) trachomatis is one of the most common sexually transmitted 
pathogens in the world. In women, chlamydial infections can result in the 
progression from acute infection to disease sequelae such as cervicitis, pelvic 
inflammatory disease and tubal factor infertility (TFI). The scarring and fibrosis of 
fallopian tubes caused by C. trachomatis infections account for 10%-30% of all cases 
of female infertility.
Currently, C. trachomatis-related tubal infertility is diagnosed using 
laparoscopy and hysterosalpinography (HSG). The invasive nature of these 
diagnostic tests renders them unsuitable for routine use; and the high cost associated 
with these procedures restricts their availability to women in low-resource settings 
and developing nations. Serological diagnostic assays have been reported by several 
studies as a good alternative to these invasive strategies in diagnosing chlamydial 
infertility in women. However, commercial serological diagnostic assays are not 
used due to lack of sensitivity or specificity, and reported cross-reactivity of 
antibodies with other chlamydial species. Therefore, through this study, a novel 
multi-antigen peptide based ELISA was developed that can detect C. trachomatis-
related TFI in women. Using existing commercial serological assays, the prevalence 
and risk factors associated with C. trachomatis-related infertility were determined in 
a female population from a developing nation, Samoa. This study also investigated 
and identified the immune markers associated with C. trachomatis-related TFI from 
the peripheral blood mononuclear cells (PBMC) of women. 
The novel multi-antigen peptide based ELISA developed through this study,
the QUT Chlamydia infertility test exhibited high specificity in identifying women 
with tubal pathology (100%) and C. trachomatis-related infertility (94%). However, 
this limited the assay sensitivity to 16% and 27% respectively. The test was 
developed and evaluated on a development cohort (n=262), which included an 
infertile cohort (women with TFI and other forms of infertility; n=97), acute C. 
trachomatis infections cohort (n=112) and fertile cohort (n=53). The specificity and 
sensitivity was higher than existing commercial serological assays such as MEDAC 
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MOMP, MEDAC Infertile, ANILabsystems and Microimmunofluorescence assay 
(MIF) .
While numerous efforts have been undertaken to diagnose and control C. 
trachomatis-related infertility, the underlying mechanism leading to the disease 
progression is yet to be understood. Transcriptomic and cytokine assays of 
stimulated PBMCs from women with chlamydial infertility (n=31) identified that 
some women launched a proinflammatory (CXCL-10, CXCL11, HLA-A and IL-1E) 
response to C. trachomatis infection. 
In addition, the study further evaluates the prevalence and risk factors 
associated with chlamydial infertility in a high-prevalence, low-resource setting such 
as Samoa. The prevalence of C. trachomatis estimated by PCR in sexually active 
women between the ages of 18-29 (n=239) was 35.6%. The prevalence of C. 
trachomatis-related infertility was determined using commercial serological assays, 
which determined that 50% of self-reported infertile women (n=85), were positive 
for chlamydial infertility. Amongst commercial serological assays, MEDAC MOMP 
was the only test that could effectively identify women with self-reported infertility 
from those without (p<0.05). This shows that the prevalence of C. trachomatis
infections and its sequelae is very high in Samoa. Thus, routine testing and treatment 
strategies would ideally reduce the disease burden from infertility within this 
population. 
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1.1 BACKGROUND
C. trachomatis is one of the most common sexually transmitted bacteria in the 
world. The asymptomatic nature of the disease causes it to go undiagnosed and 
untreated, thus resulting in long -term sequelae such as pelvic inflammatory disease, 
ectopic pregnancy and infertility. The current techniques used to diagnose these 
sequelae in women are laparoscopy and hysterosalpinography. These techniques are 
invasive, expensive and prone to misdiagnoses [1]. Therefore, there is a need for a
diagnostic assay that is non-invasive, cost-effective and has high diagnostic 
performance in detecting women with C. trachomatis-related infertility. Serological 
assays are a useful technique in diagnosing ectopic pregnancies, pelvic inflammatory 
diseases and recurrent miscarriages [2]. However, due to its lack of specificity owing 
to its high rate of cross-reactivity between other chlamydial species, it is not used in 
IVF clinics as the first line of infertility investigation. Additionally, they are not 
adept to differentiate women with acute infections from women with C. trachomatis-
related infertility. Therefore, this study aimed to develop a novel multi-antigen 
peptide ELISA that has high specificity in identifying women with C. trachomatis-
related infertility. 
1.2 CONTEXT
Through this study, a novel peptide based ELISA, The QUT Chlamydia
infertility test was developed that showed high specificity in diagnosing women with 
C. trachomatis –related infertility. The assay was robust and reproducible, and also 
outperformed current commercial serological assays in detecting women with tubal 
pathology and chlamydial infertility. Additionally, women who tested positive for C. 
trachomatis-related infertility in this assay had equal likelihood of achieving 
successful outcome in an IVF procedure as those who were infertile due to other 
reasons. Thus, women tested positive in this assay could proceed directly for IVF 
treatment without undergoing additional tests and surgeries, therefore making it an 
ideal diagnostic tool for early infertility investigation in IVF clinics. The 
development of sequelae in some women is attributed by immune responses induced 
by host/pathogen factors that lead to pathology, ultimately resulting in infertility.
Therefore, in order to understand the underlying mechanisms that lead to pathology 
in some C. trachomatis-infected women, this study also investigated and identified 
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immune markers that are associated with C. trachomatis-related infertility in women. 
Since the rate of C. trachomatis-related infertility in women is higher in low-
resource, high prevalence settings, using commercial serological assays, this study 
determined the sero-prevalence and risk factors associated with C. trachomatis-
related infertility in women from a developing country, Samoa. High prevalence of 
chlamydial infertility was detected in this population, hence, drawing attention to 
need for immediate screening and treatment strategies to control C. trachomatis
infections and its associated sequelae in the population. 
1.3 PURPOSES
The overall purpose of the study is to develop a highly sensitive and specific 
diagnostic assay for C. trachomatis-related infertility in women. However, the study 
also explored epidemiological and immunological aspects of C. trachomatis-related 
infertility. The three specific aims of this project were:
1) To develop a novel multi-antigen peptide ELISA for the diagnosis of 
C. trachomatis-related infertility in women. 
2) To identify immune markers in mononuclear cells that is associated 
with chlamydial infertility in women.
3) To determine the sero-prevalence and risk factors associated with C. 
trachomatis-related infertility in women from Samoa.
1.4 THESIS OUTLINE
Chapter two is the literature review relevant to the project
Chapter three includes the general procedures used in this study
Chapter four aims to develop a multi-antigen peptide ELISA for the diagnosis 
of women with C. trachomatis-related infertility. The chapter pertains to 
identification of suitable peptides for the assay and its development. The diagnostic 
performance is assessed and compared with current commercial assays. 
Chapter five identifies immune markers that are associated with C. 
trachomatis-related infertility. The regulation of immune genes was assessed in 
women with chlamydial infertility compared to women with other forms of 
infertility. The study also evaluated the level of cytokines secreted. Thus, these 
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markers reveal one of the underlying mechanisms associated with C. trachomatis
pathogenesis and subsequent infertility in some women.
Chapter six estimates the sero-prevalence of chlamydial infertility in the female 
population in Samoa. The risk factors associated with this disease have also been 
identified. 
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Chlamydia (C.) trachomatis is one of the most common bacterial sexually 
transmitted infections in the world, with WHO’s most recent estimates indicating 
approximately 105.7 million new infections annually [3], and in the United States of 
America alone, the Centre for Disease Control estimated approximately 2.86 million 
new Chlamydia STI in 2008 [4]. The infection is widely reported to result in 
devastating reproductive consequences in a proportion of infected women, including 
pelvic inflammatory diseases (PID), ectopic pregnancy and infertility. Haggerty et al. 
[5] illustrated that 2%-5% of women with chlamydial infections develop PID within 
two weeks, and about 18% of women with PID develop infertility. C. trachomatis is 
a Gram Negative, obligate intracellular bacterial pathogen with a unique biphasic 
developmental cycle [6]. The organism has been characterized using biology and 
genomics as a highly evolved or ancient pathogen with evidence of a reduced and 
customized genome, specifically tailored for its human host and obligate intracellular 
niche [8]. In spite of the considerable worldwide burden of chlamydial disease it is 
still not well understood what host and pathogen factors are associated with
infertility. The following review focuses on a range of topics such as the morphology 
and developmental cycle of C. trachomatis; factors that are associated with its 
ascension into the upper genital tract; the host/human factors and host genetic factors 
that contribute to chlamydia-related infertility; immunological response induced in 
infertile women; and diagnostic techniques used to detect women with chlamydia-
related infertility. 
2.1 DEVELOPMENTAL CYCLE AND MORPHOLOGY OF C. 
TRACHOMATIS
C. trachomatis has a unique biphasic developmental cycle characterized by 
functionally and morphologically distinct cell types that are adapted for intracellular 
multiplication and extracellular survival [9]. The bacteria comprises regularly-
spaced dome shaped projections on its surface, followed by a peptidoglycan-free 
rigid cell wall, and an lipopolysaccharide outer cell membrane [10, 11]. Microscopic 
analysis and antibody reaction to Chlamydiae reveal that similar to organisms with 
peptidoglycan cell wall, the chlamydial cell envelope possess penicillin binding 
proteins that make the organism sensitive to peptidoglycan inhibiting drugs [11]. The 
peptidoglycan is a closed covalent polymer with glycan strands made of alternating 
N-acetylglucosamine and N-acetylmuramic acid residues of C. trachomatis that are 
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cross-linked by peptides [12]. The outer membrane proteins are cross-linked by 
disulfide bonds which are thought to maintain the structural integrity of the cell wall
in reported absence of peptidoglycan [11]. Hence, it has been described as an 
anomaly. However, recent studies by Liechti et al. [13] have shown demonstrated the 
presence of peptidoglycan by using dipeptide probes which are incorporated into 
chlamydial peptidoglycan and captured via click chemistry reaction. Based on the 
characteristics of their outer membrane proteins, C. trachomatis are categorized into 
nineteen different serovars [14, 15]. 
The developmental cycle consists of infections and non-infectious stages of 
Chlamydia with unique morphological, biological and biochemical properties. The 
extracellular, infectious and non-dividing Elementary body (EB) is designed for 
passage between host cells; while the replicating, intracellular form of the bacteria is 
referred to as the reticulate body (RB) [6, 17]. Through ligand-receptor interaction, 
the small dense EB establishes contact with the host epithelial cell, and during the 
course of the infection they remain within a parasitophorous vacuole called the 
inclusion vacuole [18, 19]. Microscopic analysis revealed that EB differentiates into 
RB, which further replicates by binary fission [19]. The elementary body (EB) is a 
small (0.3μm), round, electron dense, infectious form of the organism [20]. The 
nucleoid of elementary body are highly compacted due to condensation of nuclear 
material by histone-like proteins HctA and HctB [21]. These morphologically 
different forms dictate the unique developmental cycle of the Chlamydiae species. 
The pregenomic investigations of metabolic functions of the bacteria had established 
that only RBs are metabolically active, and EBs were inert forms of the organism. 
The failure to detect ATPase and cytochrome c oxidase activities in EB indicated that 
the infectious form of the bacteria was metabolically dormant [22]. In the RBs, the 
reduction of cross-linked cysteine rich outer membrane of MOMP (Major outer 
membrane protein) by DTT (dithiothreitol) generates a channel for passage of 
nutrients and ATP. However, the treatment of EB with DTT revealed that although
cysteine rich outer membrane of MOMP (Major outer membrane protein) complexes 
were reduced, it failed to stimulate ATP transport or incorporate methionine [23, 24].
Thus, this further demonstrates that EBs are metabolically inactive. The advent of 
genomic investigations revealed a wide range of genes with unknown functions that 
were involved in several metabolic pathways (as reviewed in [25]. Through the 
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whole proteome study, Skipp et al. [26] identified several proteins in EBs that are 
involved in metabolism and transcription. Quantitative proteomic analysis 
undertaken by Saka et al. [27] also identified proteins required for central 
metabolism and glucose catabolism in EBs. Additionally, Omsland et al. [28]
measured de novo protein synthesis of Chlamydia intracellular phosphate -1 (CIP-1) 
in axenic medium, and showed that EBs preferentially used glucose-6-phosphate as 
an energy source, while RB required ATP. This proves that EBs are metabolically 
active. The developmental cycle is completed when an unidentified signal assumed 
to be triggered by depletion of nutrients and dearth of ATP induces asynchronous 
differentiation of RBs back into EBs [6, 29]. The EB is released from the inclusion 
through host cell lysis such that it can infect neighbouring epithelial cells to 
propagate the infectious process [6]. Depending on the species, the developmental 
cycle varies from 36 and 72 hours [17]. The developmental cycle is illustrated in 
Figure 2.1.
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Figure.2.1:Diagram representing the various stages in the developmental cycle 
of Chlamydia trachomatis
The developmental cycle begins with attachment of EBs on the host cell 
facilitated by Type Three secretion system (TTSS). Once inside the host cell, it 
resides within a parasitophorous vacuole called inclusion. Within 24-30 hours post 
infection, the EBs differentiate into replicative RBs, which further replicate through 
binary fission. The RBs revert back to EBs through TTSS preloading and extruded 
from the host cell through lysis at 48-72 hours post infection. Figure copied directly 
from Hammerschlag [30]. 
2.1.1 Chlamydial entry into the host cell
C. trachomatis EB initiates infection by attachment and internalization into 
host epithelial cells through receptor-mediated endocytosis [31]. Chlamydial entry 
into host cell through adsorptive endocytosis and intracellular translocation is 
facilitated by proteins F- actin and Clathrin [32]. Glycosaminoglycans and outer 
membrane proteins act as adhesions to bridge unknown receptors for cell attachment 
[31, 33, 34]. Although there are numerous studies elucidating the role of clathrin-
mediated endocytosis, ultrastructural and biochemical analysis conducted by Boleti 
et al. [35] demonstrated that C. trachomatis also utilizes clathrin-independent and 
actin-dependent pathway. This suggests that C. trachomatis enters a host cell through 
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a process similar to phagocytosis [35]. The role of actin-dependent mechanism in 
chlamydial internalization has been evaluated by addition of actin inhibiting agent, 
cytochalasin D, which resulted in significant reduction in internalization [36, 37]. 
Thus, actin plays an important role in chlamydial internalization by inducing changes 
in the microvillar structure [36]. This further supports the receptor-mediator 
phagocytic entry of C. trachomatis into the host cell. 
In vitro inhibitor studies and in vivo CFTR deficient mutant mice showed that 
the bacteria also utilized a chloride channel located in the apical membrane of 
epithelial cells called cystic fibrosis transmembrane conductance regulator (CFTR) in 
its entry and internalization into the host cells [31]. Caveolae are glycosphingolipid 
are cholesterol-enriched invaginations in plasma membrane that are involved in 
endocytic pathways [38]. Although several studies provide evidence of C. 
trachomatis entry via caveolae –mediated endocytosis [31, 38, 39], Hybiske and 
Stephens [40] showed that targeted disruption of caveolae did not alter the 
internalization and infectivity significantly. However, caveolin plays an important 
role in the formation of inclusions by preventing chlamydial phagosome from fusing 
with lysosomes in most chlamydial species [38, 39]. In contrast, the entry of 
chlamydial species including C. trachomatis serovars A, 36B, and C, LGV serovar 
L2 and MoPn were not mediated by caveolin [39]. Tyrosine phosphorylation of host 
and bacterial proteins triggers a signalling pathway that induces actin mobilization 
for the entry of the organism [41]. The proteins that are phosphorylated are of 
chlamydial origin and are referred to as translocated actin-recruiting phosphoprotein 
(TARP) and it plays an important role in actin remodelling [42]. The TARP assists in 
translocation of tyrosine kinase substrates that stimulate actin-driven invasion by C. 
trachomatis, and subsequently subverts host cell functions [42]. Lane et al. [43]
identified Rac-dependent signalling pathway (WAVE2 and Arp2/3) in facilitating 
TARP mediated actin recruitment for chlamydial entry and invasion. Interestingly, 
female hormones also play an important role in enhancing chlamydial attachment. It 
was reported that chlamydial attachment on oestrogen-dominant primary human cell 
was increased from 65% to 90%, while progesterone-dependent human epithelial cell 
decreased chlamydial attachment from 50% to 30% in a dose-dependent fashion [44, 
45]. In vitro studies and co-culture models by Hall et al. [46] showed that exposure 
Chapter 2: Literature Review 11
to oestrogen activated the phosphatidylinositol-3 kinase (PI3K) pathway that aids in 
the entry of C. trachomatis into the host cell. 
2.1.2 The nascent inclusion vacuole –trafficking & modification
After entering the host cell, the Chlamydiae reside inside an inclusion which is 
a parasitophorous vacuole that is nonfusogenic with endocytic pathway and 
intercepts exocytic vesicular traffic from Golgi apparatus [47]. The inclusion has 
been characterized as nonfusogenic vacuole with lysosomal and endosomal 
membranes due to the absence of the lysosomal (acid phosphatase) and endososomal 
markers (transferrin receptor and cation-independent mannose-6-phosphate receptor) 
[48]. Within 2 hours of entry into the host cells, chlamydial inclusions fuse with a 
subset of host vesicles containing sphingomyelin in the Golgi apparatus [20]. If the 
bacteria fail to modify the inclusion within the first 2 hours of infection, it could lead 
to its death by lysosomal fusion [49].
Organelle sequestration and subversion 
The intracellular membrane trafficking by C. trachomatis is controlled by 
various host factors such as N-ethylmalemide-sensitive factor (NSF) attachment 
proteins (v-SNARE), small GTP binding proteins, ADP ribosylating factors and Rab 
GTPases [50]. Among these cellular factors, Rab GTPases play a primary role in 
SNARE recruitment, vesicle tethering and other distinct membrane trafficking 
process through specific recruitment of Rab effector molecules to C. trachomatis
[50]. Moreover, the inability to detect specific associations between endosomal Rabs, 
GFP- Rab7, GFP- Rab9 and GFP-Rab5 through immunofluorescence microscopy, 
further support the theory that during the formation of inclusion, the bacteria 
bypasses the early endocytic pathway completely [50]. Some of the Rab GTPases 
that are actively involved in the biogenesis of chlamydial inclusion are Rab1, Rab4 
and Rab11 that belong to endocytic/phagocytic pathway, and ER-Golgi related Rab 
1, 6 and 10 [51, 52]. Rab 6, 11 and 14 were reported to be recruited in the absence of 
microtubules, and their presence has been detected throughout the developmental 
cycle [50]. They also play an important role in sphingomyelin delivery to the 
inclusion [49]. In addition to Rab GTPAses, the organelle identity is also governed 
by specific phosphoinositide (PI) species that are present on the organelle [53].
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Phosphoinositides are short-lived phosphorylated derivatives of 
phosohatidylinositol that play an important role in vesicle –mediated trafficking by 
controlling subcellular localization, cellular signalling and activation of effector of PI 
binding proteins [54]. The Golgi-to-Plasma membrane trafficking is aided by PI4P, a 
product of Oculocerebral syndrome of Lowe protein 1 (OCRL1) gene that is 
localized in the Golgi complex [53]. Moorhead et al. (2010) proposed that unlike 
Legionella pneumophila, C. trachomatis does not secrete PI4P binding proteins. 
Instead, chlamydial maturation is inhibited by OCRL1 via endosomal pathway 
through PIP2 substrate removal. The protein further facilitates intracellular 
trafficking of clathrin-coated vesicles between early endosome and trans-Golgi 
network [53]. Through time course analysis of isoleucine incorporation into the 
phospholipids of C. trachomatis infected cells, Wylie et al. [55] demonstrated that 
infection by C. trachomatis is also associated with the bacterial acquisition of host-
derived lipids. The trafficking of eukaryotic phospholipids is yet another way the 
bacteria uses to evade lysosomal fusion as the vacuole would resemble a cytoplasmic 
organelle. 
Lipid trafficking
Sphingomyelin from Golgi apparatus is acquired early in the cycle and it is 
essential for chlamydial development [56]. Fluorescent microscopy analysis by 
Hackstadt et al. (1997) [57] indicated that sphingomyelin is localized to the luminal 
surface of exocytic vesicles which on fusion with chlamydial inclusion is adsorbed 
by the Chlamydiae into the inclusion. The study also reported that sphingomyelin 
prevents fusion of inclusions with lysosomes by modifying the inclusion membrane. 
Mittal and Hackstadt [58] reported that Src family tyrosine kinase Fyn plays an 
important role in sphingomyelin acquisition. Although, the sphingomyelin synthesis 
or trafficking was not altered by the siRNA mediated silencing of Fyn in the absence 
of chlamydial infection, it reduced the amount of sphingomyelin trafficked into the 
inclusion [58]. Scr family kinase phosphorylation of dynamin 2 also leads to Golgi 
fragmentation, and inhibition of Golgi fragmentation that results in the reduction of 
sphingomyelin acquisition [58]. Although, chlamydial requirement for 
sphingomeylin is low initially, the demand increases with increased bacterial 
replication and expansion of the inclusion, during which Golgi fragmentation also 
takes place [59]. This suggests that fragmentation of Golgi apparatus is a pathway for 
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lipid transport and acquisition. C. trachomatis also obtains its lipid requirement 
through lipid droplets (LD) which are translocated from the host cytoplasm to the 
inclusion membrane, as observed through fluorescence microscopy and electron 
microscopy. The translocation of LDs is facilitated by inclusion membrane protein 
IncA and chlamydial Lda3 protein that link cytoplasmic LDs to inclusion membrane 
[60]. Soupene et al. [61] established that human acyl-CoA carrier hACBD6 binds to 
LDs during development and expansion of C. trachomatis by modulating the 
acyltransferase activity of bacterial protein CT775 and formation of 
phoatidylcholine. Therefore by harnessing LD function, C. trachomatis may co-opt 
non-vesicle mediated phospholipids and cholesterol transport [62].
Inc Proteins 
The Chlamydial inclusion membrane proteins (Inc) reside within the inclusion 
membrane and interact with host proteins. These proteins share a common bilobular 
hydrophobicity motif that spans the inclusion membrane, but only a limited number 
of proteins are conserved amongst themselves [20, 63]. Inc proteins were first 
identified in C. psittaci [64] and subsequently identified in C. trachomatis [20, 65]. 
By using fusion proteins and antifusion antibodies, Li et al. [66] reported that out of 
50 Inc proteins in C. trachomatis, 22 were localized in the inclusion membrane, 
while 3 were detected in the inclusion and the location of remaining 21 were 
indeterminable. The study showed that most of the membrane localized proteins 
identified were immunogenic. 
IncA, first identified in C. psittaci, regulates the fusion of inclusions and 
interaction between the inclusion and intracellular compartment [67-70]. In addition 
to IncA, Inc G and Inc F are exposed to the cytosol and undergo phosphorylation, an 
integral step in chlamydial entry and infection [70]. Src Kinase and Fyn co-localizes 
four inc proteins including Inc B, CT101, CT222 and CT850 in inclusion membrane 
microdomains where it affects the centrosome stability of the organism by interacting 
with the microtubule network [71]. Yeast two hybrid analysis suggests a guanine 
nucleotide-dependent interaction between C. trachomatis specific Inc CT229 and 
host Rab4, which subsequently promote interactions with host secretory pathways 
through recruitment of Rab GTPases [49, 72]. Inc D recruits CERT, a host factor that 
is involved in C. trachomatis infection through nonvesicular transfer of ceramide at 
ER-Golgi membrane contact sites (MCSs) and induces metabolism or signalling 
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events favourable to replication and development of the organism [73]. Several 
putative Inc proteins possess a high probability of coiled-coil conformation which is 
consistent with the hypothesis that proteins exposed to the cytosol regulate 
interaction between the inclusion and cellular compartments of the host [73]. About 
90% of these proteins also possess Type III secretion signals which suggest that the 
proteins are secreted and translocated through the type III secretion system [74].
Type III secretion systems 
Similar to other Gram-negative pathogens, the Type III secretion system 
(T3SS) serves as a conduit in C. trachomatis that connects bacterial cytosol and host 
cell cytoplasm, whereby the pathogen secretes proteins into the host cell or into 
inclusion membrane [75, 76]. Although the expression of T3SS apparatus occurs mid 
cycle, EBs contain the fully assembled apparatus that mediate secretion of substrates 
during initial stages of host cell infection and establishment [29]. One of the earliest 
roles of T3SS in chlamydial developmental cycle includes EB invasion by 
remodelling actin cytoskeleton through translocation of effector proteins translocated 
actin-recruiting protein (TARP) and CT694 [41, 75, 77]. Using bacterial two-hybrid 
and size exclusion chromatography, Brinkworth et al. [75] elucidated the role of 
putative type III secretion chaperone Slc1 (SycE-like chaperone 1) in enhancing 
TARP translocation for actin remodelling. Other extended apparatus of T3SS 
secretion system are Chlamydia outer proteins CopN and CopB and host interactive 
proteins such as Chlamydia protein associated with death domains (CADD) [77]. 
Chlamydial protease, chlamydial protease-like activity factor (CPAF) enters into the 
host cytoplasm and facilitate inclusion expansion through a type-III independent 
secretion mechanism independent mechanism by degrading a wide array of host 
proteins [77, 78]. The protein TepP (Translocated early phosphoprotein) facilitates 
early establishment of niche for chlamydial replication within the cell by recruitment 
of additional scaffolding proteins like Crk, which in turn recruit proteins to nascent 
inclusions [79]. Although, CPAF induces Golgi fragmentation, the fragmentation and 
sphingomyelin acquisition is not dependent on cytosolic CPAF [80]. The pivotal role 
of T3SS in manipulating host cell processes and replication has been elucidated with 
the help of chemical inhibitors such as compound 1 (C1), which inhibited the T3SS 
secretion system. This resulted in the suppression of multiple sigma factors, reduced 
amount of late cycle genes (hctB, omcA and omCB) required for differentiation of 
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RB to EB, low abundance of T3SS secreted apparatus components (CopN, CopB2) 
within bacteria and inhibition of IncA [78]. 
2.1.3 Exit from the inclusion 
The EB accumulate within the inclusion until released by extrusion from the 
host cells or inclusions rupture inside host cytosol for lateral entry into uninfected 
host cells [77]. Extrusion includes a packaged release process by which chlamydial 
inclusion are released by membranous protrusion [81]. The asynchronous process of 
differentiation of RBs back to EB begins about 18 h after infection and continues 
upto 44 h in C. trachomatis L2 strain [82]. Using RT-PCR, Shaw et al. (2000) 
confirmed the role of OmcB (60kDa cysteine-rich outer membrane protein) and 
chlamydial nucleoprotein Hc1 (encoded by hctA gene) in the later stages of 
developmental cycle and are facilitate the production of EB from RB. Hc1 regulates 
the repression of transcription and condensation of nucleoid that is characteristic of 
differentiation of RB to EB [82, 83]. OmcB confers structural stability to EB as it 
forms a component of the disulphide-liked outer membrane protein complex [23]. 
Through microarray analysis, about 26 late genes were identified such hctA and hctB
that encode for chlamydial histone-like proteins which facilitate nucleoid 
condensation [84]. Recruitment of actin and actin polymerization plays an integral 
role in chlamydial extrusion. The polymerization and the coat assembly have been 
driven by products of type III secretion, and at 68 hours post- infection, the 
chlamydia prepares for extrusion by increasing the actin recruitment and enwrapping 
the entire inclusion [85]. Treatment of C. trachomatis with pharmacological 
inhibitors revealed the involvement of neuronal Wiskott-Aldrich syndrome protein, 
myosin II and Rho GTPase in extrusion mechanism. [81]. GFP analysis and mutation 
studies showed that depletion of Septins that function in organizing actin coat for 
inclusion resulted in reduced extrusion [86]. The areas marked for imminent 
extrusion were those where the inclusion was distal to nucleus or bulged out of the 
cell [85].
2.1.4 Molecular mechanisms associated with chlamydial persistence
C. trachomatis enters an alternate morphological state called ‘persistence’, 
which is a viable, but unculturable long-term state. The state of persistence in 
Chlamydiae is driven by the presence of various stress conditions including; IFN-J, 
antibiotics, and iron chelating agents [87]. Matsumoto and Manire [88] were one of 
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the first to characterize chlamydial persistence in Chlamydia psittaci. The study 
reported that the treatment with 200 units of penicillin prevented binary fission of 
RBs to EBs and resulted in large abnormal RB forms in C. psittaci. The study further 
revealed that after 36 hours post infection, masses of cytoplasmic membranes formed 
within RB and around it, resulted in the formation of immature nucleoids within the 
RBs. Skilton et al. [89] demonstrated the effect of penicillin (100units/mL) using 
high quality time lapse video analysis, and found that in addition to the 
morphological abnormalities, replication of chlamydial chromosomal and plasmid 
DNA remain unaffected. However, removal of penicillin did not induce complete 
transformation from aberrant RBs to normal RBs, and with the exception of few 
inclusions, the normal developmental cycle was re-established after 10-20 hours of 
removal. Confocal microscopy and immunocytochemistry of penicillin induced 
persistent C. trachomatis infection revealed high levels of HtrA at mid (20h PI) and 
later stages (44 hPI) of persistence [90]. This suggests that HtrA adopts a protective 
function during penicillin persistence against additional protein stress. Addition of an 
HtrA inhibitor, JO146, to C. trachomatis Hep-2 culture during recovery and 
reversion from penicillin persistence resulted in complete lethality for C. trachomatis
[91]. Thus, confirming the functional role of HtrA in chlamydial persistence. 
Persistence in C. trachomatis is also induced by inflammatory cytokine, IFN-J, 
which induces cytosolic tryptophan degrading enzyme indoleamine 2,3-dioxygenase 
(IDO) that catabolizes L-tryptophan to N-formylkynurenine [92]. However, IDO-
mediated tryptophan starvation leads to conversion of C. trachomatis into its 
persistent form [93]. Beatty et al. [93] elucidated this mechanism through HeLa cell 
models, and reported that IFN-J reduced intracellular levels of tryptophan and 
increased the activity of IDO (measured by HPLC). The study further reported that 
IDO deficient cell line and tryptophan deficient studies implicated that tryptophan 
depletion is responsible for IFN-J -mediated C. trachomatis persistence. These 
findings were further supported by Leonhardt et al. [94] who demonstrated that low 
exogenous tryptophan concentration prevented bacterial trafficking to the 
microtubule organizing centre (MTOC) and prevents lysosomal fusion. Thus, the 
organism remains in its aberrant form and exhibits low transcriptional activity, and 
despite replenishing the tryptophan levels, the rate of re-activation of Chlamydia
remain slow. Transcriptomic analysis of IFN-J -mediated C. trachomatis persistent 
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infection revealed an upregulation of genes required for tryptophan synthesis (tprR, 
trpB and trpA), phospholipid metabolism, and early cycle genes. The genes that were 
downregulated included genes that regulate RB to EB differentiation (hctA, hctB, 
ompB, and ompC). A Chlamydia- specific gene (Euo) that regulates late gene 
expression and facilitates complete silencing of these genes were also upregulated 
during persistence. Thus, during chlamydial persistence, genes pertaining to 
metabolic process were activated, whilst genes regulating late cycle genes were 
down regulated [95]. Akers et al. [96] reported that the aporepressor, TrpR regulates 
tryptophan biosynthesis genes in C. trachomatis by forming a complex with 
coreporessor tryptophan and subsequently activating the trpRBA operon. The study 
also showed that the TrpR gene also allows the bacteria to sense tryptophan 
limitation. IFN-J treatment of C. trachomatis in HeLa cells downregulates 
chlamydial protease-like activity factor (CPAF) activity and prevents cleavage of 
proaptotic BH-3 only proteins, Bad and Puma. The study further reported increased 
production of high mobility group box 1 (HMGB1) protein following prolonged 
IFN-J treatment. This suggests that although persistent C. trachomatis infections are 
apoptosis-resistant, but they contribute to chronic inflammation and disease through 
HMGB1 release [97]. 
Iron is an essential co-factor that is critical in several biochemical reactions and is 
highly regulated in most organisms [98]. Iron-chelating agents such as deferoxamine 
mesylate (DFO) deplete iron, resulting C. trachomatis persistence. The effectiveness 
of DFO in depleting iron or ferritin content from infected cells was demonstrated by 
Dill et al. [99], who reported a significant drop in ferritin level (28.2 ng/mL to 
3.2ng/ml) by DFO as compared to transfected cell line with inducible over-
expression of eukaryotic iron efflux protein ferroportin (49.3 ng/mL to 38.2 ng/mL) 
that facilitates iron starvation in C. trachomatis E. Addition of DFO also induced 
enhanced expression of cHSP60 in C. trachomatis E infected cells [100]. This 
suggests that cHSP60 facilitates persistence mediated by iron starvation in C. 
trachomatis. Thompson et al. [98] identified another iron chelator, 2-2’-bipyridyl 
(Bpdl), which is membrane permeable and exhibited a greater degree of chlamydial 
inhibition and induction of aberrant morphology compared to DFO. The study 
showed that 100 μM of Bpdl retarded chlamydial DNA replication and upregulated 
chlamydial iron responsive genes, ahpC and devB, in contrast to DFO which 
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upregulated only one gene, devB. The effectiveness of Bpdl in inducing iron 
starvation-mediated chlamydial persistence over DFO was further validated by the 
upregulation of ytgA gene, an iron-response gene that is involved in iron acquisition/ 
transport into Chlamydia.
2.2 SEQUELAE ASSOCIATED WITH C. TRACHOMATIS INFECTIONS IN 
WOMEN
Despite enhanced screening efforts and control programs, the number of 
genital C. trachomatis infections have been reported to have increased significantly 
over the last decade in Australia, United Kingdom, North America and Europe [101]. 
Furthermore, long-term C trachomatis infections pose a major problem in women’s 
health care as the disease can lead to reproductive morbidity [102]. Acute diseases 
caused by C. trachomatis include urethritis and cervicitis, while the C. trachomatis -
related infertility / chronic form of the infection include ectopic pregnancy, pelvic 
inflammatory disease and tubal infertility [102]. C. trachomatis infections are 
responsible for about 45% of reported cases of tubal factor infertility (TFI) in women 
[103]. The recurrence of chlamydial infection have been reported to be about 30-50% 
in young adolescents, and repeated exposure to the bacteria by either persistence or 
recurrent infection induces cell mediated immunological reactions and delayed 
hypersensitivity response which lead to fibrosis, scarring and tubal factor subfertility 
[7]. In the United States itself, tubal factor infertility accounts for about 10% of 
assisted reproductive technology cycles and the average cost of an in vitro cycle is 
upto $12,000 [104]. In Europe, annually about 600,000 cases of salpingitis
(inflammation of fallopian tubes) caused by C. trachomatis is reported, of which 
12,000 cases resulted in mechanical infertility [105].
2.2.1 Pelvic Inflammatory Disease
Pelvic inflammatory disease is characterized by the infection of fallopian tubes, 
uterus and adjacent pelvic structures that are not associated with surgery or 
pregnancy [106]. About 10,000 women in Australia are treated for PID each year,
and the incidence of the disease is highest in women between the ages 20 to 29 [107]. 
It encompasses a wide range of upper genital tract conditions such as endometritis, 
tuboovarian abscess, salpingitis, periappendicits, perihepatitis and pelvic peritonitis 
[108]. When the bacteria ascends from the vagina and endocervix to the 
endometrium, fallopian tubes and adjacent structures, it results in acute PID [108]. 
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PID is treated by administering antibiotics such as parenteral cephalosporin and 
doxycycline [109]. PID can result in serious C. trachomatis -related infertility such 
as chronic pelvic pain, ectopic pregnancy and infertility [109]. Each year 750,000 
women experience acute PID in the United States, of which about 10%-15% of these 
women become infertile when left untreated [110]. Davies et al. [111] reported that 
in 307 sex workers recruited from Genito- Urinary Medicine (London), the rate of 
PID in women with recent chlamydial infection was 27.4 per 100 person-years as 
compared to the 11.2 in women with previous chlamydial infection as estimated by 
direct immunofluorescence. Scholes et al. [112] showed that with the increase in 
Chlamydia diagnosis and subsequent treatment rates from 449 cases/10,000 per year 
in 1997 to 806/ 10,000 per year in 2007 resulted in a decrease in the PID rates from 
823 cases/100,000 per year in 1997 to 473/100,000 per in 2007 in USA (P<0.01). 
These findings were further supported by a mathematical modelling study, wherein 
an implementation of hypothetical screening intervention resulted in prevention of 
187 PID cases per 100,000 women in 5 years and 956 PID cases per 100,000 women 
in 10 years [113]. Thus, increasing the screening strategies and intervention for C. 
trachomatis could significantly reduce the incidence of PID in women.
2.2.2 Acute Salpingitis 
Acute salpingitis is caused by an ascending infection from the lower genital 
tract and it may result in peritubal adhesions, post- inflammatory fibrosis and tubal 
restriction [114]. It is diagnosed laproscopically and it is characterized by the 
presence of erythema and odema in the fallopian tubes [115]. The odema associated 
with salpingitis augments intraluminal agglutination which leads to clubbing of 
fallopian tubes that result in dysfunctional, partially or completely obstructed 
fallopian tubes [116]. The agglutination may develop into a filmy, thick pelvic 
adhesive disease resulting in pelvic pain [116]. Sweet et al. [117] established a 
relationship between the menstrual cycle and the onset of acute salpingitis caused by 
C. trachomatis. The study highlighted the importance of hormonal changes in 
chlamydial pathology, which explains the increased prevalence of acute salpingitis 
during the beginning of menses rather than other times in the menstrual cycle. This 
has been further supported by Rank et al. [118], in which treatment with hormones 
such estradiol on a guinea pig enhanced infection in the cervix and resulted in 
hydrosalpinx. Hydrosalpinx is characterized by occlusion of fimbriated end of the 
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fallopian tube and distension of the distal end with fluid [119]. Treharne et al. [120]
reported that C. trachomatis antibody titers were found in two-thirds of women with 
acute salpingits (n=143), while only two tested positive in women without salpingitis 
(n=19). Based on the histopathology, the study also showed that salpingitis is often 
accompanied by endometritis. 
2.2.3 C. trachomatis-related infertility in women 
Subclinical PID is clinically recognized as acute PID (caused by ascending 
spread of organisms from lower genital tract to upper genital tract) and it stimulates 
the development of PID-related C. trachomatis-related infertility [121].The disease is 
often referred to as “silent epidemic” as it is asymptomatic and hence goes 
unnoticed. Malik et al. [122] showed that the predominant cause of infertility were 
asymptomatic C. trachomatis infections. Chlamydia positive cases could be 
characterized by clinical presentations such as bleeding per vaginum (on touch) and 
vaginal discharge. Prolonged infection in either of these tracts may result in 
subfertility, or infertility. Subfertility generally describes any form of reduced 
fertility for long periods of time of unwanted non-conception [123]. Infertility is 
similar to subfertility, however subfertility is characterized by sporadic occurring 
spontaneous pregnancies [123].
Long term C. trachomatis -related infertility or chronic infection develops due 
to reinfection, persistence or treatment failure [124]. It was reported that Australian 
women show a re-infection rate of 22.3 per 100 person-years and it is more prevalent 
in women between the ages of 16-20years [124]. In developing countries such as 
Nigeria, the overall prevalence rate of asymptomatic C. trachomatis infection 
estimated by PCR in 132 infertile women attending Gynaecological clinic was 20.5% 
as opposed to 10.4% in the UK and other developed countries [125, 126]. In Brazil, 
the prevalence of IgG antibodies against C. trachomatis were significantly higher in 
subfertile group (n=55) as compared to parous women (n=55) (56.4% vs 31%; 
P<0.01)[127]. The prevalence of C. trachomatis in infertile women attending 
gynecological clinic in South West Nigeria was 20.5% (n=130)[125]. The infection 
often results in recurrent spontaneous abortion [129]. The infection is also transferred 
to the fetus as evident from the presence of IgM antibodies to C. trachomatis in the 
cord blood of infants of mothers who delivered preterm [130]. This results in 
stillbirth, which occurs in 20-30 gestational weeks.
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Ectopic pregnancy is one of the major causes of maternal mortality in the first 
trimester in developing countries [102]. Coste et al. [131] reported that C. 
trachomatis was the strongly associated (25.2%) with ectopic pregnancy in women 
(n=624) recruited from 15 maternity hospitals in France. Svensson et al. [132]
showed that out of 112 women with ectopic pregnancy, 75% showed the presence of 
IgG antibody to C. trachomatis as compared to 21% of the controls. In addition to 
the IgG antibodies, cHSP60 antibodies have also been found in abundance in the sera 
of infected females [133]. In Nigeria, a greater number of women with ectopic 
pregnancy (confirmed by laparoscopy) (n=98) were seropositive for C. trachomatis
as compared to age matched pregnant controls (n=98) (48% vs 16%; P<0.001)[134]. 
A prospective study by Sziller et al. [135] reported that the antibody responses to 
cHSP60 in women with ectopic pregnancy correlated with decreased subsequent 
spontaneous fertility and repeated ectopic pregnancy. 
Thus, the prevalence of C. trachomatis-induced sequelae could be reduced with 
routine testing and timely treatment. The mechanism of reproductive sequelae of C. 
trachomatis infections in certain women is yet to be understood.
2.3 PROPOSED MODELS FOR THE DEVELOPMENT OF INFERTILITY 
FOLLOWING C. TRACHOMATIS INFECTION IN WOMEN
This review outlines four models that are most commonly referred to within the 
field to explain the process that underlies the development of infertility following 
Chlamydia infection. The models are not exclusive of each other and there is 
evidence for and against each model. Figure 2.2 summarises the factors associated 
with chlamydial infertility.
2.3.1 Ascension model
This model suggests that the infection ascends to the upper reproductive tract 
in only some women, and this ascension is usually typified by the presence of 
symptoms, development of PID and if unchecked consequent development of tubal 
pathology. There is considerable direct evidence that the chlamydial infection can
ascend beyond the cervix, however, the proportion of cases in which this ascension 
occurs is unknown. The following studies provide evidence to the ascension model 
of C. trachomatis pathology. In a study by Lan et al. [136] , salpingentomy tissues 
(n=48 from 37 women) were tested for C. trachomatis DNA by PCR and it was 
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reported that Chlamydia DNA was detected in the salpingectomy (removal of 
fallopian tubes [137]) specimens of one woman with ectopic pregnancy.While six of 
the 37 women tested positive for C. trachomatis DNA in endometrial and cervical
specimens. A hospital- based study in Myanmar comprising of 113 women with 
ectopic pregnancies, showed that higher C. trachomatis DNA was detected in tubal 
specimens (15%) as compared to cervical specimens (8%) from women with ectopic 
pregnancy [138]. The presence of C. trachomatis in upper genital tract and the 
affected organs were further elucidated in Barlow et al. [139], where women 
recruited from hospitals in UK with ectopic pregnancy (n=33) and tubal factor 
infertility (n=14) were tested by PCR and In situ hybridisation (ISH). The study 
reported that C. trachomatis was detected in 44% of TFI patients (ISH), of which 
five patients had C. trachomatis DNA in the fallopian tube while two patients were 
positive in the endometrium. Using PCR, C. trachomatis DNA was detected in 71% 
of the TFI patients, of which C. trachomatis DNA was present in the endometrium of 
seven patients, while five patients showed positivity in the fallopian tube and five
others in the ovary [139]. C. trachomatis organism presence was associated with 
endometritis (plasma cell influx in the endometrium) [140, 141]. A small study in the 
UK identified the presence of C. trachomatis in the upper genital tract from 4 out of 
10 women all of whom had no symptoms suggesting that is it possible to have 
asymptomatic ascension and that ascension may not occur in all women [142].
This ascension model is also supported by substantial evidence of chlamydial 
inducing a pathological immune response in human cell and tissues and is mutually 
inclusive with the Persistence and/or Cellular Paradigm models. However, there is 
only limited evidence to support that; 1. Ascension of the infection occurs in some 
but not all women or that; 2. that lower genital tract symptoms and/or signs typify 
upper reproductive infection because mucopurulent cervicitis and other 
cervical/genital symptoms/signs have been reported in both the presence and absence 
of upper reproductive tract symptoms or with laparoscopic evidence of salpingitis 
(ascending infections) [143, 144]. However, upper genital tract infection does not 
happen in the absence of cervicitis/lower genital tract symptoms of inflammation. 
This was supported by Westrom and PEACH PID studies [145, 146] whose 
diagnostic and inclusion criteria included women with mucopurulent cervicitis. 
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It seems possible or even likely that ascension may be independently 
moderated by numerous other factors that could explain the low frequency of 
pathology development, supporting that it only occurs in some women. These 
moderating factors could include host factors such as menstrual cycle stage or 
hormone status at time of infection, as chlamydial or gonococcal endometritis was 
found to be more likely to be detected in women in the proliferative phase [147]. 
Equally important moderating factors could include immune status, genotypic 
factors, other co-infections, or reproductive tract microbiome composition. However, 
there is no published evidence that associate these factors with ascension of C. 
trachomatis infection into the upper genital tract. Furthermore, pathogen factors 
could also moderate the likelihood of ascension such as infectious burden (although 
chlamydial serovar alone has not been able to be significantly associated with 
pathogenic potential or clinical manifestations [143]).
2.3.2 Persistence model
Chlamydia persistence, or the presence of viable but non-culturable chlamydial 
organisms, develops in response to adverse conditions, and can remain dormant but 
present for considerable lengths of time (as reviewed in [18]). C. trachomatis are 
tryptophan auxotrophs which they obtain from their host and the host cell 
intracellular pools of tryptophan are inhibited by IFN-γ induced tryptophan 
catabolizing enzyme (indoleamine 2,3-dioxygenase) [18]. IFN-γ mediated persistent
C. trachomatis infection results in the absence of EBs, and they are typically in the 
form of larger RBs with altered morphologies with fewer cells in each inclusion [18].
C. trachomatis persistence is mediated by virulence factors, environmental 
factors and host immune factors [148]. It was reported that following treatment for 
chlamydial infection, LCR (Ligase Chain Reaction) testing of urine showed that 
about 13.4% of women had persistent infection after a median of 4.3 months [149].
Ligase Chain Reaction detects C. trachomatis infection in urogenital speicmens and 
urine, and targets nucleotide sequences of chlamydial cryptic plasmid [102]. The 
study diagnosed women with persistent C. trachomatis infection if they were still 
positive for the infection, despite abstaining from sexual activity during the first and 
second follow-up. In contrast, women werer diagnosed with recurrent infection if 
they had resumed sexual activity or had multiple sexual partners, and tested positive 
for the infection in their first and second follow-up. Persistence can also be induced 
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by antibiotics such as ciprofloxacin and ofloxacin that restrict productive infection 
but cause the bacteria to go into a viable, metabolically inactive period during the 
course of the treatment [150]. Removal of the antibiotic allows the organism to 
resume its normal growth, reactivating the infection [150]. In vitro, the persistent 
stage can be induced by treatment with IFN-γ [151-154], penicillin and nutrient 
starvation [154, 155]. IFN-γ secreting CD4+ and CD8+ T cells induce the production 
of indoleamine 2,3-dioxygenase (IDO) which mediates tryptophan starvation by 
catabolising it to kynurenine [156-158]. This induces persistence of C. trachomatis in 
the host as it interferes with the growth of the bacteria, a tryptophan auxotroph [156]. 
[158]. The IFN-γ induced persistent C. trachomatis could be eradicated by 
azithromycin, which is also effective in treating chronic infections at MBC100 (2.5-
5µg/mL)[159]. In vitro studies have demonstrated the effect of different classes of 
antibiotics such as tetracyclin, penicillin, cephalosporin and E-lactamase based drugs 
induced persistence (characterized by abberrant RBs and immediate recovery on 
removal of antibiotics) at physiologically relevant conditions [160]. Removal of 
tryptophan prompts the bacteria to import it from the neighbouring cells and use it to 
overcome IFN-γ induced persistence [157]. Low intracellular amino acid 
concentrations give rise to abnormal organism development with reduced infectivity 
yields [155]. A similar effect was observed when the media was deprived of glucose 
[155]. Infected cells treated with IFN-γ was found to have increased levels of 
cHSP60 [161], major outer membrane protein (MOMP) (omp1)[161, 162] and LPS 
[153, 163].
Persistence in vivo has been proposed as a model where this on-going presence 
of the organism may drive a long-term pathological immune response resulting in the 
tissue damage to the fallopian tubes (certainly the high expression of the dominant 
antigen cHSP60 has been detected in laboratory persistence models) (reviewed, 
[164]). There are studies that have presented evidence of C. trachomatis DNA or 
antigens being present in the tubal material of women with tubal infertility or ectopic 
pregnancy or salpingitis, supporting that organism persistence in some form occurs 
in vivo [139, 166-168]. Recently, morphologies consistent with laboratory models of 
persistence were observed in endocervix samples associated with IFN-J, and 
transcriptomic analysis revealed down-regulation of genes associated with RB-EB 
differentiation and reactivation of euo and omcb genes that are differentially 
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expressed in active and IFN-J associated persistent growth [169]. Thus, further 
supporting the likely in vivo relevance of laboratory models of persistence. It is 
difficult to determine if chlamydial persistence results in pathology. Persistent 
infection may resolve at any time after pathology develops and prior to detection, 
given the difficulties in specimen collection from the upper genital tract the evidence 
is reasonably compelling that chlamydial persistence (either consistent with the lab 
models or a distinct in vivo form) could be a relevant factor in pathology. It is 
important to highlight a recent review that suggested that some forms of persistence 
may be ‘colonisation’ and in fact not associated with ‘pathogenesis’ and disease 
[170]. The evidence that chlamydial persistence is induced by a range of conditions 
in vitro (reviewed, [18, 164]), and persistence like morphology and/or chlamydial 
antigen/DNA detection in the absence of active infection has been observed in 
clinical samples, suggests that persistence may be a relevant physiological status in 
vivo particularly in the case of ascension to the upper reproductive tract tissues, and 
therefore likely a determinant of pathological outcome of infection.
2.3.3 Cellular paradigm model
The cellular paradigm model proposes that the chlamydial infected epithelium 
immediately responds to the presence of the Chlamydia or specific antigens from 
Chlamydia in a pro-inflammatory manner, typified by pro-inflammatory cytokines 
and growth factors which in turn induces a pro-inflammatory secondary immune cell 
activation and migration to form a local lymphoid follicle resulting in cell damage 
and fibrosis or scarring (comprehensively presented and reviewed elsewhere [171]). 
Kinnunen et al. [172] showed that human leukocyte antigen (HLA) class II 
molecules regulates the production of interleukin 10 (IL-10) at inflammation site, 
and it acts as a substantial suppressor of cellular immunity by enhancing Th2-type 
immune response and suppressing Th1- type immune response. The study also shows 
that cHSP60 is a marker for TFI in women, as it was associated with enhanced IL-10 
production in women with TFI. Interleukin-1 production results in destruction of 
ciliated cells and subsequent scarring of the fallopian tubes by triggering and priming 
superoxide production [173]. IL-10 is an anti-inflammatory cytokine that decreases 
tissue damage significantly by inhibiting IL-1β and IL-8 and subsequently generate a 
weakened inflammatory response that accounts for the asymptomatic nature of 
infection in women [173]. 
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This model is widely supported by the published evidence of human epithelia 
and immune cell responses to Chlamydia and a primary tissue ex vivo model. This 
model also presumes that chlamydial ascension is associated with pathology and also 
mutually allows for persistence of Chlamydia in the upper reproductive tract [171]. A 
pathological adaptive memory response proposed as the secondary component of this 
model is also supported by the existing data that repeat infections increase the 
likelihood of pathological outcomes in women [174], and by numerous 
immunological results. 
2.3.4 cHSP60 induced delayed hypersensitivity model
There has been considerable focus on a pathology model that involves delayed 
hypersensitivity and/or molecular mimicry in response to specific chlamydial 
antigens (reviewed [175]). This model has largely resulted from a body of literature 
demonstrating high titre human antibody response to cHSP60 in participants with 
tubal pathology and additionally that in several animal models tissue pathology 
developed after repeated inoculations with cHSP60 protein (reviewed [171]). In 
humans, delayed hypersensitivity (immune responses mediated by CD4+T cells) 
could be induced either at the conjunctival mucosal surface or the vaginal mucosal 
surface [176]. Both murine and human models have revealed that the correlation 
between host resistance and chlamydial infection and the role of DTH could 
contribute to mucosal scarring [176, 177]. In one study, using IL-10 KO mouse, it 
was reported that IL-10 inhibits Th-1 like immune responses via inhibition of IL-12 
and TNF-α and thereby inhibit DTH following chlamydial infection [177]. 
However, this model is subject to considerable controversy due to; 
inconsistencies between the different published findings; problems with protein 
preparations that involved a hypersensitive detergent being used in some animal 
models; and cross reactivity or poor specificity for some of the antibody tests [178-
182]. On the other hand there is no doubt that cHSP60 is a predominant chlamydial 
antigen that does frequently elicit an immune response. Furthermore, in human 
trachoma cases it is frequently possible to observe ongoing follicles present and 
disease pathology in the absence of PCR detectable Chlamydia suggesting that there 
is continuing immune activity in the absence of organism during pathology 
development [183].
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Interestingly, one group proposed that cHSP60 antibodies detected in the 
follicular fluid of female IVF patients may induce early destruction of the embryo by 
cross reacting against embryo human HSP60 and result in lower transfer success 
[184]. They observed a 74.1% cHSP60 seropositivity in women without embryo 
implantation (n=47) and 47.9% seropositivity in women with successful embryo 
implantation (n=91) (p=0.0004). However, this observation directly contradicts a 
finding in separate and much larger study (n=1279) that cumulative IVF cycle 
pregnancy rates are the same for women who are chlamydial seropositive compared 
to those who are seronegative [185]. A study in France also contradicted the possible 
role of adverse embryo implantation impact of anti-chlamydial immunity as it that 
for found for both men and women with PCR or serological evidence of Chlamydia
(n=52) the IVF pregnancy rate and semen characteristics were not different 
compared to controls that were negative for chlamydial testing (n=119) [186]. 
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Figure 2.2: Summary of host and pathogen factors that are associated with the 
development of chlamydial infertility in women
The factors that contribute to chlamydial infertility at a broader level include 
pathogen factors that depend solely on the serovar, infectious burden, sensitivity to 
antibiotics and persistence. The epidemiological factors affect a particular population 
or cohort, characterized by their age, sexual behaviour, smoking status, co-infections 
and repeat infections. Although immunological factors are shared between 
individual, depending on their immune system the sequelae may develop due to 
cellular pathology, cHSP60 antibodies, arrested immunity and IFN-J mediated 
protection. The host factors such as hormone status, genotype and microbiome vary 
between individuals. 
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2.4 HOST/HUMAN FACTORS ASSOCIATED WITH CHLAMYDIAL 
INFERTILITY IN WOMEN
There are several human/ host factors that increase the risk of C. trachomatis –
related infertility in women. The factors may be attributed to repeat infections, 
treatment failure, co-infections with other STIs, hormonal status or sexual lifestyle. 
Although these factors are not consistent among different populations, they play an 
integral role in the increasing rate of C. trachomatis –related infertility in women.
2.4.1 Repeat infection and infertility
Repeat infection represents a substantial proportion of chlamydial infections 
detected annually (re-infection review; [187]). It is likely that these repeat infections 
are made up of reinfection, treatment failure, and persistent infections [188]. 
Batteiger et al., [188] conducted a longitudinal cohort of 210 adolescent women (14-
17 years old) participants (USA) and identified that 121 experienced a repeat 
infection. In a longitudinal cohort in Australia, 1116 women (16-25 year old) were 
followed, and 14 re-infections were observed from a total of 81 women (three of 
these had two episodes of re-infection) (cumulative risk over 12 months of 20.3%, 
95% CI: 13.2-37.6%) [124]. The infection was classified as re-infection, if the 
genotype of C. trachomatis in the second infection was different from the first 
infection. Walker et al. [124] used the same criteria to characterize women with 
repeat infection; the difference in serovars between the first and second infections, 
and it was further confirmed by negative tests between two positive tests.
Interestingly, in this study in Australia organism load was lower in re-infections 
compared to prevalent infections detected at the study baseline, but there were no 
associations between participant characteristics and re-infection [124] (although this 
was possibly a statistical power issue). However, careful consideration into study 
design is needed when evaluating repeat infection, the Batteiger and Walker studies 
tested quarterly for Chlamydia, and PCR may detect residual DNA from dead 
organisms causing a false positive. A study conducted in Vancouver, showed that the 
repeat infection occurred in 8 of 42 participants in a longitudinal study (both 
genders) indicating a cumulative incidence of 29% (95% CI: 12-46%), although the 
study was confounded by re-testing immediately being conducted in some 
participants [189]. A study in the UK showed re-infection was 29.9 (19.7-45.4) per 
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100 person years from a GP clinic setting [190]. Infection and repeat infection 
significantly associates with sexual behaviour risk factors such as new partners or 
failure to use condoms [124]. These repeat infection rates appear to be higher than 
the reported infertility outcome rates in women who have had a positive Chlamydia
test in the Low et al. [191] retrospective cohort study, suggesting that repeat 
infection alone is not the sole determinant of infertility or pathology. However, there 
is some evidence to suggest that repeat infection increases the risk of developing 
infertility. A retrospective cohort study by Hillis and co-workers in Wisconsin 
examined the risks of hospitalisation for ectopic pregnancy or PID in 11000 
Wisconsin women who had one or more chlamydial infections. They identified 
elevated risks of ectopic pregnancy in women who had two (OR 2.1; 95% CI: 1.3-
3.4), and three or more infections (OR 4.5; 95% CI: 1.8-5.3) [174]. Pelvic 
inflammatory disease risk was also increased for women who had two (OR 4.0; 95% 
CI: 1.6 - 9.9) and three or more chlamydial infections (OR 6.4 95% CI 2.2-18.4) 
[174]. Therefore, repeat infection is likely to be a significant contributing factor in at 
least some cases of chlamydial infertility.
Treatment failures or persistence induced by antibiotics have also been 
proposed to be contributing to repeat infection rates (reviewed [192]). Batteiger et al.
[188] showed that repeat infections in 13.7% of the patients were due to possible or 
probable treatment failures. Additionally, in vitro studies have shown that 
azithromycin induces chlamydial persistence [193]. Therefore, treatment failure or 
persistence (presenting as treatment failure) could be a contributing factor to 
development of infertility in some women via all four of the proposed pathology 
models.
The rise of repeat infections detected over time has resulted in the proposal that 
increased public health investment into chlamydial screening and treatment is 
preventing the development of natural immunity to the infection (arrested immunity 
hypothesis) [194, 195]. These repeat infections may also be the source of 
pathological sequelae that may not occur in women who have a protective immunity 
from a naturally resolved infection [194, 195].
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2.4.2 Role of co-infections or microbiome in C. trachomatis pathology
The interactions of Chlamydia trachomatis with microbiome in the human 
genital tract are likely to contribute to the progression of the disease to sequelae. Co-
infections with Neisseria gonorrhoea and Mycoplasma genitalium increase the risk 
of developing PID and tubal factor infertility. Co-infections with other STIs are not 
uncommon, for example 46% of female patients positive for N. gonorrhoeae were 
also be positive for Chlamydia in a family planning clinic in the USA [196]. 
However, a serology study in Zimbabwe, demonstrated that women with antibodies 
to either C. trachomatis of N. gonorrhoeae were significantly more at risk of 
developing PID, ectopic pregnancy, or abnormal fallopian tubes than those women 
with antibodies to both pathogens [197], suggesting that it is not necessary to have 
had infection with both pathogens to develop reproductive pathology. Patients with 
bacterial vaginosis who were a recent contact of a male with chlamydial urethritis 
had an odds ratio of 3.4 (95 % CI: 1.5-7.8) to test positive for chlamydial infection. 
The presence of H2O2 producing lactobacilli in the vagina was protective against 
acquisition of infection (odds ratio 0.4, 95% CI: 0.2-0.8) [198]. Recently an in vitro
model was used to demonstrate that it is actually the acid or pH lowering impact of 
the lactobacilli that confers the anti-chlamydial activity [199]. It has been 
hypothesized that indole producing organisms that increase in the microbiome during 
or subsequent to bacterial vaginosis enable C. trachomatis to synthesize tryptophan 
from indole [200], consequently evading the activity of interferon gamma at the 
infected site and thus may facilitate the infection [200, 201]. 
Bacterial vaginosis (BV) during C. trachomatis or N. gonorrhoeae infection 
was recently found to be associated with risk of PID, although the authors conclude 
that difficult to determine if the bacteria underlying the vaginosis facilitated 
ascension and PID caused by the STIs or alternatively if the bacteria responsible for 
vaginosis cause the PID [202]. Patients with BV were about 3.4 times more likely to 
test positive for C. trachomatis, as it alters the vaginal flora and the succinate 
produced during the infection alters leukocyte function and compromises host 
defences, thereby increasing susceptibility to C. trachomatis infection [198, 203]. 
Although several studies have implicated the role of BV in tubal diseases by 
encouraging ascension of C. trachomatis into upper genital tract [203], Gaudoin et 
al. [204] found that they were independent of each other and found no association 
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between active BV or past chlamydial infection in the development of PID. 
However, due to the low power of the study, co-infection with BV might still result 
in the increased risk of tubal infertility in women. Clearly, there is increased 
chlamydial infection risk associated with co-infection or bacterial vaginosis, and also 
evidence for an association with PID, supporting those co-infections could therefore 
result in an increased likelihood of development of infertility. 
2.4.3 Sexual behaviour and age of sexual contact
Age is a risk factor in likelihood of contracting chlamydial infection [205, 
206]. Cross national studies from 1999-2008 in Denmark, Australia and Sweden 
showed that increasing C. trachomatis-related PID rates were associated with 
increasing age (30-34 years), with the exception of New Zealand, where the rates 
were higher in women of ages 15-19 [207]. This could be because New Zealand has 
the highest Chlamydia testing rates compared to any of the countries included in the 
study, and this has led to early detection of Chlamydia-related PID. Consistent with 
previous findings, the highest incidence of C. trachomatis infections were reported in 
women between the ages 16-24 [124]. These studies support the finding that the 
pathology associated with C. trachomatis is more predominant in younger women.
Consistent with these studies, being under 20, having cervical symptoms were all 
risk factors for endocervical chlamydial infection in women, and the organism 
burden was also higher in younger women when measured by viable culture counts 
[208]. Potentially the organism burden may influence the ability to ascend to the 
upper reproductive tract and ability to maintain a longer or persistent infection, 
therefore even though there is no direct evidence, there seems to be the potential for 
younger age of acquisition of chlamydial infection to increase the risk of 
pathological outcomes. 
Sexual behaviour (new partners or higher number of partners) is often 
significantly associated with increased risk of C. trachomatis infection [209, 210]. 
As shown in the study by Skjeldestad et al., 2009 [211], there was a 37% probability 
of a woman acquiring C. trachomatis infection if she has had 3 more partners within 
42 months. A younger age at first coitus, higher number of sexual partners, and self-
reported history of medically diagnosed sexually transmitted infection were all 
significantly associated with tubal infertility compared to fertile controls (p<0.01) 
[212]. However, as these are also known to be significant factors for increased 
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likelihood of acquisition of chlamydial infection it is not certain if they directly 
influence the likelihood of pathology outcomes from the infection.
2.4.4 Confounding variables and covariates associated with chlamydial
infertility in women
Several environmental and lifestyle factors may contribute to the development 
of female infertility, that may present as potential confounders to C. trachomatis-
induced infertility.
Age is considered an important predictor of female infertility. Women of 
advanced age (above 36 years) have 41% chances of conceiving, which is much 
lower than women who are below 30 years, as the likelihood of conceiving could be 
as high as 71% [213]. In Spain, a cross-sectional population based study of women 
between the ages of 30 and 49 (n=443) revealed that 17.5% of women could not 
achieve pregnancy within 1 year, and the prevalence of primary and secondary 
infertility was 6.12% and 11.2% respectively [214]. A cross-sectional based survey 
of 623 women seeking infertility evaluation in USA reported that 30% of women 
between the ages of 37-40 years have undergone infertility evaluation and treatments 
as compared to 8% women between the ages of 25-28 years and 17% of women 
between the ages of 29-32 years [215]. Several studies have demonstrated that 
infertility is more predominant at advanced age due to the decreased levels of ATP in 
oocytes that result in aneuploidy and chromosomal misalignment that cause 
implantation failures and miscarriages [216, 217]. Thus, age has an adverse effect on 
infertility and therefore considered an important covariate with regards to chlamydial 
infertility in women.
Body mass index (BMI) has a negative impact on the reproductive outcomes,
as overweight women (BMIt 25kg/m2) take longer to conceive and have lower 
spontaneous conception [218]. A retrospective study of 52 women seeking infertility 
treatments at Stanford University Medical Centre reported that a meaningful weight 
loss (10% of their maximum weight) yielded significantly higher conception (88% vs 
54%) and live birth (71% vs 37%) rates than those who did not lose weight [218].
Although not significant, the spontaneous conception rate was also higher amongst 
women who had lost t10% of their body weight (35% vs 17%). A similar study 
conducted by Clark et al. [219] reported that 67 anovulatory women who lost 10.2 
kg/m2 after 6 months, resumed ovulation (>66%) of which 77.6% and 67% had
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conceived and attained live births. Based on the hospital records of 6305 subfertile 
couples obtained from 24 hospitals in Netherlands, a lower probability of 
spontaneous pregnancy was observed in women with BMI over 29 kg/m2 (hazard 
ratio: 0.96; 95% CI: 0.91-0.99), and with a unit increase in kg/m2, the probability to 
conceive reduced by 4% [220]. Obese women are at a higher risk of infertility due to 
lower levels of Leptin (product of ob gene) that not only regulates adipose mass 
levels but also embryo implantation [221]. Thus, BMI is an important risk factor for 
infertility. 
Amongst lifestyle factors, smoking and alcohol have been implicated in 
reducing fertility in women. Casreta et al. [222] reported that among 296 infertile 
women, the antra follicle count (AFC), a significant predictor of ovarian response 
was significantly higher in non-smokers (n=194) than current smokers (n=102). The 
study also reported higher levels of follicle stimulating hormone (FSH) in smokers as 
compared to non-smokers. Thus, reduction of AFC and elevation of FSH as a result 
of smoking could lead to follicle atresia and decline in ovarian reserve and oocyte 
quality [222]. Heavy smokers had a higher proportion of immature diploid oocytes as 
compared to non-smokers (21.2% (n=102) vs 5.1% (n=14)), which suggest that
smoking impedes meiotic division in oocytes and reduces the function and viability 
of the oocytes [223]. Due to its effect on oocytes, smoking also has a negative effect 
on the fertility outcome of women undergoing IVF. Van Voohris et al. [224] reported
that the adverse effect of smoking on ovarian function was dose-dependent and 
prolonged, as women who quit smoking before an IVF procedure (33.3%, n=111)
were as likely to have the same ongoing pregnancy rate as non-smokers (35.3%, 
n=351), and they were significantly higher than current smokers (16.2%, n=37). 
Interestingly, several studies have a established a strong correlation between BMI 
and smoking status [225, 226], which in turn may have a detrimental effect on the
fertility in women. A cross-sectional study encompassing 4305 women from 
Germany, Denmark, Sweden, France and Italy reported that women with higher BMI 
(<30 kg/m2) showed strong correlation with infertility only in smokers and not in 
non-smokers (odds ratio (95% CI): 11.54 (3.8, 36.15) [227]. This suggests that the 
risk of infertility may be higher in obese women smokers as compared to obese non-
smokers. The leptin levels in current smokers (19.7ng/mL) were reported to be 
significantly lower than in non-smokers (24.5ng/mL) in a cross-sectional study of 
Chapter 2: Literature Review 35
Mexican Americans and non-Hispanic white population in San Antonio (n=91)[225]. 
Since smoking reduces the leptin levels, it positively correlates with obesity and 
therefore has a negative impact on fertility.
Alcohol consumption has also been reported to impact female fertility 
negatively. A prospective observational study of 124 women between the ages of 23-
41, revealed that the conception rate was highest in women who did not consume 
alcohol (24.5%, n=28) and the lowest levels were reported in heavy drinkers 
(>91g/week; 8.3%, n=13)[228]. Additionally, alcohol consumption negatively 
impacts the success rate of IVF treatments. The number of oocytes aspirated was 
reported to be 13% more in women who consumed less than 12g of alcohol per week 
(1 year before the procedure) as compared to those who consumed more than 12g of 
alcohol per week (n=148), and the miscarriage rates were 2.2times higher in the latter
a week before the procedure (1 week before the IVF treatment; n=14) [229].
Wdowiack et al. [230] reported that amongst 54 women between the ages 25-39 
years who underwent IVF, the embryo with the best reproductive potential (based on 
embryo implantation capability, same size of blastomeres and symmetry in 
positioning) were the lowest amongst those who consumed alcohol (4.35% (n=23) vs 
41.94% (n=31), particularly those who consumed more than 25g of alcohol daily 
(4.55% (n=19) vs 70% (n=10)) as compared to those who did not consume alcohol. 
As expected, the embryos with abnormalities and lowest reproductive function were 
reported to be highest in women who consumed more than 25g of ethanol daily
(22.73% (n=19) vs 0% (n=10)) and no abnormalities were reported in those who did 
not consume alcohol. Additionally, women undergoing IVF (n=250) who reduced 
their alcohol consumption (20.4%) or abstained (24.8%) before the treatment, were 
twice as likely to be pregnant as compared to those who continued their drinking 
habits (OR (95% CI): 2.27 (1.01-5.15); p=0.049)[231]. This suggests that by 
adopting healthy lifestyle choices, the risk of infertility in women could be 
diminished. 
2.4.5 Hormonal status at time of infection
Oral contraceptive use was found to be a risk factor for C. trachomatis
infection (p=0.006), and the organism burden was found to be higher in oral 
contraceptive users (p<0.001) [208]. Prospective recruitment of young female 
participants (>17) attending genitourinary medicine clinics in the UK identified that 
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those who had a Chlamydia infection were also more likely to have elevated 
progesterone concentrations (p=0.05) [232]. In contrast, oral contraceptive usage has 
been linked to protection against subsequent infertility or conception problems by 
two different studies [146, 233]. However, it would be extremely difficult to link 
hormone status at time of infection with subsequent pathological outcomes such as 
infertility, even in a longitudinal study, given the high numbers of oral contraceptive 
users, and the independent importance of these factors in the risk of acquiring an 
infection. 
Following infection, C. trachomatis infects trophoblast cells which play an 
important role in implantation and placentation, and reduces chorionic gonadotropin 
expression and depletes oestrogen and progesterone synthesis which impairs 
trophoblast functions of implantation and placentation, resulting in infertility [234]. 
Higher prevalence of serum IgG to C. trachomatis in patients whose ovarian 
response was poor to gondatropin suggests that C. trachomatis impairs ovarian 
function [235]. Progesterone is reported to peak during the third week of menses and 
inhibit cell-mediated immunity in several in vitro models. Moreover, it has been 
shown to enhance chlamydial growth in uterine epithelial of several species [236].
2.5 HUMAN GENOTYPIC FACTORS ASSOCIATED WITH C. 
TRACHOMATIS INFERTILITY IN WOMEN
It is interesting to note that among women with asymptomatic infections, 8%-
10% of women infected by C. trachomatis develop sequelae, while 20% resolve the 
infection [203, 237]. C. trachomatis infection and ascension into the upper genital 
tract is greatly influenced by the host genetic factors. The development of C. 
trachomatis related infertility in only some women may be a consequence of a 
genotypic pre-disposition (reviewed comprehensively [238]). 
Toll-like receptors (TLRs) recognize and bind to antigens of pathogen, and 
signal to upregulate an immune response. There are 10 Toll like receptors (TLR) 
identified in the human body, and TLR 1-4 are expressed in the female genital tract 
[239]. TLR2 and TLR4 are also expressed on macrophages, dendritic cells and 
epithelial cells and they bind chlamydial lipopolysaccharide [240]. In a prospective 
genotypic study of female participants attending a sexual health clinic and a fertility 
clinic in Amsterdam, Karimi et al. (2009) [241] demonstrated a possible protective 
role of a TLR2 haplotype. The haplotype consisting of two distinct single nucleotide 
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polymorphisms (SNPS) was found to be present in a significantly higher proportion 
of women with a history of Chlamydia who did not have tubal pathology and in 
sexual health clinic attendees was present in a higher proportion of women who were 
asymptomatic [241]. In the PEACH PID study TLR1 and TLR4 polymorphisms 
were found to significantly associate with chlamydial PID [242], whilst SNPS from 
TLR2 (different SNPs from those included in the Karimi study), TLR6, Myd88, and 
TIRAP did not significantly associate with chlamydial PID [242]. 
Den Hartog et al. [243] identified that the risk of tubal pathology was higher in 
C. trachomatis IgG positive women with multiple TLR polymorphisms. The study 
also showed a trend towards association of various individual polymorphisms in 
TLR9 and TLR4 with increased risk of tubal pathology in C. trachomatis IgG 
positive women [243]. However, the small sample size in the study makes it difficult 
to draw a correlation between the polymorphisms and level of risk for female 
infertility. NLRP3, a component of the inflammasome that activates a pro-
inflammatory response has been identified to have polymorphisms reported to result 
in altered IL-1β secretion (a pro-inflammatory cytokine) [244]. Several NLRP3 
polymorphisms were tested in women prospectively recruited at a sexual health 
clinic and fertility clinics in Amsterdam, women heterozygous or homozygous with 
the one of the NLRP3 polymorphisms were at significant risk of developing 
abdominal pain during C. trachomatis infection [244]. 
Mannose-binding lectin (MBL) is a pro-inflammatory protein that activates 
complement and is locally synthesised in the vagina [245]. MBL and MBL promoter 
polymorphisms have been previously demonstrated to alter the levels of MBL 
produced [245]. It was identified that women with tubal factor infertility who were 
chlamydial seropositive more frequently had the low MBL producing genotypes 
compared to healthy controls [245]. However, this was not the case in an ectopic 
pregnancy group who were less likely to have the MBL-deficient genotypes [245]. 
This later finding sheds some doubt on the role of MBL genotypes, given that it 
seems unlikely that the pathology associate with ectopic pregnancy is distinct from 
tubal infertility.
Human leukocyte antigen (HLA) class II molecules (DR, DQ and DP) present 
peptides to CD4 T cells and induce adaptive immunity. DQ polymorphisms were 
more frequent in women with tubal infertility who were also C. trachomatis
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seropositive [246].Whilst another polymorphism was negatively associated with C. 
trachomatis positive tubal infertility [246]. Wang et al., [247] showed that in 
adolescent females with recurrent chlamydial infections, certain HLA 
polymorphisms were significantly associated with recurrent infections. A recent 
study attempted to link different immune genotypes to immunological outcome by 
testing a functional role for HLA DQ alleles combined with an IL-10 allele for both 
frequency in a tubal factor infertility (Chlamydia positive) cohort compared to 
controls and also for lymphocyte proliferative response to cHSP60 [172]. The HLA 
alleles and IL-10 allele were more frequently identified in the chlamydial tubal factor 
cohort compared to the control, however the lymphocyte proliferation in response to 
cHSP60 was not significantly different in relation to the alleles [172]. However, in a 
different study, distinct IL-10 and IFN-J polymorphisms were found to significantly 
impact on lymphocyte proliferation in response to chlamydial antigens (cHSP60)
[248].
A range of cytokine polymorphisms have been shown to significantly associate 
with women with C. trachomatis tubal infertility, including: IL-10 [249], TNF- D
[249] and IL-12 [250]. Polymorphism in IL-1β and receptor genes were not 
associated with C. trachomatis related tubal pathology [251]. Adolescent females 
with recurrent chlamydial infections had a lower frequency of three IL-10 promoter 
polymorphisms [247]. Eng et al. [252] demonstrated that a CD14 allele (TLR-4 co-
receptor) was associated with increased TNF-α production when whole blood was 
stimulated with C. trachomatis and C. pneumoniae [253]. 
Whilst none of these studies were able to account for all chlamydial tubal 
infertility cases, it is a convincing body of evidence that human genotype is a 
contributing factor in pathology development. It is interesting that to date the vast 
majority of studies have focussed on immune factors, yet as an obligate intracellular 
pathogen Chlamydia has key host nutritional requirements, inclusion vacuole 
requirements, and therefore the ability to ascend and cause pathology may in fact be 
independently determined by a as yet unknown non-immune host genotype. 
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2.6 IMMUNE RESPONSES ASSOCIATED WITH CHLAMYDIA 
TRACHOMATIS IN WOMEN
Insight into the immunological factors that may be involved in C. trachomatis
infertility in women has been obtained through various human studies, including
investigation of; local secretions (cervical and vaginal lavages), human tissues, 
peripheral blood mononuclear cells (PBMC), as well as through in vitro cell culture 
models. A commonly used framework to categorize the immune response is the 
Th1:Th2 paradigm (reviewed [254]). This paradigm suggests that the immune 
response can polarize towards a cytotoxic pathological response (Th1) or a humoral 
antibody mediated response (Th2). The profiles of these responses include Th1 
subset of T helper lymphocytes (Th) and cytokine production such as: IL-2, IL-6, 
tumor necrosis factor (TNF-α), and interferon-gamma (IFN-γ) [255, 256]; and Th2 
responses involve IL-6, IL-4, IL-10, IL-5 and IL-13 [255]. In addition to Th1:Th2 
regulatory immune profiles typified by IL-17 or IL-23 have also recently been 
described (reviewed [257]). The immune responses in different models reviewed 
below and summarised in Table 2.1 enable a better understanding of the chlamydial 
pathology resulting in female infertility.
2.6.1 Immune responses from reproductive sites and tissues
Genital secretions have been used to reveal the immunological responses that 
occur at the site of infection, although it is not possible to link these with subsequent 
pathology. IFN-γ levels were found to be five times higher in the endocervical 
secretions of women with C. trachomatis infection detected by culture (n=47) 
compared to uninfected women (n=52) [258]. Analysis of immune factors using 
multiplex immunoassay in cervical-vaginal lavages of women attending a STD clinic 
with acute C. trachomatis infection (n=5) compared to controls with no infections 
(n=13), revealed significantly higher levels of IL-1β, lactoferrin, TNF-α, IL-8, 
VEGF, G-CSF, IL-10, IL-3, IL-7, IL-12 and IL-6 [259]. However, in a separate 
study in India, IFN-J levels were only significantly higher in women with recurrent 
C. trachomatis infections compared to controls but not higher than those with 
primary infection [260]. IL-17 and IL-22 were 5 times and 3 times higher in the 
cervical secretion of C. trachomatis positive women (n= 27) compared to negative 
controls (n=17) [261]. IgG and IgA antibodies to C. trachomatis EBs were higher in 
the cervical washes of C. trachomatis positive fertile women during primary 
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infection compared to recurrent infection [260]. However, cervical IgG to specific 
chlamydial antigens (cHSP60 and cHSP10) was higher in recurrent infection than 
compared to primary infection, which is what would be expected [260]. Stimulation 
of cervical monocytes with chlamydial EBs showed an increased expression of Toll-
like receptors (TLRs) TLR2 and 4, and both receptors were also expressed at higher 
levels in cervical cells from women with infection compared to uninfected women 
[263]. The levels of IL-1β, IL-4, IL-5, IL-6 and IL-10 were reported to be 
significantly higher from enriched cervical T cells stimulated with chlamydial 
inclusion membrane (Inc) proteins from C. trachomatis related infertile women 
(n=18) as compared to C. trachomatis positive fertile women (n=14) [264]. Whilst 
not always a Chlamydia related pathology, a study by Balasubramaniam et al. [265]
which found that level of cytokines IL-8 and IL-6 were significantly upregulated in 
the fallopian tube immediately in the location of implantation of ectopic pregnancy, 
but not in the fallopian tubes of women undergoing benign hysterectomy. A very 
recent study identified that differences in IFN-J levels correlated with differences in 
the chlamydial cellular morphologies at the cervix when comparing two patients 
[169]. These local responses all support that immune mediated pathology and key 
chlamydial antigens are likely involved in the development of infertility.
The effects of chlamydial infection in human tissue ex vivo studies provided a 
controlled insight into the cellular responses that likely occur in vivo during the 
immediate primary infection. Though ex vivo fallopian tube studies, Hvid et al. [266]
showed that addition of IL-1RA receptor antagonists, blocked IL-1β and IL-8 
production preventing the pathology from chlamydial infection [266]. This confirms 
that IL-1β along with IL-8 are likely major factors for tubal pathology [266], 
supporting the cellular paradigm of pathology development and not supporting the 
hypersensitivity model. Fallopian tube explants from ectopic pregnancy cases that 
were C. trachomatis seropositive were used to demonstrate that C. trachomatis
induced higher expression of a prokineticin receptor via TLR2 binding [267]. The 
prokineticin pathway impacts on smooth muscle contraction and intrauterine 
implantation as well as angiogenesis, which may imply a mechanism for C. 
trachomatis damage leading to ectopic pregnancy [267]. T lymphocytes from 
endometrial and salpingeal tissues cultured ex vivo in the presence of Chlamydia or 
cHSP60 showed induction of lymphocyte proliferation and IFN-J secretion from PID 
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or ectopic pregnancy cases [268]. In the same participants, higher levels of IFN-γ 
mRNA expression and lower levels of IL-5 in fallopian tube and peritoneal cavity 
specimens of PID patients who had T cells proliferating in response to the organism 
ex vivo further implicated Th1 cytokine production in C. trachomatis related 
pathology [268]. Primary endocervical cell cultures infected with C. trachomatis also 
demonstrated a pro-inflammatory cytokine response with abundant production of IL-
8, IL-1α and TNFα, all of which were maximally detected during live infection with 
active bacterial protein synthesis [269]. Combined these data predominantly support 
the cellular paradigm and ascending infection models of pathology and link to a Th1 
profile of immunity.
2.6.2 Immune responses in peripheral blood mononuclear cells (PBMC) in 
women
Peripheral blood mononuclear cells (PBMC) are often used to provide insight 
into immune cell responses to Chlamydia from different participant cohorts. PBMC 
proliferation induced by purified C. trachomatis EBs showed a prominent secretion 
of IFN-γ in women with genital infection [270]. PBMC from women at high risk of 
acquiring an infection (commercial sex workers) were stimulated with cHSP60 and 
the production of IFN-J strongly correlated with protection against incident C. 
trachomatis infection [271]. In a separate study PBMC from healthy donors were 
incubated with C. trachomatis serovar K, leading to the finding that pro-
inflammatory gene expression (measured by microarray and validated by qRT-PCR) 
was sustained for up to seven days, especially for IFN-J, and IL-2receptor [272]. 
However in a separate study, cHSP60 PBMC production of IFN-J was lower in 
women with PID or repeat infections compared to women with current infections 
[273, 274]. Human dendritic cells prepared from human PBMC were infected with 
C. trachomatis serovar E or L2 that induced production of IL-1E, IL-12p70, IL-6, IL-
8, IL-18 and TNF-α [275]. A separate study also detected production of IL-12 and 
TNF-α by human PBMC sourced dendritic cells infected with C. trachomatis L2 
[276]. Hook et al. [277], showed that stimulation of PBMC with chlamydial EBs 
elicited IFN-γ production by natural killer cells. Cohen et al. [271] showed IFN-γ 
production from PBMC stimulated with cHSP60 correlated with participants who 
were protected from acquisition of infection in a longitudinal study of 143 female 
participants [271]. This study also showed the PBMC production of IL-13 in 
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response to chlamydial EBs also correlated with a reduced risk of infection [271]. IL-
6 production was reported from endometrial and endocervical primary ex vivo
cultures from live infections with C. trachomatis [278].
2.6.3 Immune pathway elucidated by in vitro culture models
Epithelial cell culture are most commonly used for in vitro growth and 
characterization for C. trachomatis infection [44]. C. trachomatis infection in HeLa, 
SiHa (human cervical carcinoma epithelial cell) and HEp2 (human epithelial cell) 
were used to demonstrate that IL-1α regulated IL-8 production from these cell lines 
during infection [279]. Similarly, mRNA measurement of cytokine gene expression 
after C. trachomatis infection of HeLa, SiHa cervix squamous carcinoma cells and 
HT-29 colon adenocarcinoma cells showed increased levels of IL-8, GROα, GM-
CSF, IL-6 and IL-1α levels. These cytokines are activators of neutrophils, monocytes 
and T lymphocytes, and potent chemoattractants [269]. A HeLa/THP-1 co-culture 
model attempting to re-capitulate the in vivo cellular cross-talk also identified 
sustained IL-6 and IL-8 cytokine secretion during C. trachomatis infection with IL-
1β transiently detected [280]. IL-6 and IL-8 were also detected in a separate study 
using infections of cervical and epithelial cell models [269]. A HeLa and THP-1 
(mono-nuclear cell) co-cultures model identified that there are distinct profiles of 
innate immune responses to C. trachomatis serovar E compared to L2. The results 
also showed that the monocyte released innate cytokines (such as TNF-D) had 
different effectiveness in controlling the infection in infected epithelia model cells by
the two serovars [281]. Using a similar co-culture model as Rasmussen et al. [269],
Cunningham et al. [278] also demonstrated a sustained IL-6 production in response 
to C. trachomatis L2 infection. A RNAseq- based examination of host and 
chlamydial gene expression enabled investigators to identify that a fibrotic profile of 
gene expression being induced in infected HEP-2 cells [282]. The role of TNF-α in 
inhibiting chlamydial development was evaluated by addition of recombinant TNF-α 
to Hep2 cells prior to infection which resulted in smaller inclusion bodies [283]. 
Furthermore, addition of IFN-γ to the cell line showed that in combination with 
TNF-α, chlamydial replication was inhibited [283]. Lu et al., [284] showed that 
chlamydial infection of several epithelial cell lines resulted in the secretion of mature 
IL-18. IL-18 is known to potentiate the Th1 immune response and enhance 
production of IFN-γ [284].
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Table 2.1: Immune responses associated with C. trachomatis-related infertility in women
Type of model Sample Immune Response References
Reproductive sites 
and Tissues
Cervical secretions from women with acute C. 
trachomatis infection (n=5)
Increased expression of IL-1β, lactoferrin, TNF-α, IL-8, 
VEGF, G-CSF, IL-10, IL-3, IL-7, IL-12 and IL-6
[259]
Cervical washes stimulated with 
C.trachomatis HSP60 and HSP10
High IFN-J production in women with recurrent C. 
trachomatis infections (n=197)
[260]
Cervical secretions from C. trachomatis positive 
infertile women (n=17)
High IFN-J, TNFa, IL-10, IL-12 levels in infertile patients [285]
Cervical secretions stimulated with IncB, Inc C and 
C. trachomatis EBs
Increased expression of IL-1β, IL-4, IL-5, IL-6 and IL-10 in 
women with C. trachomatis-related infertility. 
[264]
Tissue sections of fallopian tube stimulated with C. 
trachomatis serovar D
High levels of IL-1β and IL-8 associated with tubal scarring 
and pathology. 
[266]
Fallopian tube specimens from women with past C. 
trachomatis infection (n=14)
High expression of prokineticin (PROKR2) receptor via 
TLR2 binding. PROK signalling reduces embryo 
implantation and play an active role in tubal ectopic 
pregnancy.
[267]
Salpingeal tissues stimulated with cHSP60 High IFN-J levels in women with PID (n=14) and TFI 
(n=22) may be associated with tubal infertility. 
[268]
Primary endocervical epithelial cell stimulated with 
C. trachomatis L2
IL-8 and IL-1α induce epithelial cytokine production and 
proinflammatory cytokines
[269]
PBMC stimulated with cHSP60 and a mixture of C. 
trachomatis serovars (E, F, K, L2) EB
Increased production of IFN-J and IL-13 conferred a 
protective effect against C. trachomatis infection in 
commercial sex workers (n=18). 
[271]
PBMC stimulated with cHSP60 High IL-10 and low IFN-J and IL-12 production in women 
with PID (n=9) 
[273]
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Peripheral Blood 
Mononuclear Cells 
(PBMC)
Dendritic cells stimulated with viable and heat-
inactivated C. trachomatis serovar E or L2 
Increased production of IL-1E, IL-12p70, IL-6, IL-8, IL-18 
and TNF-α. These pro-inflammatory cytokines activate Th1 
T cell responses (resolve infection).
[275]
Dendritic cells stimulated with viable or UV 
inactivated C. trachomatis L2
High levels of pro-inflammatory cytokines, IL-12 and TNF-
α. 
[276]
PBMC stimulated with viable C. trachomatis L2 High levels of IL-6 in women with chlamydial infertility 
(n=3)
[278]
In vitro cell culture
SiHa (human cervical carcinoma epithelial cell) and 
HEp2 cells stimulated with C. trachomatis L2 
High levels of IL-1α and IL-8. [279]
HeLa and SiHa cells infected with C. trachomatis L2 High levels of chemoattractants and pro-inflammatory 
cytokines IL-8, GROα, GM-CSF, IL-6 and IL-1α levels.
[269]
Co-culture of HeLa and THP-1 cells infected with 
CtTsp, CtHtrA, and UV-killed 
C. trachomatis L2 infection
High levels of IL-6. The cytokine may be associated with 
disease pathology. 
[278]
Infection of HeLa , A549 airway epithelial (CCL185) 
and HT-29 colonic epithelial (HTB38) cells with C. 
trachomatis serovars L2, E, F, and K 
Increased production of IL-18 through caspase-1 mediated 
pathway, which facilitates immune evasion of C. 
trachomatis.
[284]
HeLa and SiHa cells infected with C. trachomatis L2 Downregulation of major histocompatibility complex (MHC) 
molecules. 
[277]
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2.7 CHLAMYDIAL FACTORS THAT MAY INFLUENCE THE 
DEVELOPMENT OF PATHOLOGY
Although host/human factors and the host immune response influence the 
outcome of the C. trachomatis infection, the pathogenesis of the bacteria is also 
influenced by characteristics inherent to the bacteria. These factors include 
chlamydial serovars, chlamydial genotypes and virulence factors. 
2.7.1 Association of chlamydial serovars with repeat infection and symptoms 
that may link to a propensity to cause pathology and infertility
Chlamydial serovars are assigned based on the outer membrane proteins, 
typically by sequencing so studies that refer to serovars are actually frequently 
referring to genovars [286]. Serovar E and serovar F are generally found to be 
predominant in most countries including: Australia, Netherlands, and Sweden [287-
291]. Using omp1 PCR based RFLP genotyping Lan et al. [292] reported that in 
women less than 30 years old, serovars D (4/21 asymptomatic women) and I (4/21 
asymptomatic women) were associated with asymptomatic infection, while serovar 
G was associated with symptomatic infections (4/30 symptomatic cases). Similarly, 
Gao et al. [289] also reported the predominance of serovar G in symptomatic 
infection, particularly lower abdominal pain (18/33 patients) as compared to 
asymptomatic patients (P<0.001) amongst female sex workers and STD patients in 
China. 47.5% (28/59) asymptomatic patients had serovar E [289]. Verweij et al., 
(2014) reported that different serovars induced differential serological responses in 
510 women with PCR confirmed C. trachomatis infection [293]. The study showed 
that serovar D (n=45) and E (n=217) from serogroup B elicited the highest IgG 
response (Median IgG titre of 200) followed by serovar H (n=20) [293]. Women 
with persisting infections were found to have twice as may serovar E infections 
(67%, 8/12) compared to women who naturally cleared infections (33% 3/9) during a 
longitudinal study of women with asymptomatic C. trachomatis infections, however 
this was not significantly different [294]. Consistent with previous findings, 
Workowski et al. [295] also showed that while serovars F, B and C showed no 
apparent association with infertility in women with PID, serovar F exhibited different 
symptoms compared to B and C in women with lower genital tract infection (n=99), 
and it was accompanied by fewer clinical manifestations of mucopurulent 
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endocervical. However, several study design flaws have been raised and therefore it 
may not be relevant to include these data to make conclusions about the effect of 
serovars on resolution of infection [296, 297]). Whilst not linked directly to 
infertility, the majority of evidence from these studies support that different serovars 
do have different associations with symptoms, re-infection, or infection duration, all 
of which may contribute to pathology development. 
2.7.2 Chlamydial genotypes can mediate tissue tropism and may be a factor in 
pathology development
There are several published examples of C. trachomatis genotypic changes 
associating with tissue tropism, however, no reports yet aligning chlamydial 
genotype with pathology development and infertility. The most well know genotype 
that mediates tissue tropism is actually polymorphisms in the trpAB operon and the 
ability to synthesis tryptophan from indole between C. trachomatis ocular and genital 
strains [201, 298] which we will mention here given the significance of this finding 
to the field even though this review is focussed on infertility. There is also evidence 
of positively selected genotypes that align with tissue trophism (ocular, genital, 
mononuclear/invasive), for example in a review of 59 C. trachomatis genome 
sequences, it was reported that tarp, and the pmp genes have positively selected 
polymorphisms that significantly cluster with tissue niche [299]. Polymorphisms in 
three distinct open reading frames have been found to associate with rectal but not 
cervical serovar G isolates, and two further open reading frame polymorphisms were 
found to associate with rectal and cervical tropism of serovars E, F and J [300]. 
These studies do not identify pathology-associated polymorphisms, however they do 
support the theoretical potential for chlamydial genotypes to exist that either 
improved ascension, or upper reproductive tract survival or polymorphisms that alter 
the immune response. Any association a chlamydial genotype has with pathology 
development would only be possible by a longitudinal study of a large group of 
women throughout their reproductive years with continual sampling and analysis of 
infecting chlamydial strains.
2.7.3 Virulence factors associated with chlamydial pathology in women 
Secretion of immunomodulatory antigens is one of the principle virulence 
mechanisms of Chlamydia trachomatis. These proteins enable organisms to evade 
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host immune system thus leading to the development of serious sequelae such as 
Tubal factor infertility and ectopic pregnancy.
Heat shock proteins (HSPs) are chaperones that aid in correct folding of 
intracellular proteins [126]. Chlamydial heat shock proteins (cHSP60) are strong B 
and T cell antigens that play an important role in the immunopathology of sequelae 
of chlamydial infections [172, 301]. Kinnunen et al. (2003) [270] showed that when 
PBMCs were stimulated with cHSP60, a higher level of IFN-γ, IL-2 and IL-10 was 
produced, as opposed to weaker IL-10 production by the C. trachomatis Elementary 
bodies. Since, protective immunity and chlamydial clearance is dependent on the 
mutual interplay between IL-12 and IFN-γ, any imbalance could result in the 
development of TFI. Additionally, IL-10 does not support protective immunity and 
control of infection, thus leading to pathology [270]. The development of sequelae is 
highly dependent on the balance Th1 and Th2 immunity. Based on the cytokine 
expression obtained from salpingeal tissues and PBMC of patients with endometritis, 
PID and multiple infections, it was reported that cHSP60 induced a dominant Th2 
response, which leads to chronic inflammation [273, 302]. Th1 immunity is 
associated with clearance of infection, while Th2 induces pathology. Hence, based 
on his findings, Debattista et al. (2002) [273] proposed that during chronic 
inflammation, a premature switching from Th1 to Th2 occurs. In addition to cHSP60, 
cHSP10 has also been shown to elicit T and B cell responses that contribute to 
pathology [303, 304]. cHSP10 is genetically linked to cHSP60 and perform similar 
roles as cHSP60 in protein folding and denaturation. On comparing acute infection to 
TFI, Srivastava et al. (2008)[303] found that in conjunction with higher antibody 
titres, both cHSPs induced higher production of IL-10 and IFN-γ in the latter. TNF-α 
was not found to be significant between patients with acute infection and patients 
with C. trachomatis-related infertility. The higher antibody titres for cHSP10 in the 
previous study is concurrent to the study Betsou et al. [304] which showed that anti-
cHSP10 IgG antibodies are associated with chronicity. 
Chlamydial protease like activity factor (CPAF) is a major [305] virulence 
factor that is secreted into host cytosol and has been reported to manipulate host 
immune system [305-307]. It is an atypical serine protease conserved within the 
chlamydiales [305]. The protease plays an important role in the developmental cycle 
of C. trachomatis through expansion of inclusion [307]. CPAF degrades host 
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transcription factors USF-1 and RXF-5 that are required for MHC Class I and II gene 
activation [308]. In women with cervicitis, antibody response to CPAF was found to 
be higher than MOMP and cHSP60 [306]. Downregulation of chlamydial protease-
like activity factor (CPAF) and upregulation of high mobility group box 1 (HMGB1) 
protein renders the bacteria apoptosis-resistant and pro-inflammatory, thus promoting 
chronic inflammation [309]. 
The inclusion membrane proteins (Inc) are the only known proteins that reside 
in the inclusion membrane that interact with host proteins. These proteins share a 
common bilobular hydrophobicity motif that spans the inclusion membrane, but the 
common amino acid sequences among themselves are limited [20, 63]. Inc proteins 
were first identified in C. psittaci [64] and subsequently identified in C. trachomatis
[20, 65]. IncA, first identified in C. psittaci, regulates the fusion of inclusions and
interaction between the inclusion and intracellular compartment [67-70]. The 
SNARE-like fusion protein IncA facilitates fusion between endoplasmic reticulum 
and inclusion membrane, and the ER is essential in antigen processing and 
presentation [310]. IncB and IncC were reported to be higher in the cervical cells of 
infertile women (C. trachomatis infection) than women with acute infection. They 
also induce higher levels of IL-12, IFN-γ, TNF-α, IL-6, IL-4 and GMCSF in the 
PBMC of C. trachomatis infected fertile women [311]. The expression of these 
cytokines indicates that InC and IncB induce strong Th1 immune response in the 
genital tract. 
2.8 DIAGNOSIS OF CHLAMYDIA TRACHOMATIS
Historically, cell culture was the diagnostic technique for C. trachomatis
infections. This was followed by the DFA (direct fluorescent antibody) techniques, 
and today the most widely used techniques are the NAATs (nucleic acid 
amplification tests). However, the asymptomatic nature of the disease means many 
people do not get tested. Table 2.1 illustrates the sensitivity, specificity and the 
characteristics of the various diagnostic techniques used to detect C. trachomatis
[312].
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Table 2.2:A brief summary of the various diagnostic techniques for C. 
trachomatis infections
The table lists the specificity and sensitivity, advantages and disadvantages 
associated with cell culture, antigen testing, enzyme immunoassay, nucleic acid 
amplification testing and point of care tests. (Table directly adapted from Mylonas et 
al. [286]. 
Test procedure Sensitivity Specificity Advantages Disadvantages 
DNA 
amplification 
80-90% >98% Sensitive test 
Non-invasive 
specimen 
collection
Cost 
Appropriate 
material storage 
and processing 
Cell culture 60-80% >99% Appropriate for 
medical-legal 
issues
Specific strain 
Low sensitivity
Labour intensive 
Direct 
fluorescence of 
antibodies 
(DFA)
65-75% 97-99% Simple test 
Unit test
Low sensitivity
Labour intensive 
Subjective 
reading 
Enzyme 
immunoassay 
(EIA)
60-75% 97-99% Automation Low sensitivity
Verification test 
recommended
Rapid point of 
care test (POC)
25-67% >97% Low cost 
Unit test
Very low 
sensitivity 
Verification test 
recommended
Chapter 2: Literature Review 50
2.8.1 Cell culture 
Tang et al. [313] were the first to successfully isolate and culture a trachoma 
biovar strains of C. trachomatis from embryonated chicken eggs. C. trachomatis
strains infect only certain cell lines such as HeLa-229, McCoy, Buffalo green 
monkey kidney and BHK-21 [314]. Studies by Hodinka et al. [315] suggested that 
cell line infection by C. trachomatis is enhanced by centrifugation which promotes 
phagocytic entry and prevents phagosome-lysosome fusion. The chlamydial 
inclusion bodies are visualised with the help of immunofluorescence and iodine or 
Giesma stain [316]. Despite isolating the bacteria from specialized culture medium, 
and with the assistance of skilled staff, cell culture techniques achieves a sensitivity 
of around 70-80% for detecting C. trachomatis [314]. Additionally, the technique is 
difficult, time consuming and costly [314].
2.8.2 Non-Culture Techniques (Non-nucleic amplification tests)
The non-culture techniques involve direct visualization of the chlamydial 
organism through cytologic examination, immunohistochemical detection of antigen 
and hybridization to DNA probe (EIA and DFA) [317]. Unlike culture techniques, 
non-culture techniques are standardized test that are rapid and less labour intensive 
[317]. 
Direct immunofluorescence assay involves the use of fluorescein-tagged 
monoclonal antibody specific for C. trachomatis to detect the infection [318]. 
Another technique that employs the use of fluorescein tagged molecule is the 
commercially available MicroTrak test which detects individual elementary bodies of 
C. trachomatis using fluorescein-labelled monoclonal antibodies [319]. Using this 
technique, the sensitivity and specificity of detecting C. trachomatis antigen in 
endocervical swabs of infertile women (n=200) was reported as 66.7% and 100% 
respectively, which was much higher than EIA (sensitivity=48.1%; specificity 
=100%)[320]. DFA is a rapid technique that has a higher specificity. However, its 
broad range of sensitivity suggests that it is highly subjective and is not suitable for 
large number of samples [321]. A study conducted by Rahm et al. [321] showed that 
the sensitivity of DFA was only about 85% among asymptomatic patients, thus it is 
not the preferred diagnostic technique for asymptomatic patients. Thejls et al. [322]
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reported that C. trachomatis elementary bodies were detected in 8.2% (n=256)of 
women with infertility using DFA and it was comparable to EIA. EIA. is prone to
false positives due to cross-reactions with lipopolysaccharide (LPS) of other 
microorganisms [323]. 
2.8.3 Nucleic acid amplification tests 
Nucleic acid amplification tests are highly accurate techniques that are widely 
used in C. trachomatis diagnosis [318]. They detect small amounts of chlamydial 
nucleic acids, transcripts from genital specimens, and non-invasive samples such 
urine specimens and self -obtained vaginal swabs [318]. NAATs have a sensitivity of 
95% and specificity of 100%, hence they are considered the “gold standard” for 
chlamydia diagnosis. The amplification techniques include PCR, real-time PCR, 
strand displacement amplification, transcription-mediated amplification and nucleic 
acid sequence based amplification [323]. NAAT is particularly useful in 
asymptomatic women because it is capable of detecting C. trachomatis at low IFU 
(inclusion forming units) counts which is a direct correlation to the endocervical 
discharge and other anatomical changes associated with chlamydial infection [324]. 
Although, NAAT is capable of detecting C. trachomatis in FCU (First- catch urine) 
from women, vaginal swabs specimens are preferred over FCU due to the presence 
of inhibitors in urine such as phosphate that inhibit LCR reactions [325] . The 
evaluation of the sensitivity and specificity of NAAT techniques such as strand 
displacement amplification (SDA), PCR and Abott ligase reaction (LCR) to C. 
trachomatis showed that the three techniques performed similarly with regards to 
sensitivity and specificity [326]. However, when compared to the performance of 
EIA, the detection rate by PCR was 62% higher than that of EIA [327]. The
commercial NAATs for C. trachomatis that are widely used due to their high 
specificities and sensitivities are COBAS Amplicor test (Roche systems; 16S rRNA 
PCR-based NAAT), Abbott m2000 (Abbott systems; LCR-based NAAT), APTIMA 
C. trachomatis (Gen-Probe; Transcription-mediated NAAT) and BD ProbeTec 
(Becton Dickson, USA; SDA-based NAAT). The sensitivities for detecting C. 
trachomatis in vaginal swabs of 575 women recruited from sexual health clinics for 
APTIMA (Gen-Probe), Abbott m2000 and ProbeTec were 96.2%, 98% and 90.6% 
respectively, while in urine samples the sensitivities were reduced to 88%, 76.9% 
and 75.5% respectively [328]. The specificities all the assays ranged between 98.4% 
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to 100%. Among self-collected vaginal swabs (n=675), COBAS ® 4800 (Roche 
systems) and Abbott m2000 (Abbott systems) had sensitivities of 97.1% and 100% 
respectively, and specificities of 99.7% and 99.5% respectively, in detecting C. 
trachomatis infections [329]. Despite their high specificities and sensitivities, in 
Sweden, the NAATs yielded a high number of false negatives owing to the lack of 
detection of a new variant of C. trachomatis (nvCT) that was discovered in the 
country in 2006 [330]. This 377-bp deletion in the cryptic plasmid of the bacteria is 
often the target sequence for most NAATs and thus the bacteria was not detected. 
Moller et al. [331] compared the performance of Roche COBAS Amplicor CT 
(RCA), Abbott m2000 (Abbott systems), Gen-probe Aptima combo 2 assay (targets 
23S rRNA) and Aptima C. trachomatis assay (targets 16S rRNA) in detecting nvCT 
in first catch urine samples and vaginal swabs from female participants in Sweden 
(n=1231). The study reported that both Gen-probe NAATs (specificity=100%; 
sensitivity =99.6%-99.9%) had higher sensitivity and specificity in detecting nvCT 
than m2000 (sensitivity= 68.7%; specificity= 99.9%) and RCA (sensitivity = 63.8%; 
specificity= 99.9%) in detecting all mutant strains characterized by in-house PCR 
[331]. Klint et al. [330] reported that in 2007 counties in Sweden that used 
Abbot/Roche systems had high proportion of nvCT, while counties using BD Probe 
Tec had lower proportion of nvCT, but after rountine testing the proportion declined 
in 2009 (65% to 48% with Abbot/Roche, 24% to 18% in Uppsala with BD). A 5-year 
follow-up revealed that in 2011 the proportion of the new variant had reduced to one-
fifth of the absolute and relative numbers, while the proportion of wild type remained 
the same in Skane (Sweden) [332]. Thus, this highlights the importance of 
appropriate and routine screening of chlamydial strains in order to control their rate 
of transmission. 
The disadvantages of NAAT is that they require sophisticated laboratory 
conditions [333, 334]. Several studies have used PCR testing to determine the 
prevalence of C. trachomatis infections in a population [320, 335-337], the organism 
load [338-341] and rapid detection of multiplex detection of C. trachomatis along 
with other microorganisms such N. gonorrohoeae [342-346]. In Iran, PCR testing of 
150 women with infertility and 200 fertile healthy women revealed that C. 
trachomatis was detected in 32% of women with infertility as compared to 8% of 
healthy fertile women [347]. In another study, the prevalence of C. trachomatis
Chapter 2: Literature Review 53
among infertile women (n=106) recruited from fertility clinic in Brazil was 
determined as 58% using PCR amplifying C. trachomatis DNA plasmid [348]. In-
house real time PCR targeting cryptic plasmid and omp1 gene in endocervical swabs 
collected from 200 infertile participants in an fertility clinic in India, showed that C. 
trachomatis was present in 13.5% infertile women. 
2.8.4 Point of Care tests to detect C. trachomatis infections
Point of care tests (POC) are assays that are affordable, sensitive, specific, user 
friendly, rapid and robust, equipment free and deliverable (ASSURED) [349]. There 
are several commercial POC tests such as Chlamydia Rapid Test, QucikVue test and 
Clearview Chlamydia for chlamydial diagnosis. Although, they are cost-effective and 
rapid, their sensitivity and specificity falls short in comparison to the current “gold 
standard”; nucleic acid amplification tests. Alarmingly poor performance has been 
reported by Dommelen et al. [333] which revealed that the sensitivities of Chlamydia
Ag test, QuickVue Chlamydia test and Handilab-C were extremely poor and were 
prone to false positive results. Similar results were obtained in the study conducted 
by van der Helm et al. [334] who reported poor sensitivities (41.2%) for Chlamydia
Rapid test (CRT). However, continued efforts have been undertaken to improve the 
performance of POC tests and some of the techniques developed recently have 
demonstrated improved diagnostic performance. Cepheid GenXpert CT/NG test is 
the first genetic POC that amplifies one chromosomal target for C. trachomatis
detection and it can detect 15 serovars of C. trachomatis including nvCT [349]. A 
field evaluation trial of POCs GenXpert and Diaquick CT for C. trachomatis
detection in remote Aboriginal communities of Australia reported that GenXpert CT 
had a sensitivity of 100% and a specificity of 99.5% (n=198), while Diquick CT had 
a sensitivity of 27.3% and a specificity of 66.7%[350]. Similar sensitivities and 
specificities for GenXpert CT were also reported by Gaydos et al. [344], wherein 
testing of endocervical, vaginal and urine samples from 1722 females yielded
sensitivities between 97.4% -98.7%, while maintaining a specificity of 99%. Several 
novel POC techniques with superior sensitivities and specificities have been 
developed, but they are yet to be used widely. Some of the techniques include Velox 
technology [351] that utilizes novel electrochemical detection principle and reported 
a sensitivity of 98.1% and specificity of 98% in a pre-clinical validation of 306 
clinical samples. aQcare Chlamydia TRF kit which is based on the newly based 
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lateral flow immunoassay that uses europium (Eu) (III) chelated nanoparticles as a 
labeling substances also yielded a high sensitivity of 93% and a specificity of 98% 
(n=441) [352]. Thus, quick, user friendly and cost-effective POC could improve 
screening strategies and effectively control C. trachomatis infection and prevalence. 
2.8.5 Serological diagnosis 
Serological assays for C. trachomatis involve detection of antichlamydial 
antibodies [2]. It is a useful technique in diagnosing ectopic pregnancies, pelvic 
inflammatory diseases and recurrent miscarriages [2]. Serological diagnosis 
overcomes the problem of invasive sampling using techniques in upper genital tract 
infection in women, such as needle aspiration of the affected fallopian tubes in 
women with salpingitis [353]. The type of antibody and the specific antigen/epitope 
in the serum may also aid in differentiating between past and present infection. For 
instance, IgA and IgM antibodies have a half-life of five to six days, hence they are 
markers of active chlamydial infection [355], while IgG are markers of previous or 
long-term infections [356]. 
Van den Broek et al. [357] analyzed the association of serum IgG, serum IgA,
mucosal IgG and mucosal IgA with infertility and active C. trachomatis infection. 
The anti-chlamydial antibodies obtained from the sera and vaginal swabs of infertile 
women attending fertility clinics (n=85) and women attending STI clinic (n=117) 
demonstrated strongest correlations between infertile participants and serum IgG and 
mucosal IgA (P<0.001), but not mucosal IgG. Similar results were reported for 
women recruited from STI clinics with active infection (PCR positive), who showed 
strong associations to serum IgG, IgA and mucosal IgA, but not mucosal IgG. This 
shows that serum IgG had stronger associations with current or past infections, and 
local IgA had a better diagnostic predictive value than mucosal IgG in detecting tubal 
pathology. In women with a history of PID, immunofluorescence test revealed that 
although the proportion of serum IgG was higher than serum IgA and cervical IgA, 
there was a correlation between both serum antibodies [358]. Although IgA 
antibodies have also been implicated in chronic infection as reliable markers of 
persistent infection [356], the findings by Muvunyi et al. [359] contradict previous 
studies by showing that the role of IgA is negligible in chronic C. trachomatis
infection in women. IgG antibodies were also so found to be higher in women with 
tubal occlusion or with prior ectopic pregnancy [360]. Additionally, In sub-fertile 
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women, the IgG seroprevalence ranged between 17.3% to 18.8% and IgA 
seroprevalence rates was 7.4% [359]. 
Regardless of test performance, numerous studies have identified a correlation 
of Chlamydia serology positivity (Chlamydia antibody testing: CAT) with diagnosed 
tubal factor infertility (typically using a case: control design of tubal infertility 
compared to other causes of infertility). These studies include the following: a 
significantly higher percentage of women with tubal pathology were CAT positive 
(50.2%, n=141) compared to infertile for other reasons (29.6%, n= 326, p<0.001) 
using microimmunoflourescence (MIF) [361]. In a separate study high CAT titres 
using MIF correlated with presence of tubal damage (n=434) compared to all women 
with infertility n=1006 (p<0.001), as did pelvic adhesions [362]. The study further 
demonstrated that participants with tubal damage (median 1:1024) had significantly 
higher titers than participants with endometriosis (median <1:64) (P<0.001). The 
degree of tubal adhesion also positively correlated with C. trachomatis seropositivity 
[363]. Thus, the level of antibody titers is instrumental in diagnosing the type of 
infertility. Another study reported that CAT (MIF) was 74% sensitive and 93% 
specific for detection of tubal disease (total 210 patients) p<0.001 [364]. In contrast, 
a study by Muvunyi et al. [359] reported that the sensitivity and specificity of three 
different chlamydial ELISAs in detecting C. trachomatis infection in subfertile 
women from Rwanda was low compared to the fertile post-natal controls (n=312).
The study concluded that Chlamydia is not a major cause of tubal pathology in this 
population because despite having high proportion of tubal pathology among infertile 
participants (185 of 303 infertile participants), the prevalence of C. trachomatis
infections were reported to be low in this cohort.
The Microimmunofluorescence (MIF) test developed by Wang and Grayston 
[366] showed a high sensitivity and it is still considered the serologic “gold 
standard”. However, it is labour intensive and highly subjective [2]. Enzyme linked 
immunosorbent assay (ELISA), overcomes the problems posed by MIF and further 
enhances the specificity to C. trachomatis with the help of recombinant chlamydia 
antigens [367]. ELISA-based serological tests are capable of detecting C. 
trachomatis antibodies in a large number of samples, and are less expensive, rapid 
and less labour intensive than MIF [2]. Serological assays are instrumental in 
identifying novel antigens that are specific to C. trachomatis. 
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The commercial ELISAs are generally based on recombinant peptide antigens 
derived from immunodominant antigens such as cHSP60 and MOMP (major outer 
membrane protein). The MEDAC pELISA (MOMP peptides) in the Netherlands was 
able to predict tubal disease in infertile women (n=40 CAT positive, compared to 
n=167 CAT negative) with a sensitivity of 0.37 (95% CI: 0.26-0.49) and specificity 
of 0.88 (95% CI 0.82-0.92) [368]. IgA reactive with MOMP has been detected in the 
urogential tract, which suggest that MOMP might confer protective immunity and 
maybe associated with host clinical outcomes [369]. Among the serological 
diagnostic techniques, the majority of the studies have demonstrated that ELISA had 
a higher sensitivity and specificity compared to MIF [370, 371]. Furthermore, it was 
also reported that in asymptomatic infertile women, a decline of IgG antibody titers 
were observed after a 4-7 year interval by MIF, however, it was not reflected in the 
ELISA [372]. Thus, it highlights the credibility of MIF in detecting tubal infertility 
after a long-term persistent infection. Additionally, comparison of MIF positive 
subfertile participants with MIF negative subfertile participants revealed a significant 
difference in the prevalence of C. pneumoniae antibodies (P<0.0005), which 
indicates a high rate of cross-reactivity between C. trachomatis and C.pneumoniae
[373]. However, a meta-analysis of individual patient data found that the diagnostic 
accuracy of MIF in diagnosing tubal pathology was significantly better than accuracy 
of ELISA and IF alone [374]. In another study, the performance of six enzyme 
immunoassays were compared on women with ectopic pregnancy (n=90), infertility 
(n=187), and PID (n=33), and MEDAC MOMP ELISA was reported to have highest 
specificity (97.2%) and showed a high correlation to whole inclusion 
immunofluorescence (correlation coefficient =0.7)[375]. This was supported by 
another study that showed that the MEDAC MOMP pELISA was the best of three 
ELISAs (compared with Savyon and Labsystems) for detection of tubal pathology in 
infertile women at a fertility treatment clinic with 55% sensitivity and 87% 
specificity [376]. The same study compared two MIF tests (n=315, with 51 tubal 
pathology cases) reported that with a cut-off titre of 1/64 the Biomerieux test had 
71% sensitivity and 74% specificity, compared to 47% sensitivity and 95% 
specificity for the Labsystems test [376]. Bax et al. [377] compared the performance 
of a Chlamydia enzyme immunoassay (EIA) (ANILabsystems), MEDAC MOMP 
pELISA and MIF in women with subfertility (n=76)and reported that despite its low 
sensitivity (36.4%), MEDAC MOMP had the highest specificity (85.7%). Therefore, 
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making MEDAC MOMP a good alternative for MIF in detection of chlamydial 
infertility. However, a meta-analysis conducted in 2011 compared MIF and several 
ELISA and found that MIF had the highest accuracy (area under the curve) for 
detection of tubal pathology P<0.001, and P=0.01 (for bilateral occlusion) [374]. 
Although, MIF is still considered a ‘gold standard’, ELISAs also show great promise 
as a diagnostic tool for C. trachomatis- related infertility due to its ease of use and its 
ability to exploit a wide range of antigens to achieve high sensitivity and specificity. 
One of the important markers for C. trachomatis sequelae is the Chlamydia
heat shock protein 60 (cHSP60) [378]. Antibody responses to cHSP60 was detected 
in women with Chlamydia-associated tubal infertility (n= 72) with a sensitivity and 
specificity of 81.3%, and 97.5% respectively. However, these women were first 
tested by laparoscopy for tubal damage and for a positive result in the MIF 
serological assay to assign case group before testing the ELISA so this study has 
likely over-reported the test performance [379]. In a subsequent study of a further 77 
participants this group further reported that cHSP60 antibodies were 92% specific 
and 44% sensitive for tubal factor infertility [380]. cHSP60 ELISA positivity was 
also found to be significantly more frequent in women with tubal factor (n=88) 
compared to controls of infertile women with other know factors for infertility or 
healthy blood donors (n=163) (43.2% vs 13.5%) in a study conducted in Helsinki 
[381]. Although, antibody response to cHSP60 is expected to be abundant in the 
serum of C. trachomatis infected women, it was found that contrary to expectations, 
anti-cHSP60 antibodies were not detected in women infected less than four months 
and a very small proportion (18%) were found in patients with PID, multiple 
infection and post infection [382]. In addition to cHSP60, antibody response to
cHSP10 exhibited a strong correlation to women with TFI (n=33) when compared to 
women with acute C. trachomatis infections (n=139) (P<0.001) [383]. Serological 
analysis of infertile women before their initial IVF cycle revealed that antibodies to 
cHSP10 was more predominant in women with hydrosalpinx (46.8%) than in women 
with tubal occlusion (P=0.0009; 15.5%)[179]. Antibodies to cHSP10 had a 
sensitivity of 41.7% and a specificity of 86.1% in detecting women with ectopic 
pregnancy (n=72), however it was reported to have high cross-reactivity with C. 
pneumoniae (78.4% identity) and 14.5% of the participants showed cross-reactivity 
[304]. Persson et al. [384] reported that in addition to correlating with women with 
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TFI (n=163; rs = 0.46, P <0.001), cHSP60 antibodies showed no correlation with C. 
pneumoniae (rs = 0.17, P =0.03).Women with secondary tubal infertility were 
reported to have a higher number of anti-cHSP60 (54.8%, 30%) or cHSP10 (40.5%, 
26.7%) than women with primary infertility, of which higher specificity was 
obtained for cHSP60 [378]. Hence, a commercial ELISA screening test has been 
developed using cHSP60 (Medac) to facilitate easy diagnosis of C. trachomatis. 
Thus, the Medac-cHSP60 assay is not the preferred diagnostic technique as it has a 
sensitivity of only 69% and specificity of 93% [126].
Identification of novel antigens associated with chlamydial infertility
In addition to cHSP60, several new antigens have been discovered that could 
improve the serological approach for diagnosing tubal pathology associated with C. 
trachomatis in women. Antigens used in combination have proved to be more 
specific and sensitive than those used alone in serological diagnosis, at least in 
research studies, although large scale commercial or clinical trials have not yet been 
reported with many of those discussed here. Rodgers et al. [385], conducted a 
genome wide identification of antigens, using a proteome array containing individual 
chlamydial GST (glutathione-S transferase) fusion proteins, and the serological 
response in women with TFI (n=31) and infertile women with no TFI (n=25) was 
estimated. The study reported that a high antibody titer to C. trachomatis (P<0.001) 
as compared to C. pneumoniae (P=0.269) was obtained in participants with TFI, the 
study further identified 10 antigens specific only to the participants with TFI (CT110 
(HSP60), CT322, CT376, CT381, CT414, CT443, CT681, CT795, CT798, and 
CT813). While these antigens maintained 100% specificity, combination of all 10 
antigens yielded a sensitivity of 67.7% (n=21). However, the sensitivity was also 
maintained with the combination of four antigens (HSP60, CT376, CT381 and 
CT798) and two antigens (CT443 and CT381). Interestingly, Combination of CT443 
and CT381 yielded higher specificity and sensitivity than other techniques used to 
diagnose tubal infertility, such as hysterosalpinogram (sensitivity=65%; specificity 
=83%) and Hsp60 (sensitivity=35.5%; specificity =100%)[386]. Using the same 
glutathione-S-transferase fusion protein microplate ELISA as in the previous study, 
Budrys et al. [387] reported that combination of HSP60, CT376, CT557 and CT443 
identified women with TFI from fertile controls with a sensitivity of 63% and 
specificity of 100%. Furthermore, the study also reported that a combination of 
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CT875 and CT147 identified women with acute C. trachomatis infection from 
women with C. trachomatis indued TFI with a sensitivity of 63% and specificity of 
100%. Other immunodominant antigens include OmcB [388] [identified through 
fusion protein microplate ELISA]; CT795 [369, 389], CT089[369], CT694 [369]
[identified using microplate array with 156 chlamydial fusion proteins] and Pgp3
[390] [identified through western blotting and indirect ELISA]. CT147 and CT314 
found in female patients are associated with multiple C. trachomatis infections [382]. 
CT396 antigen is conserved between C. trachomatis and C. pneumoniae, while 
CT157 is the least conserved antigen between the chlamydial species and it is greatly 
decreased in C. pneumoniae [382]. Using two-dimensional proteomic analysis and a 
novel line immunoassay, Forsbach-Birk et al. [353] identified proteins such as PmpD 
(polymorphic membrane protein D) (sensitivity =71%; specificity=82%) and OMP2 
(outer membrane protein) (sensitivity=94%; specificity =100%) that had high 
sensitivity and specificity in PCR-confirmed women with upper genital tract 
infection (n=20). Another immunodominant antigen is Pgp3, which is a plasmid 
encoded, membrane associated protein that is found within the chlamydial inclusion 
[391]. Among the antigens (OMP2, LPS, cHSP60) analysed using serum ELISA, 
pgp3 exhibited the highest specificity (89%) for C. trachomatis infection [391]. The 
IgG pgp3 antibody responses were evident in patients seropositive for C. 
trachomatis, but not in patients whose serum contained C. pneumoniae antibodies. 
This suggests that pgp3 antigen is specific for C. trachomatis infection in the human 
genital tract [391]. Furthermore, the immunization of mice with pgp3 inhibited the 
spread of C. trachomatis infection from LGT to UGT in C3H/ HeN mice [392]. 
Although the pgp3 antibody response is reported to be specific to C. trachomatis in 
humans, it is also evident in majority of chlamydial infected animals, hence the 
degree of cross-reactivity between different species need to be evaluated [370]. 
Proteomic techniques have been widely used to identify novel 
immunodominant antigens. Protein microarray technology is valuable in serological 
diagnosis because it is a rapid technique that involves a semi-quantitative antibody 
detection and requires low volume of sera [2]. In addition to protein microarray 
techniques, a general proteomic approach to identifying novel antigens include 
protein solubilisation and digestion, isolation of immunoreactive proteins using 
western blot or two-dimensional blots, identification of proteins by Mass 
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spectrometry analysis followed by protein expression, purification and testing [353, 
393, 394]. Using this technique, several antigens such as MOMP, OMP2, cHSP60, 
PmpD, TARP, TSAP, RpsA and HP 17 have been identified and evaluated for 
diagnostic purposes [353]. Therefore, by identifying novel antigens and developing 
specific-peptide based serological assays, the sensitivity and specificity of the 
chlamydial diagnosis could be enhanced.
The value of serological diagnosis in C. trachomatis-related tubal factor 
infertility 
Infertility is estimated to affect 8%-12% of the population worldwide, and in 
high prevalence regions, the rates of infertility could reach upto 30% [395]. Tubal 
pathology are among the most common causes of infertility and it affects 30%-35% 
of couples [396]. A mathematical model, including a number of assumptions, and 
adjusting for serology test sensitivity and specificity estimated that 45% of tubal 
factor infertility episodes are likely to be attributable to C. trachomatis (CI: 28-62%) 
[103]. Currently, the techniques that are used to diagnose C. trachomatis-related 
tubal infertility are laparoscopy and hysterosalpinography (HSG). Laparoscopy is the 
gold standard for diagnosing tubal infertility, however it is invasive, expensive, can 
lead to major surgical complications [1] and are prone to misdiagnosis [397].
Hysterosalpinography is commonly used in the detecting tubal pathology [364] and 
based on the meta-analysis of seven primary articles (n=4521), its sensitivity and 
specificity in detecting tubal occlusion was 53% and 87% respectively [398]. 
However, several studies [396, 399] have demonstrated that HSG has lower 
diagnostic accuracy than laparoscopy. Additionally, they cannot detect adenxal and 
peritubular adhesion [399] and may not be effective in detecting bilateral tubal 
occlusion.
As desribed previously, CAT has also emerged as one of the techniques that 
can effectively diagnose tubal infertility in women. Thomas et al. [400] demonstrated 
that CAT could potentially replace laparoscopy in routine testing as it is non-
invasive, cost-effective and was able to identify women with tubal damage from 
those without (P<0.001). It was also reported that HSG followed by CAT did not 
provide additional diagnostic value in detecting tubal pathology [401]. Additionally, 
The receiver operating (ROC) curves obtained from meta-analyses of 188 studies 
revealed that the discriminative capacity of CAT using MIF, immunofluorescence 
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and ELISA were comparable to that of HSG [402]. Dabekausen et al. [403] showed 
that in 112 infertile women, CAT had a higher positive likelihood ratio as compared 
to HSG in detecting TFI (9.1 vs 2.6). Johnson et al. [404] used ELISA for CAT and 
validated with MIF and reported that in women with tubal disease (n=36), a negative 
predictive value of 81% was obtained for CAT which was significantly higher than 
when clinical features were analyzed (61%). 
The diagnostic performance of CAT could be augmented by complementing 
the assay with medical history. Coppus et al. [368] demonstrated that using CAT or 
medical history alone in 207 subfertile women, yielded low sensitivities of 37% and 
38% respectively, but on combination, the sensitivity increased to 54%. In another 
study, the seropositivity of C. trachomatis (ELISA) in women with a history of 
infertility (n=50) and women with more than three abortions (bad obstetric history) 
(n=80) was 35% and 62.5% respectively [405]. While healthy fertile women (n=50) 
and women with a history of fewer than two abortions showed low seropositivity of 
4% and 7.3% respectively [405]. In addtion to gynecological history, risk factors 
such as smoking can be identified through medical history. Smoking was identified 
as a risk factor in C. trachomatis-induced tubal infertility (P<0.001) [362]. 
Although, serological diagnosis could identify tubal pathology in women and 
recommend IVF treatment, they may not be able to predict the outcome of the 
treatment. A prospective observational study at a reproductive health centre in New 
York used MIF serological prediction of previous C. trachomatis infection to 
compare with infertility diagnosis and treatment outcomes. A total of 1279 
participants were screened and 70 (5.5%) were positive for C. trachomatis [185]. Of 
those selected for investigation of tubal disease seropositive women were 
significantly more likely to have hysterosalpingography detected tubal blockage 
(37.5% compared to 10.1%; P= 0.001) or laparoscopically diagnosed tubal damage 
(85.7% compared to 48.9%, P= 0.002) [185]. In women with secondary infertility 
(n=40), 63% of women seropositive for C. trachomatis had tubal occlusion [406]. 
Seropositive women also had 57% less pregnancy rates than seronegative women 
prior to IVF but once IVF treatment commenced they were equally likely to conceive 
by IVF as women with other causes of infertility [185]. Concurrent with previous 
findings, Barberyrac et al. [186] showed that the presence of past or current C. 
trachomatis did not affect the IVF outcome of subfertile couples as the number of 
Chapter 2: Literature Review 62
oocytes retrieved, fertilization rate, the mean embryos transferred and transfer rate 
was not different between C. trachomatis- positive and C. trachomatis- negative 
women. Combined, these studies provide substantial evidence that a past history of 
chlamydial infection is significantly associated with tubal pathology and infertility in 
women, regardless of serological assay performance. However, they do not allow us 
to determine how frequently this tubal infertility is an outcome of primary infection, 
and therefore the attributable risk of Chlamydia for infertility is not known. 
In a 2002 survey, Collins [407] estimated that the cost of a single IVF cycle 
varied between countries, the most expensive being USA with each cycle costing 
upto $9547 and the average cost from 25 countries were estimated at $3518. As the 
costs associated with Assisted reproductive technologies (ART) are high and a pose a 
significant economic burder on the health care systems, it is important to ensure that 
the diagnostic techniques used to evaluate tubal infertility are highly sensitive and do 
not yield false positives. Thus, there is a need to develop a serological diagnostic 
technique that could detect C. trachomatis-related infertility that would result in 
recommendation for progress directly to IVF, without additional diagnosis by 
laparoscopy/dye studies. Additionally a serological assay would be non-invasive, 
cost-effective and that could be widely applied in early infertility investigation in 
IVF clinics.
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3.1 GENERAL STOCKS AND SOLUTIONS 
3.1.1 10X Phosphate buffered saline 
10X Phosphate buffered saline was prepared by a combination of 0.007M of 
disodium hydrogen phosphate (Na2HPO4.H2O), 0.027M sodium hydrogen phosphate 
(NaH2PO4.H2O), 1.37M of sodium chloride (NaCl) and 800mL of distilled water. 
The pH was adjusted to 6.6 and the final volume was topped up to 1L. 
3.1.2 Phosphate Buffered saline (PBS)
Phosphate Buffer Saline (PBS) was prepared from 10X stock by adding 100ml 
of 10X PBS to 900mL of distilled water. The pH was adjusted to 7.3. For cell 
culture, PBS was autoclaved at 121qC for 15 minutes prior to use.
3.1.3 1X PBS-Tween (PBST)
PBST was prepared by adding 0.1% Tween 20 to 1XPBS. The solution was 
stored at room temperature. 
3.1.4 2X PBS-Tween (PBST)
2XPST was prepared by diluting 10XPBS stock in the ratio 1:5 with distilled 
water (200mL of 10 X PBS in 800 mL of distilled water) and 0.1% Tween 20. 
3.1.5 Sucrose Phosphate Glutamate (SPG)
SPG was prepared by adding 10mM sodium phosphate (Na3PO4), 250mM 
sucrose and 5mM L-glutamine. The pH of the solution was maintained at 7.2 by 
addition of 1M sodium hydroxide (NaOH). The solution was filter sterilized and 
stored at 4°C. 
3.1.6 3,3,5,5- Tetramethyl benzadine (TMB)
TMB stocks were prepared by dissolving 0.1g of TMB in 10mL Dimethyl 
sulfoxide (DMSO). The solution was stored at room temperature and it is light 
sensitive.
3.1.7 Red blood cell (RBC) lysis buffer
RBC lysis buffer was prepared by adding 155mM Ammonium chloride 
(NH4Cl), 10mM Sodium bicarbonate (NaHCO3) and 0.1mM of 
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Ethylenediaminetetraacetic acid (EDTA). The solution was prepared by adding 1L of 
milli-Q water and the pH was adjusted to 7.4. The solution was filter sterilized (0.22 
µm filter) and stored at 4qC. 
3.2 HUMAN CELL LINE CULTURE AND MAINTENANCE 
3.2.1 Fetal Calf serum (FCS)
Heat inactivated Fetal calf serum (Lonza, Mt. Waverly, Victoria) was added to 
cell culture media. FCS was heat inactivated by placing the bottle in water bath at 56 
°C for 42 minutes. 
3.2.2 Growth Media
Dulbecco’s Modified Eagle Medium (DMEM) was used as a culture medium 
for McCoy and HeLa cells. The media was supplemented with 10% Heat inactivated 
Fetal calf serum (HI-FCS) (Lonza, Mt Waverly Australia), 25µg mL-1 Gentamycin 
(Invitrogen) and 100µg mL-1streptomycin sulphate (Sigma-Aldrich).
3.2.3 Cell lines
Cell lines used in this project were obtained from American Type Culture 
Collection (ATCC). Hep-2 (ATCC CCL-23), human adherent epithelial cells and 
McCoy B (ATCC CRL-1696), mouse adherent fibroblast cells, THP-1 (ATCC TIB-
202), human peripheral blood monocyte cells were used in this study. For McCoy 
and HeLa cells, DMEM supplemented with FCS, gentamycin and streptomycin were 
used. THP-1 cells were grown in RPMI 1640 medium with 2mM L-glutamine and 
10% FCS. THP-1 cells were made adherent using PMA (phorbol myristate acetate) 
treatment. All three cell lines were cultured in 175cm2 tissue culture flasks (BD 
Bioscience, North Ryde, Australia) with their appropriate growth media at 37°C and 
5% CO2 . They were periodically tested for Mycoplasma spp. contamination using 
PCR in section 3.2.4.
3.2.4 Testing of Mycoplasma spp. in human cell lines
All cell lines were tested for Mycoplasma spp. contamination by PCR 
periodically. The cells were cultured in 175cm2 tissue culture flasks (BD Bioscience, 
North Ryde, Australia) for 24 hours until they were confluent. On achieving the 
confluency, the cells were dislodged by adding 1mL Trypsin (Invitrogen) and 
incubating for 5 minutes at 37qC. The DNA was extracted using the QIAamp DNA 
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mini kit (Qiagen, Victoria, Australia). The primers for PCR was a universal primer 
targeting the conserved 16s rRNA gene of Mycoplasma spp. Cycling conditions was 
initiated at 94qC for 3 minutes, followed by denaturation at 94qC for 60 seconds, 
annealing at 55qC for 30 seconds and extension at 72 qC for 60 seconds repeated for 
a total of 32 cycles. The amplicon size was 425bp and it was verified on an agarose 
gel electrophoresis. 
3.3 CHLAMYDIA STRAIN CULTURE 
C. trachomatis D (ATCC VR-885) and F strain (ATCC VR-346) were cultured 
in McCoy cells. Confluent cells were infected with the strains and incubated at 37qC 
for 44 hours. The infection was enhanced by centrifugation at 500 u g at 25qC for 60 
minutes. The media was changed after four hours of infection and 1mg mL-1
cycloheximide was added along with the fresh media to control further propagation 
of McCoy B cells. Following infection, the strains were harvested and semi-purified 
or ultra-purified as described in section 3.3.2. 
3.3.1 Semi-purification of Chlamydia strains 
The infection was stopped by removing the media and adding cold SPG. The 
cells were dislodged using cell scraper and homogenized using glass beads. The 
samples were centrifuged at 300 u g for 5minutes at 4qC to pellet the cell debris. The 
supernatant was removed and centrifuged at 18,000 u g for 30 minutes at 4qC to 
pellet the semi-purified chlamydial strains. The pellet was resuspended in SPG and 
stored at -80qC. The semi-purified Chlamydia strains may contain host cells, which 
was removed through ultra-purification. 
3.3.2 Ultra-purification of Chlamydia strains 
The semi-purified Chlamydia strains were further purified through Ultra-
purification. 500U/mL of Heparin, 10mM/mL MgCl2, 40U/mL DNase I were added 
to the semi-purified Chlamydia strains and incubated at 37qC for 30 minutes. A 
density gradient was prepared by adding 29% v/v urografin Ultravist® (Bayer, USA) 
in ultracentrifuge tubes Optima® L-90K ultracentrifuge (Beckman Coulter, 
Gladsville, Australia). The strains were centrifuged at 335 u g for 5 minutes and the 
supernatant was layered on top of the 29% v/v Ultravist solution and the tube was 
topped up with 1xPBS. The solution was centrifuged at 70,000 u g (20,000 rpm 
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using SW-40) for 35 minutes at 4qC. The Chlamydia that has been pelleted was re-
suspended in SPG and it is devoid of host debris. 
3.3.3 Quantification of C. trachomatis
To quantify the amount of C. trachomatis yielded during an infection, 96-well 
plates were seeded with Hep-2 cells and incubated for 24 hours at 37qC. After 
obtaining 90% confluency, the cells were infected with several dilutions (ten-fold 
dilutions) of C. trachomatis stored in SPG. The plates were centrifuged at 500 u g for 
30 minutes at 25qC to enhance the infection and the media was replenished after 4 
hours of infection with 1mg mL-1 cycloheximide. After 24 hours of incubation, the 
media was removed and cells were washed with sterile PBS. The cells were fixed 
with 100% methanol for 10 minutes and subsequently washed with PBS. The plates 
were then permeablised with 0.5% Triton-X and blocked overnight with 1% Bovine 
serum albumin (BSA). The cells were incubated at room temperature for 1 hour with 
1:500 of primary antibody anti-HtrA rabbit sera and 125ng/mL of 4’,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Invitrogen). The cells were washed with 
PBST (0.2% v/v Tween-20) and treated with 1:600 dilution of secondary antibody 
goat anti-rabbit IgG (H+L)- Alexa Flour 488 (Invitrogen), incubated at room 
temperature for 1 hour. The plates were washed thoroughly with PBS, and stored in 
PBS solution at 4qC in the dark. 
The plates were viewed under a Nikon Eclipse TE2000-U fluorescent inverted 
microscope with Nikon Digital Eclipse DXM 1200C camera (Nikon Pty Ltd, 
Lidcombe, Australia). The chlamydial inclusion- forming units (IFU) were 
determined using a Metamorph Imaging series 7.6 software (Molecular Devices, 
Sunnyvale, USA). The IFU/well was determined by multiplying the average 
IFU/FOV (field of view) x Total FOV/well. The IFU/mL was determined by 
multiplying the IFU/well with the dilution factor of 1000, and dividing it by the 
volume of strain aliquoted in each well.
3.4 SEROLOGICAL DIAGNOSIS OF C.TRACHOMATIS AND 
C.PNEUMONIAE INFECTIONS USING COMMERCIAL KITS
Serological assays are a useful technique in diagnosing ectopic pregnancies, 
pelvic inflammatory diseases and recurrent miscarriages [2]. The presence of C. 
trachomatis specific antibodies in the participant sera was tested using commercial 
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serological assays such as MEDAC C. trachomatis IgG p-ELISA (Medac GmbH, 
Wedel, Germany), MEDAC cHSP60 IgG p-ELISA (Medac GmbH, Wedel, 
Germany), ANILabsystems C. trachomatis IgG ELISA and 
Microimmunofluorescence (MIF) IgG assay. The presence of IgG antibodies against 
C. trachomatis indicates previous exposure to C. trachomatis. Since MIF is 
considered a gold standard among chlamydial serological assays, the assay was 
included in cohort definition and participants positive for C. trachomatis MIF assay 
were considered positive for C. trachomatis infections. The diagnostic performance 
of the in-house peptide ELISA on the cohorts was compared to existing commercial 
chlamydial serological assays. 
3.4.1 MEDAC serological assays
The MEDAC serological assays used in this study were C. trachomatis IgG p-
ELISA and MEDAC cHSP60 IgG p-ELISA. The MEDAC C. trachomatis IgG p-
ELISA is based on the peptides derived from immunodominant antigen MOMP 
(major outer membrane protein). MEDAC cHSP60 IgG p-ELISA is based on 
cHSP60, an immunodominant antigen associated with chlamydial infertility [270, 
380].
According to the recommended guidelines by The Dutch Society for Obstetrics 
and Gynaecology, the absorbance values of MEDAC C. trachomatis IgG p-ELISA 
greater than 1.1 could be used to determine the potential risk of infertility and could 
be used as a first line of investigation for subfertile couples [409]. Additionally, 
guidelines by MEDAC manufacturer’s highlight that positive outcomes in both 
MEDAC assays in participant sera indicate a high risk of C. trachomatis induced 
infertility (Referred to as MEDAC infertile in this study). Therefore, the sera from all 
cohorts were tested with Chlamydia trachomatis-IgG ELISA-plus MEDAC 
(specificity=87%; sensitivity=55%; determined against women with infertility 
(n=315)) [410] and cHSP60-IgG ELISA MEDAC (cHSP60 protein) (specificity = 
93%; sensitivity=69% determined against women with tubal factor infertility (n=70))
[126].
The assay was validated by the mean absorbance values of negative (<0.1) and 
positive control (<0.8). The cut off was determined by adding the mean absorbance 
value of negative control to a previously established value of 0.34 and 0.35 for 
MEDAC IgG C. trachomatis pELISA (MEDAC MOMP) and cHSP60 IgG ELISA 
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(MEDAC cHSP60) respectively. The absorbance values of participant sera that were 
above the cut-off value was considered positive for C. trachomatis infection, while 
those whose absorbance values were below the cut-off value were considered 
negative for C. trachomatis infections. The absorbance values of those participants 
that were within 10% less than and more than the cut-off value were considered to be 
in the grey zone. The samples that were in the grey zone were considered as 
equivocal (neither positive nor negative) for the test and the testing was repeated on 
the sera. 
C. pneumoniae in the serum was tested using Chlamydia pneumoniae IgG 
ELISA plus MEDAC. The assay uses a purified C. pneumoniae antigen. The assay 
was validated by the absorbance value of a negative (<0.1) control and the lot–
specific absorbance value of positive control. The mean OD value of calibrator was 
also lot-specific and the absorbance was corrected by dividing the nominal 
absorbance value of the calibrator (lot-specific) by the measured absorbance value of 
the calibrator. The concentration was determined using the formula: concentration 
[AU/mL]= b/(a/OD corrected-1); a and b were arbitrary values specific to the lot that 
was used for the assay. The cut-off value was set at 25 AU/mL and the absorbance 
values of sera that were above the cut off value was considered positive for C. 
pneumoniae infection and those that were below the cut-off value were considered 
negative for the infection. 
3.4.2 ANILabsystems C. trachomatis serology kits
The sera was also tested with another commercial serological assay, 
ANILabsystems C. trachomatis IgG ELISA, which is based on synthetic peptides 
from C. trachomatis -specific variable domain of MOMP (major outer membrane 
protein). The specificity and sensitivity of the assay was estimated to be 84% and 
86% respectively, by screening the sera of 330 women with infertility and PCR 
diagnosed C. trachomatis infection [365]. The assay was considered valid if the 
mean absorbance value of negative control was < 0.2 and the mean absorbance of the 
positive control was between 0.7 and 2, and the calibrator values lay between 0.4 and 
1.2. The participants were considered negative for C. trachomatis infection if the 
Signal (S)/ Cut-off (CO) was <1 and positive for the infection if the ratio was above 
1.4.
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3.4.3 C.trachomatis IgG Microimmunofluorescence assay (MIF)
Microimmunofluorescence assay was used to characterize the participants as 
serologically negative or positive for C. trachomatis IgG antibodies. The Focus 
Diagnostics Chlamydia MIF IgG assay (mdi Europa GmnH, Langenhagener, 
Germany) comprised of a slide with twelve wells. Each well constitutes elementary 
bodies of a single strain of C. pneumoniae, 2 strains of C. psittaci and 8 serotypes 
(D-K) of C. trachomatis. Chlamydial elementary bodies devoid of interfering LPS 
were diluted in 3% yolk sac served as a control for background fluorescence. The 
detectable control served as the positive control while non-detectable control was the 
negative control. The sera were loaded onto the slide and incubated at 37qC for 30 
minutes. The plates were then rinsed with PBS and treated with IgG conjugate for 30 
minutes at 37qC. The slides were rinsed again with PBS and mounting medium was 
added onto the slide and covered with 24x50mm coverslip. The slides were 
subsequently viewed under a fluorescence microscope at a final magnification of 
400X.
3.5 IN-HOUSE PEPTIDE ELISA
The in-house peptide ELISA developed through this study was based on 
peptides selected through bioinformatics analysis from a series of 55 unique peptides 
that showed serological response to C. trachomatis. Stansfield et al. [411] developed 
and designed the peptides that was capable of distinguishing women with C. 
trachomatis-related infertility from those without. The methodology is outlined as 
follows. 
3.5.1 Peptide identification and design for in-house ELISA
The peptides were derived from immunodominant proteins such as HtrA (High 
temperature requirement protein), cHSP60 (chlamydial heat shock protein 60) and 
CT443 (outer membrane chlamydial protein). The B cell epitopes, antigenicity and 
hydrophilic domains were identified using software such as BepiPred algorithm 
software, antigenicity prediction software respectively [412]. The specificity of the 
linear B cell epitopes were tested using BLAST and the peptides were selected if 
their E values were <0.0004 for C. trachomatis and >0.1 for C. pneumoniae. The 
epitopes were used to design a series of peptides. The peptide epitopes were 
synthesized commercially using solid phase synthesis onto a Biotin-SGSG motif 
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(Mimotopes, Melbourne, Australia) and solubilized in 50% isopropanol overnight to 
make up a concentration of 1mg ml-1. 
The serological responses of the peptides to C. trachomatis-related infertility 
were tested using an ELISA format and screened against 39 participant sera 
belonging to five cohorts. The five cohorts included sequelae (tubal factor infertility, 
ectopic pregnancy, PID), acute, multiple, negative (infertile but C. pneumoniae
seropositive) and negative (seronegative for C. trachomatis and C. pneumoniae, 
infertile but no tubal damage). The peptides that obtained a higher absorbance in the 
sequelae cohort as compared to negative and acute cohort (>0.015), and obtained an 
absorbance <0.015 between the two negative cohorts were chosen to design the in-
house ELISA. Based on these criteria, peptides HSP60-E2 [SGSGVFSSPPFSNKPP-
NH2](derived from chlamydial heat shock protein 60), 443-N2 
[SGSGPVSFSGPTKGTIT-NH2] (derived from outer membrane protein Ct443) 
and 443-A3 [SGSG VDRKEVAPVHES –NH2](derived from outer membrane 
protein Ct443) were selected for in-house peptide ELISA. One of the higher 
performing peptide, peptide 11 (ADTRGILVVAVE) (derived from HtrA) was tested 
on 129 women with primary and secondary infertility, and a specificity of 95% and 
sensitivity of 46% were obtained on this cohort. In order to improve the sensitivity of 
the assay, peptide based ELISA was designed with peptide 11 in combination with 
peptides from other immunogenic peptide antigens such as Hsp60-E2, 443-N2 and 
443-a3. 
3.5.2 ELISA based on peptide 11 in combination with other immunogenic 
peptides
The biotinylated peptides were coated on high binding capacity streptavidin 
plates (Thermofisher Scientific, Victoria, Australia). Peptide 11, Hsp60-E2, 443-N2 
and 443-A3 at concentration of 1mgmL-1 (0.25µg well-1) was diluted in 1XPBST 
(1:100) and coated separately on each well. The peptides were incubated for 1 hour 
at room temperature. The plates were then blocked overnight with SuperBlock PBS 
(Thermofisher Scientific, Victoria, Australia) at 4qC. The sera was diluted in 
superblock blocking buffer PBS with 0.1% Tween20 at 1:200 dilutions, and 
incubated for 1 hour at 37°C. The plates were rinsed thoroughly with 2X PBST. The 
secondary antibody, goat anti-human IgG HRP was then coated at a dilution of 
1/15,000 in superblock blocking buffer PBS with 0.1% Tween 20. The plate was 
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developed by addition of 100µg/mL of 3,3,5,5-Tetramethyl benzadine (TMB) in 
DMSO dissolved in phosphate citrate buffer with sodium perborate and incubated at 
10 minutes at room temperature. The reaction was stopped with 1M H2SO4 and the 
plates were read on Bio-Rad xMark microplate spectrophotometer at 450 nm. The 
optimization of the assay for superior sensitivity and specificity included assessment 
of the influence of several parameters such as peptide concentrations and 
combinations, dilution of secondary antibodies and peptide solubility. 
3.6 PERIPHERAL BLOOD MONONUCLEAR CELLS ISOLATION
(PBMC)
The PBMC were processed from the whole blood from patients as soon they 
were obtained. The blood was centrifuged at 78 u g for 10 minutes to remove the 
plasma layer. The removal of plasma layer was followed by dilution of the blood 
with 2mL DMEM media. The blood was then layered onto a tube containing 2mL 
Ficoll-PlaqueTM Premium reagent (GE Healthcare). The solution was centrifuged at 
754 u g for 25 minutes at 4qC (deceleration set to zero). The centrifugation separated 
the solution into three layers, of which the middle layer that comprised of the 
lymphocytes was transferred to a tube containing the media. To the solution, 5mL of 
RBC lysis buffer was added to remove the red blood cells. The solution was 
centrifuged at 754 u g for 10 minutes at 4qC, and the pellet was resuspended in 
DMEM. The pellet was washed until it appears white and resuspended in 1mL of 
media. The cells were counted using a hemocytometer and the desired number of
cells were added to the wells and stimulated with the antigen. The cells were 
incubated for 15 hours at 37qC. 
3.7 STATISTICAL ANALYSIS
All statistics (relative risk, sensitivity, specificity, chi squared statistics and 
forest plots) were calculated in the R statistical environment (3.0.1) using the ‘EpiR’
(0.9-48) and ‘metafor’ package (1.9-1) for conducting meta-analyses in R 
(Viechtbauer 2010). Mixed-effects models were used to combine cohort data using a 
fixed-effect model with a restricted maximum likelihood estimate of the log odds 
ratio [413]. All calculations were performed in the R statistical environment (v 3.0.1) 
using the Linear and Nonlinear Mixed Effects Models package ‘nlme’ (v 3.1-111) 
[414] .
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4.1 INTRODUCTION
Sexually transmitted C. trachomatis infections in women can have adverse 
effects on their reproductive health [195]. The infection can manifest as 
mucopurulent cervicitis and urethritis in the lower genital tract. However, it can 
progress to pelvic inflammatory disease (PID), ectopic pregnancy (EP) and tubal 
factor infertility (TFI) in the upper reproductive tract [102]. The risk of developing 
PID after a lower genital tract infection is reported to be 9.5% in untreated women 
(n=1275) [415], and in about 20% of cases, PID leads to tubal pathology [416]. The 
prevalence of tubal factor infertility in sub-fertile couples is reported to be between
10%-30% [417], and analysis of published literature indicate that 45% of TFI is 
caused by C. trachomatis infection [103]. Heinonen et al. [418] reported that C. 
trachomatis was the primary pathogenic agent in 44% of women with acute PID 
(n=72) (laparoscopy confirmed). The study further reported that C. trachomatis was 
more predominant in women with severe PID (n=35) as compared to other 
pathogenic agents such as Neisseria gonorrhea. C. trachomatis was also more 
predominant in women with endometritis (n=26) (p<0.001) than in women without 
endometritis or salpingitis (n=83) [419]. 
The techniques that are used to diagnose tubal fertility are typically 
hysterosalpinography and laparoscopy. Hysterosalpinography (HSG) detects tubal 
patency using oil or water based contrast medium in the uterine cavity and fallopian 
tubes [398]. In a study by Lavy et al. [420], among 23 women who were HSG 
positive for bilateral tubal occlusion, 30% were found to have patent tubes by 
laparoscopy. While in another study, omission of tubal patency verification by 
laparoscopy in 41% (n=126) of participants who were diagnosed for bilateral 
occlusion by HSG, would have resulted in 60% of the participants being 
misdiagnosed [421]. Thus, laparoscopy is recommended for diagnosis of tubal 
pathologies even after HSG treatment. 
Although laparoscopy is considered a gold standard for diagnosing tubal 
pathologies, the invasive nature of the technique increases the risk of complications
[422]. In addition, the high costs associated with laparoscopy (upto $976) limits its 
availability to women in developing nations and low resource settings [423].
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Chlamydia antibody testing (CAT) has been widely employed during the 
infertility investigation to identify women who may have tubal damage [362, 402]. 
Jones et al. [424] established the earliest association of C. trachomatis in TFI women, 
by reporting that antichlamydial antibodies were detected in 35% of infertile women 
(n=172) and 75% of women with tubal infertility. These findings were supported by 
Sellors et al. [425] who reported significantly higher levels of anti-chlamydial IgG 
and IgM (p<0.0001) antibodies in participants with TFI (n=52; 79.1%) as compared 
to participants who are sterile due to tubal ligation (n=114) and have had a 
hysterectomy as a result of PID (n=99). Mol et al [402] showed that although the 
ability of CAT to diagnose tubal pathology did not vary significantly between 
laparoscopically verified tubal pathology and verification of tubal pathology using a 
combination of HSG and laparoscopy (p=0.8). Thus, the diagnostic performance of 
CAT is comparable to both laparoscopy and HSG.
The two main CAT methods are MIF and ELISA. The IgG titers in MIF is 
instrumental in determining the risk of developing tubal damage, as low titers (1:32) 
indicated 5% incidence of developing tubal damage, while titers greater than 1:32 
were associated with tubal pathology (n=57) [400]. In Brazil, MIF assay on a 
relatively small cohort of infertile women (n=33), revealed that 42% of the 
participants had a MIF IgG titer greater than 1:64 and the IgG titer was greater than 
1:128 in women with tubal occlusion (42.4%) and ectopic pregnancy (40.9%) [360]. 
Gijsen et al. [372] compared the MIF test results with ELISA (ANILabsystems IgG 
ELISA) in women with TFI (n=39) and, and reported a decline in MIF IgG titers
from an initial titer of >1:64 after 4-7 years in 18% of the participants, however these 
changes were not reflected in the ELISA and the signal remained the same. Thus, 
ELISAs are capable of detecting past C. trachomatis infection long after the 
infection. Although, MIF is considered the “gold standard”, it is labor intensive, time 
consuming and shows high cross-reactivity between different chlamydial species
Meta analysis of 14 primary studies containing data of 3453 women by Broeze 
et al. [374] showed that the sensitivity and specificity for ELISA, MIF and IF assays 
for any tubal pathology ranged between 23%-91% and 41%-100% respectively, 
while for bilateral tubal pathology the sensitivities and specificities ranged between 
31%-70% and 52%-86% respectively. Thus, this suggests that in order for serological 
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assays to be used for early infertility investigations, the sensitivity and specificity for 
diagnosing tubal pathology need to be improved. 
Although most commercial serological assays are often based on antigens such 
as chlamydial elementary bodies, variable regions of outer membrane protein 
(MOMP) and chlamydial LPS, the sensitivity and specificity of the assays needs to be 
improved. Hence, several novel antigens that are immunodominant in women with 
TFI have been identified that may have diagnostic value. Chlamydial heat shock 
protein has been widely reported to be immunodominant in women with chlamydial 
infertility [126, 179, 380, 387]. Serological analysis of infertile women before their 
initial IVF cycle revealed that antibodies to cHSP10 was more predominant in 
women with hydrosalpinx (46.8%) than in women with tubal occlusion (p=0.0009; 
15.5%)[179]. 
Shaw et al. [426] identified 21 proteins through 2-D electrophoresis and 
MS/MS, and with immunoblotting with the sera from participants with PID, Omp-2, 
HtrA, HSP70 was identified [427]. Forsbach-Birk et al. [428] used two- dimensional 
immunoblot analysis of chlamydial proteins and electrospray ionization MS/MS 
identified MOMP, OMP2 and CPAF to have a specificity of 100% and sensitivities 
of 87%, 90% and 94% respectively in diagnosing women with upper genital tract 
infections (n=33). 
Development of a peptide ELISA involves the following steps; identification of 
immunodominant antigen through proteomic [371, 389, 390] or in silico methods 
[429]; evaluation of immunogenicity of the antigen through western blot [390, 429, 
430] analysis against participant sera from well- defined cohorts; determine the 
performance of the assay by estimating it’s sensitivity and specificity; comparison of 
diagnostic performance of the assay with existing commercial assays [389, 390, 430]; 
and validation of the assay by estimating its reproducibility and testing against a 
separate validation participant set [390, 429, 430]. The diagnostic performance is 
determined by constructing a receiver operating characteristic (ROC) curve which 
establishes a cut-off value based on sensitivity or specificity, and the accuracy is 
determined by the area under the curve (AUC) that usually ranges from 0.5 (least 
accurate) to 1 (perfect test) [431]. Sensitivity is defined as the ability of test to 
correctly classify an individual as diseased (function of true positive and false 
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negative), while specificity is the ability of a test to correctly classify an individual as 
non-diseased (function of true negative and false positive) [432]. 
In this study, an in silico approach was applied to identify and design novel 
peptide antigens that are specific to women with C. trachomatis-related infertility, 
and develop a peptide ELISA that could potentially replace invasive techniques such 
as laparoscopy for the infertility investigation. This is a follow up to the study 
conducted by Stansfield et al. [411] wherein, using an in silico approach, peptide 11 
was identified and its sensitivity and specificity in diagnosing C. trachomatis
associated tubal factor infertility was estimated as 47% and 95% respectively. 
Through this study, the diagnostic performance of peptide 11 ELISA has been 
improved by combination of other C. trachomatis-specific immunodominant peptide 
antigens.
4.2 METHODS AND MATERIALS
4.2.1 Identification of immunodominant peptides specific to C. trachomatis –
related infertility
The ‘initial proof of concept’ of peptide ELISA has been detailed in Materials 
and Methods 3.5. The peptides identified by Stansfield et al. [411] through in silico
analysis were used in this study. The peptides were derived from proteins the targets 
HtrA [433], cHSP60 [387] and CT443 (Omcb) [385, 387] which have been shown to 
be immunodominant in women with tubal factor infertility. The peptides were 
identified from a series of 55 unique peptides that were selected through 
bioinformatic analyses. The B cell epitopes, antigenicity and hydrophilic domains 
were identified using software such as BepiPred algorithm software, antigenicity 
prediction software respectively [412].The peptides selected for diagnostic purposes 
were chosen based on the criteria as outlined in section 3.5.1. The peptides chosen 
were Peptide 11 (ADTRGILVVAVE), Hsp60-E2 (VFSSPPFSNKPP) and 443-N2 
(VSFSGPTKGTIT). The peptides were screened for homology between other 
chlamydial species and the BLAST E values for C. trachomatis were peptide 11, 
HSP60-E2 and 443-N2 were 0.001, 0.0003 and 0.0005 respectively. The BLAST E 
values for C. pneumoniae were 0.11, 0.86 and 12 respectively. The peptides were 
considered specific for C. trachomatis if the E values < 0.004 for C. trachomatis and 
>0.1 for C. pneumoniae. Since all the peptides met these conditions, they were 
selected based on their specificity and antigenicity. The peptide epitopes were 
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synthesized commercially using solid phase synthesis onto a Biotin-SGSG motif 
(Mimotopes, Melbourne, Australia). These peptides were used in combination in 
single-well and in multi-well ELISA formats to optimize the assay for the best 
diagnostic performance in identifying participants with tubal factor infertility. 
4.2.2 Development of In-house peptide ELISA 
The peptide ELISA involves coating of high binding streptavidin plates with 
biotinylated peptides. These peptides were coated individually in separate wells 
(multi-well) and in combination in one well (single well). The specificity and 
sensitivity of both multi-well and single well formats were assessed. The secondary 
antibody used in this study was goat anti-human IgG HRP (1:15,000) (Invitrogen). 
The combination and the multi-well format that had the diagnostic performance was 
designated the QUT Chlamydia infertility test. The peptide ELISA was performed as 
described in 3.5.2. 
4.2.3 Commercial serological assays used to detect acute C. trachomatis
infections and chlamydial infertility 
The commercial assays used in the study have been detailed in 3.4.4. The 
commercial assays include Focus Diagnostics Microimmunofluorescence (MIF) IgG 
assay (described in 3.4.3) (mdi Europa GmnH, Germany), which is considered to be 
gold standard among serological assays in detecting chlamydial infertility. Among 
ELISAs, MEDAC IgG ELISA (MEDAC MOMP) (Medac GmbH, Wedel, Germany) 
and cHSP60 IgG ELISA MEDAC (MEDAC cHSP60) (Medac GmbH, Wedel, 
Germany) was used. A positive result in both MEDAC MOMP and MEDAC 
CHSP60 would indicate that the participants are at a risk of developing TFI and was 
referred to as MEDAC Infertile assay as recommended by manufacturer. 
ANILabsystems C. trachomatis IgG ELISA was also used in the study to determine 
the presence of past C. trachomatis infection. The participants were also tested for C. 
pneumoniae with Chlamydia pneumoniae IgG ELISA plus MEDAC) (MEDAC
GmbH, Wedel, Germany). 
4.2.4 Characterization of participants based on gynecological and C. trachomatis
infection history
The participant recruitment process and the Human research ethics committee 
approval numbers are detailed below. The participants recruited for this study were 
characterized into cohorts based on their gynecological history. Figure 4.1 shows 
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experimental design for the development and validation of QUT Chlamydia infertility 
test.
Determination of sample size of women recruited for development of multi-
antigen peptide ELISA 
The required sample size was estimated based on the method outlined by 
Buderer et al. [434]. Based on a conservative estimate of 7% prevalence chlamydial 
infertility in Australian IVF clinics, the sample size required to yield 98% specificity 
(with 1% precision) would be 120 participants. In order to obtain a 70% sensitivity 
(95% C.I of 58-82%) with 0.12 precision, a sample size of 809 participants would be 
needed. However, despite having several collaborations with hospitals and fertility 
clinics, only 354 participants were included in the study.
Recruitment of women with Tubal Factor Infertility and healthy controls 
Human Research Ethics Committee approval was granted for these, including 
Sexual Health Clinics (Prince Charles Human Research Ethics Committee approval 
number EC2809), Ipswich and West Moreton Health Services District (Human 
Research Ethics Committee approval number (10-09)), Gold Coast Hospital District 
(Human Research Ethics Committee approval number (200893)), Cairns Sexual 
Health Clinic (HREC/09/QCH/4-554), and Ethical approval for the study was 
obtained via Queensland University of Technology Human Research Ethics 
(1300000003 and 080000268). Participants were also recruited from several 
Australian fertility clinics including IVF clinics based in Brisbane (UC Health 
Human Research Ethics Committee approval number 1314) and Melbourne (Human 
Research Ethics Committee approval number 12099). 
The target cohort included women with tubal factory infertility and a history of 
C. trachomatis infections. Women attending IVF clinics who were trying for more 
than a year to conceive were invited to participate in the study. Participants were 
included in the study only after providing written informed and complete a 
questionnaire regarding their history, including factors such as age of the patient, 
number of sexual partners, previous C. trachomatis infections, previous sexually 
transmitted infections, smoking habits and previous record of infertility such as 
ectopic pregnancy and tubal factor infertility.
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Cohort Characterization
The participants were characterized into cohorts based on their disease state-
infertile women recruited from IVF clinics with a history C. trachomatis infections; 
infertile women recruited from IVF clinics with no history of C. trachomatis
infections; women with acute C. trachomatis infections (women recruited from 
sexual health clinics with current C. trachomatis infections as diagnosed by PCR); 
and fertile healthy controls (women recruited from obstetrics clinics with current 
spontaneous pregnancies). 
Infertile cohort: women with infertility (n=97)
Infertility was defined as the inability to conceive after trying for a period of 1 
year or greater. Participants in this cohort were recruited from an IVF clinic based in 
Melbourne (n=97). They were given a unique ID and were informed written consent
was an inclusion criteria. These participants provided a blood specimen for the study. 
The participants were also requested to complete a questionnaire with information 
regarding their fertility and gynecological history. Their questionnaire included 
questions regarding history of gynecological surgeries such as endometrial polyp, 
fibroids, endometriosis, ectopic pregnancy, miscarriages, polycystic ovaries and 
patent tubes. The descriptive analyses of demographic characteristics of participants 
are enlisted in Appendix 8.1.
The participants were divided into TFI cohort and non-TFI cohort based on 
their tubal patency. The tubal patency was determined using techniques such as 
laparoscopy, hysterosalpinography and hysteroscopy. Participants with unilateral or 
bilateral tubal blockage were characterized as TFI positive (n=45). Polycystic ovary 
syndrome and fibroids were common among patients in TFI cohort. The TFI cohort
comprised of women with partial tubal patency (n=3), bilateral occlusion (n=21) and 
unilateral occlusion (n=21). The non-TFI cohort (n=52) comprised of women with 
infertility (infertility associated with other factors and not tubal damage) caused due 
to endometriosis, idiopathic PCO (polycystic ovary syndrome), fibroids or due to 
unknown reasons. 
TFI cohort was further characterized as CT TFI cohort and negatives cohort
based on the C. trachomatis infection status. The positive cohort (n=11) was defined 
by the presence of C. trachomatis specific IgG antibodies in the sera from TFI 
participants as determined by micro immunofluorescence (Focus Diagnostic, USA). 
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The negative cohort (n=251) comprised of TFI participants who were seronegative in 
MIF, and non-TFI infertile participants who were negative all the serological tests. 
Acute infection cohort: women with acute C.trachomatis infections (n=112)
The acute infections cohort comprised of participants with clinically and PCR 
diagnosed acute C. trachomatis infections, with no or minor symptoms reported. A 
total of 112 women between the ages of 22- 53 years with acute C. trachomatis
infections were included in this study. 112 participant sera and their corresponding 
medical history report enlisting their fertility and disease states were collected from 
sexual health clinics and hospitals. 
Healthy cohort: fertile women infections (n=53)
The healthy control cohort comprised of fertile women between the ages of 28-
42 years attending a tertiary care hospital (Brisbane) who have current spontaneous 
pregnancies and were able to get pregnant within less than a year of trying (n=53). 
The participants were requested to provide a written consent to participate in the 
study and had to complete a questionnaire with questions pertaining to their 
gynecological history and history of sexually transmitted infections.
Collection and storage of sera from patients 
Sera were collected from patients from IVF clinics, sexual health clinics and 
hospitals around Queensland. Each sera and the corresponding patient history sheet 
had a unique numbered-identification code for the study. 200PL of the serum was 
aliquoted into cryovials labeled with the unique code and stored in -80q C freezers. 
4.2.5 Characterization of cohorts for small –scale evaluation of peptide ELISA 
A ‘triage’ process used a small sample size of participants to optimize the 
ELISA conditions worthy of larger scale testing. For this small- scale evaluation of 
peptide assay, the CT infertile cohort included participants recruited from IVF clinics 
who were seropositive in MEDAC MOMP and MEDAC cHSP60 (n=9). The acute 
infections cohort included participants recruited from sexual health clinics who were 
diagnosed with active C. trachomatis infection by PCR, and were positive in 
MEDAC MOMP (n=9). The Negative cohort (n=9) included participants who were 
fertile (able to get pregnant within a year of trying) (n=7); infertile participants who 
were seronegative for C. trachomatis in MEDAC MOMP or MEDAC cHSP60 (n=2). 
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4.2.6 Characterization of cohorts for large-scale evaluation of peptide ELISA 
(development cohort)
The performance of QUT Chlamydia infertility test was evaluated on 262
participants (development cohort) and an absorbance threshold was established and 
the specificity and sensitivity was evaluated in this cohort (Figure 4.1). Infertile 
participants were women who required assisted reproductive technologies (ART) 
were recruited from IVF clinic based in Melbourne (n=97) (cohort characterization 
outlined in section 4.2.4); participants with PCR diagnosed acute C. trachomatis
infections were recruited from sexual health clinics and GP clinics (n=112); and 
participants with current spontaneous pregnancies were recruited from a tertiary 
hospital antenatal clinic (n=53). The acute infections cohort (described in detail in 
4.2.4) included participants who were diagnosed with acute C. trachomatis infections 
by PCR (n=112) and the fertile controls (described in detail in 4.2.4) included 
participants who were pregnant within a year of trying (n=53). Based on the C. 
trachomatis infection status as determined by microimmunofluorescence (MIF) 
assay, the participants were characterized as positive for C. trachomatis-related tubal 
infertility (CT TFI cohort) (n=11). The sera were also tested with commercial assays 
outlined in 4.2.3. An absorbance threshold was determined on this evaluation group 
when the assay was controlled for high specificity for both single-well and multi-well 
peptide ELISA formats. The peptide format that was most specific and sensitive to C. 
trachomatis-related TFI in this cohort was designated the QUT Chlamydia infertility 
assay and it was subsequently validated on the separate validation group.
4.2.7 Characterization of cohort for validation of the peptide ELISA (validation 
cohort)
The validation cohort included participants retrospectively and prospectively 
recruited from an IVF clinic based in Brisbane (Australia) (n=73) (Figure 4.1). The 
women who have completed their IVF cycle (retrospective) and those who are yet to 
complete their treatment (prospective) were included in this cohort. The participants 
were infertile. Their gynecological history consisted of information pertaining to 
tubal patency, parity and previous gynecological surgeries and diseases (PID, 
endometriosis). There were 19 participants with tubal pathology, 23 participants with 
unknown etiology and 32 participants with PCOS, salpingitis, PID and endometritis
(Table 8.3 (Appendix)). The QUT Chlamydia infertility assay was validated on this 
cohort using the cut-off obtained in the development cohort. The specificity, 
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sensitivity, positive predictive value and the negative predictive of the assay were 
determined on this cohort. 
4.2.8 Identification and evaluation of diagnostic performance of peptide variants 
of peptide 11
Peptide 11 was less soluble in 50% isopropanol solvent compared to HSP60-E2 
8% hydrophilic, 58% hydrophobic, basic) and 443-N2 (8% hydrophilic, 38% 
hydrophobic, basic). Peptide 11 has a net acidic charge and contains 25% hydrophilic 
residue and 58% hydrophobic residue. Since it is an acidic peptide, it should be 
readily soluble in aqueous solutions; however, high proportion of hydrophobic 
residues hinders its solubility. Although, peptide 11 was soluble in 0.001M NaOH, 
several smaller variants of peptide 11 were manufactured with varied antigenic 
epitopes. The peptide variants were DTRGI (20% hydrophobic, TRGILVV (neutral, 
57.14% hydrophobic), ILVVAVEAGSPA (66.7% hydrophobic, neutral) and 
ILLVVAVEAGSP (neutral, 63.64% hydrophobic). Since most of these peptides are 
neutral, they were soluble in 50% isopropanol solution. The ability of assays based 
on peptide 11 variants and their combination with HSP60-E2 and 443-N2 to identify 
C. trachomatis-related TFI in women was evaluated on the development cohort. 
4.2.9 Antibody production in rabbits immunized with peptides from QUT 
Chlamydia infertility assay
Sera from rabbits immunized with In-house peptides (peptide 11, HSP60-E2 
and 443-N2) developed for QUT Chlamydia infertility assay were used as controls 
for inter and intra assay variability studies. Prior to immunization, sera was extracted 
from the animals which served as a negative control for inter and intra assay 
variability assays. Each animal was dosed four times with 0.2-0.5mg of the peptide 
for 9 weeks. The peptides were conjugated with keyhole limpet hemocyanin (KLH) 
for HSP60-E2 and 443-N2, while peptide 11 was conjugated with cysteine at the C 
terminal. After the final dosage, the sera was collected and showed a strong 
serological response to C. trachomatis and hence they were used as positive controls 
for inter and intra assay variability tests.
The animal work and immunizations were undertaken at South Australian 
Health and Medical Research Institute (SAHMRI) (Adelaide).
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4.2.10 Inter and intra assay variability of QUT Chlamydia infertility assay 
The diagnostic accuracy and reproducibility of the QUT Chlamydia infertility 
test was further evaluated by determining inter and intra-assay variability. The intra 
assay variability was determined by testing the six samples from each cohort (CT TFI 
cohort, non-TFI cohort, acute infection and healthy cohort) six times on a single 
plate. Inter assay variability was measured by testing the same six samples on 6 
different plates at different times. The mean, the standard deviation and coefficient of 
variation (%CV= 100 x standard deviation/mean) was calculated to evaluate 
variability. 
In addition to participant sera, rabbit sera immunized with peptide 11, HSP60-
E2 and 443-N2 were also tested for intra and inter assay variability. The pre-bleed 
that was extracted from the rabbit before exposure to the antigens served as a 
negative control. 
4.2.11 Determination of diagnostic performance of QUT Chlamydia infertility 
test and statistical analysis
The performance of the QUT Chlamydia infertility test was evaluated on the 
development cohort. The absorbance threshold was determined from Area Under the 
Curve analysis (AUC). The sensitivity and specificity of the assay as a function of the 
cut- off value was determined using the receiver operating characteristic curve 
(ROC). All statistics (relative risk, sensitivity, specificity, chi squared statistics and 
correlation) were calculated in the R statistical environment (3.0.1) using the ‘EpiR’
(0.9-48) and ‘metafor’ package (1.9-1) for conducting meta-analyses in R [413]. In 
addition to sensitivity and specificity, positive predictive value (PPV) and negative 
predictive value (NPV) were determined. Positive predictive value is the probability 
that those patients positive for the infection and truly infected, and negative 
predictive value is the probability that those patients negative for the infection are 
truly negative [435]. Diagnostic odds ratio unlike the conventional odds ratio 
measures the test performance in diagnosing the disease by combing the strengths of 
sensitivity and specificity as prevalence independent indicators [436]. Mixed-effects 
models were used to combine cohort data using a fixed-effect model with a restricted 
maximum likelihood estimate of the log odds ratio. Inter and intra assay variation 
was estimated using linear-mixed effects models which were calculated for the 
different assays taking into account fixed differences in sample absorbance with 
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plate-to-plate differences as a separate stochastic variable. The resulting inter and 
intra assay standard errors were calculated as restricted maximum likelihood 
estimates. All calculations were performed in the R statistical environment (v 3.0.1) 
using the Linear and Nonlinear Mixed Effects Models package ‘nlme’ (v 3.1-111).
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Figure 4.1: Flow chart illustrating the experimental design for the development 
of QUT Chlamydia infertility test for diagnosing chlamydial infertility in women 
in the development cohort (n=262) and the validation cohort (n=73). 
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4.3 RESULTS 
4.3.1 Small-scale analysis reveal multi-well peptide ELISA format had the best 
potential for diagnostic performance 
An initial triage using a small sample size was conducted to compare multi-
well and combined well formats for the different peptides to determine which formats 
should be more rigorously tested and developed using larger sample size. The 
diagnostic performance of peptide 11, HSP60-E2, 443-N2 and 443-A3 were 
evaluated against women with C. trachomatis-related infertility (n=9) and also 
against the Negative cohort (participants with acute C. trachomatis infection (n=9) 
and healthy fertile participants (n=9). Table 4.1 lists the sensitivities and specificities 
of individual peptides, double combination of peptides in a single well and multi-
well format, triple combinations of peptides in a single well and multi-well format. 
The absorbance threshold for maximum sensitivity and specificity for each 
individual peptide assay and its combination was determined by receiver operator 
characteristic analysis (ROC). Although individual peptide assays exhibited high 
specificity ranging from 83% to 89% in detecting CT infertile cohort from negative 
cohort, peptide combinations in single well and multi-well format improved the 
sensitivity of the assay. While triple combination of peptides still demonstrated lower 
specificity (78%) and sensitivity (83%), double combination of peptide 11/ HSP60-
E2 yielded a high specificity of 100% and sensitivity of 94%. The sensitivities were 
maintained at 100% when using the multi-well format for peptide11 and HSP60-E2; 
Peptide 11 and 443-N2; HSP60-E2 and 443-N2; and peptide 11, HSP60-E2 and 443-
N2. However, compared to single-well peptide ELISA the specificity of the assay 
ranged from 78% and 89% depending on the combination of antigens. Importantly, 
the multi-well combinations had tighter confidence intervals compared to single well 
formats. This indicated lower variability in the assays. Due to greater specificity and 
sensitivity of the multi-well assay, this format was adopted for all further analysis and 
evaluation. This triage process was conducted on this smaller cohort, to enable 
streamlining of the assays to be conducted on the full development cohort as detailed 
in 4.3.2.
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Table 4.1: Small-scale evaluation of peptides 11, HSP60-E2 and 443-N2 in single and multi-well format for the detection of women with 
C. trachomatis - related infertility
CT infertile 
cohort
(n=9)
Negative cohort
(n=18)
Sensitivity 
[95% CI]
Specificity [95% 
CI]
P 
(Chisq)
Odds ratio [95%]
Assay (absorbance threshold) Assay 
+
Assay
-
Assay 
+
Assay
-
Peptide 11 (>0.296) 6 3 2 16 0.67[0.3-0.93] 0.89[0.65-0.99] 0.003 16[2.12-120.65]
Peptide HSP60-E2 (> 0.25) 8 1 3 15 0.89 [0.52-1] 0.83[0.59-0.96] <0.001 40[3.56-450]
Peptide 443-N2 (>0.22) 9 0 2 16 1[0.55-1] 0.89[0.65-0.99] <0.001 125.4[5.43-2895.88]
Single-well: aPeptide 11/
HSP60-E2 combo assay (>0.28)
9 0 1 17 1[0.55-1] 0.94[0.73-1] <0.001 221.67[8.20-5989.75]
Single-well: aPeptide 11/HSP60-
E2/443-N2 (>0.23)
7 2 3 15 0.78[0.4-0.97] 0.83[0.59-0.99] 0.002 17.5[2.36-129.51]
Multi-well: bPeptide 11 (>0.23) 
and HSP60-E2 (>0.22)
9 0 3 15 1[0.55-1] 0.78[0.52-0.94] <0.001 61.22[2.95-1272.36]
Multi-well: bPeptide 11 (0.18) 
and 443-N2 (>0.22)
9 0 4 14 1[0.55-1] 0.78[0.52-0.94] <0.001 61.22[2.95-1272.36]
Multi-well: b HSP60-E2 (>0.22) 
and 443-N2 (>0.22)
9 0 2 16 1[0.55-1] 0.89[0.65-0.99] <0.001 125.4[5.43-2895.88]
Multi-well: bPeptide11 (>0.18) 
and HSP60-E2 (>0.22) and 443-
N2 (>0.22)
9 0 2 16 1[0.55-1] 0.89[0.65-0.99] <0.001 125.4[5.43-2895.88]
a The maximum specificity and sensitivity of combination peptide antigens in a single well at established absorbance thresholds (in parenthesis) in identifying participants with C. 
trachomatis-related infertility. The level of significance tested by chi-square test at p<0.05
bThe maximum specificity and sensitivity of combination peptide antigens in multiple wells at established absorbance thresholds (in parenthesis) in identifying participants with C. 
trachomatis-related infertility. The level of significance tested by chi-square test at p<0.05
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4.3.2 Large scale evaluation of peptides in multi-well format and selection of 
assay format for the QUT Chlamydia infertility test on the development 
cohort
The multi-well format was selected for larger scale assay development after the
small-scale evaluation in 4.3.1 showed that individual wells allowed for higher 
specificity and sensitivity with smaller confidence intervals than when antigens were 
combined in a single-well. Peptide 11, HSP60-E2 and 443-N2 were coated on 
separate wells of the plate and the antibody response from women with and without 
chlamydia-related infertility was analyzed individually as well as in combination, in 
order to develop a sensitive and specific ELISA for women with chlamydial 
infertility. Using ROC analysis, an optimal absorbance threshold was achieved after 
controlling for maximum specificity in detecting C. trachomatis –related infertility, 
which is critical for assay development. The absorbance threshold for maximum 
specificity was determined against CT TFI cohort (n=11) and a cohort comprising of 
non-TFI participants and MIF negative TFI participants (n=80). The absorbance 
threshold that was determined in this analysis was later applied to evaluate the 
diagnostic performances of peptide combination multi-well assays in identifying 
infertile women with tubal pathology from those without (Evaluation 1). The 
absorbance threshold was also applied to identify women with C. trachomatis-related 
infertility in CT TFI cohort from the negative cohort (Evaluation 2). The diagnostic 
performance of several multi-well peptide combinations were tested on these cohorts 
and the combination with superior sensitivity and specificity in identifying true 
positives was designated as the QUT Chlamydia infertility test. The concordance 
between the assay and commercial serological assays were determined and its 
reproducibility was assessed through intra and inter assay variability. 
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Figure 4.2: The flow chart depicts the characterization of cohorts based on the 
gynecological data and C. trachomatis infection seropositivity (MIF) of 
participants
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Figure 4.2 depicts the serological response to C. trachomatis was determined by MIF, 
based on which the cohorts were further characterized as true positive and the 
negative cohort. Two main questions have been evaluated through this assay. 
Evaluation 1 (Assign cut-off) includes the ability of the QUT Chlamydia infertility 
test to effectively differentiate infertile participants with tubal factor infertility (TFI) 
from those without (excluding acute/fertile) by estimating the cut off controlled for 
maximum specificity. Though evaluation 2 (evaluation of cut-off), the diagnostic 
ability of QUT Chlamydia infertility test using the same cut-off to differentiate 
participants with CT associated TFI from participants belonging to the negative 
cohort (participants with acute infections, fertile healthy participants and non-TFI 
infertile participants and TFI participants seronegative for C. trachomatis infection). 
Establishing the absorbance threshold for maximum specificity of the 
ELISA to be significantly able to differentiate women with C. trachomatis-
related infertility from infertile women without TFI
The absorbance threshold controlled for maximum specificity was estimated in 
this assay. Individual peptides and their combination assays were tested against 
infertile women with and without tubal pathology (n=97). The assays were tested 
against women with C. trachomatis related infertility (women who were seropositive 
in MIF CT) (n=11) and negative cohort (n=80) that comprises of non-TFI infertile 
participants seronegative for C. trachomatis and non-TFI infertile women 
seropositive for C. trachomatis. When adjusting for confounders, six women were 
excluded due to missing information regarding BMI and smoking status. Table 4.2 
lists the absorbance threshold and the corresponding sensitivity and specificity of 
peptide ELISA in single and multi-well format in diagnosing women with C. 
trachomatis-related TFI. All commercial serological assays such as MEDAC 
infertile, MEDAC MOMP and ANILabsystems could significantly differentiate 
women with C. trachomatis-related infertility from the negative cohort (p<0.05).
MEDAC infertile had the highest sensitivity (36%) while MEDAC MOMP had the 
highest specificity (99%). Amongst peptide ELISAs, individual peptide could not 
effectively identify CT TFI cohort from negative cohort, but their combination assays 
could (p=0.009).
Double combination of peptides, peptide 11, HSP60-E2 or 443-N2 (Peptide 11 
t 0.686 or HSP60E2t0.559 or 443N2 t0.5715), peptide 11 with HSP60-E2 and 443-
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N2 (Peptide 11 t0.216 and HSP60E2 t0.106 and 443N2 t 0.4025) and peptide 11 
with 443-N2 (Peptide 11t0.216 and 443N2 t0.4025) yielded a sensitivity of 27% and 
a specificity of 95%. The odds ratio was lowered for combination assays and 
MEDAC infertile assay after adjusting for factors such as BMI and smoking status. 
This suggests that one of these factors could be a confounding variable for these 
assays. The absorbance threshold was applied in evaluation 1 and evaluation 2 to 
evaluate the performance of peptide ELISAs and identify the best ELISA format to 
diagnose C. trachomatis-related infertility in women.
Chapter 4: Development and evaluation of a novel multi-antigen peptide ELISA for the diagnosis of C. trachomatis-related infertility in women 93
Table 4.2: The diagnostic performance of individual and combination of peptides in a multi-well assay format and commercial 
serological assays in identifying infertile participants with C. trachomatis related TFI (n=11) from negative cohort (MIF-negative TFI 
and Non-TFI participants) (n=80)[Estimating absorbance threshold]. 
.
CT TFI 
cohort 
(n=11)
Negative 
cohort 
(n=80)
Assay
Absorbance 
Threshold(s) 
criteria
Tru
e 
posi
tive
s
Fals
e 
nega
tives
Fals
e 
posi
tives
True 
nega
tives
aSensit
ivity 
(95% 
CI)
aSpeci
ficity 
(95% 
CI)
bPositive 
predictive 
value 
(95% CI)
bNegative 
predictive 
value (95% 
CI)
Odds 
Ratio 
(95% 
CI)
Chi 
Squared P 
value 
(unadjuste
d)
cAdjusted 
Odds 
Ratio 
(95% CI))
MEDAC Infertile 4 7 3 77
0.36 
(0.11-
0.69)
0.96 
(0.89-
0.99)
0.57 (0.18-
0.9)
0.92 (0.84-
0.97)
14.67 
(2.72-
79.1) <0.001
7.9 (1.1-
54)
ANIlabsystems IgG ELISA 3 8 6 74
0.27 
(0.06-
0.61)
0.92 
(0.84-
0.97)
0.33 (0.07-
0.7)
0.9 (0.82-
0.96)
4.62 
(0.97-
22.15) 0.039
4.8 (0.67-
35)
MEDACMOMP
MEDAC MOMP > 
1.2 1 10 1 79
0.09 
(0-
0.41)
0.99 
(0.93-
1)
0.5 (0.01-
0.99)
0.89 (0.8-
0.94)
7.9 
(0.46-
136.4
1) 0.096
5.1 (0.17-
150)
MIF C. trachomatis
(MIF CT) 11 0 5 75
1 
(0.62-
1)
0.94 
(0.86-
0.98)
0.69 (0.41-
0.89) 1 (0.93-1)
Inf 
(NaN-
Inf) <0.001
7e+234 
(0-Inf)
MIF C. pneumoniae
(MIF CP) 7 4 21 59
0.64 
(0.31-
0.74 
(0.63-
0.25 (0.11-
0.45)
0.94 (0.85-
0.98)
4.92 
(1.31- 0.012
4.9 (1.1-
22)
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0.89) 0.83) 18.51)
MIF C. psittaci (MIF 
CS) 4 7 1 79
0.36 
(0.11-
0.69)
0.99 
(0.93-
1)
0.8 (0.28-
0.99)
0.92 (0.84-
0.97)
45.14 
(4.42-
461.0
3) <0.001
34 (2.5-
470)
Peptide 11 Peptide 11 t0.411 1 10 4 76
0.09 
(0-
0.41)
0.95 
(0.88-
0.99)
0.2 (0.01-
0.72)
0.88 (0.8-
0.94)
1.9 
(0.19-
18.73) 0.577
0.84 
(0.063-
11)
HSP60- E2 HSP60E2 t0.522 1 10 4 76
0.09 
(0-
0.41)
0.95 
(0.88-
0.99)
0.2 (0.01-
0.72)
0.88 (0.8-
0.94)
1.9 
(0.19-
18.73) 0.577
3.3 (0.26-
41)
443-N2 443n2 t 0.539 1 10 4 76
0.09 
(0-
0.41)
0.95 
(0.88-
0.99)
0.2 (0.01-
0.72)
0.88 (0.8-
0.94)
1.9 
(0.19-
18.73) 0.577
0.89 
(0.061-
13)
Double combination of 
either peptides: Peptide 
11or HSP60-E2 or 443-
N2
Peptide 11 t0.686 
or HSP60E2 
t0.559 or 443N2 t
0.5715 3 8 4 76
0.27 
(0.06-
0.61)
0.95 
(0.88-
0.99)
0.43 (0.1-
0.82)
0.9 (0.82-
0.96)
7.12 
(1.35-
37.65) 0.009
5.2 (0.67-
39)
Triple peptide 
combination: Peptide11 
and HSP60-E2 and 
443-N2
Peptide 11 t 0.216 
and HSP60E2 t
0.106 and 443N2 
t0.4025 3 8 4 76
0.27 
(0.06-
0.61)
0.95 
(0.88-
0.99)
0.43 (0.1-
0.82)
0.9 (0.82-
0.96)
7.12 
(1.35-
37.65) 0.009
3.9 (0.59-
25)
Double combination: 
Peptide 11 and 443-N2
Peptide 11 t0.216 
and 443N2 t
0.4025 3 8 4 76
0.27 
(0.06-
0.61)
0.95 
(0.88-
0.99)
0.43 (0.1-
0.82)
0.9 (0.82-
0.96)
7.12 
(1.35-
37.65) 0.009
3.9 (0.59-
25)
aSpecificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; bPositive predictive value and negative predictive value: range 0-1, 95% confidence 
intervals in parenthesis; cAdjusted ratio after accounting for BMI and smoking 
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Evaluation 1 (assign cut-off): QUT Chlamydia infertility test can 
differentiate participants with TFI from infertile participants without TFI 
with greater specificity and sensitivity as compared to commercial 
serological assays
The peptides in multi-well format were assayed against sera from participants 
with TFI (n=45) and infertile participants without TFI (n=52). The participants who 
tested equivocal in the commercial serological assays were excluded from the 
analysis (n=6). Therefore, only 47 non-TFI participants and 44 TFI participants were 
tested against commercial serological assays. Table 4.3 showed the performance of 
individual peptides and combination of peptides in multi-well formats against TFI 
and non- TFI participants. The absorbance threshold that was determined in Table 4.2 
was applied in Evaluation 1 and the corresponding specificity and sensitivity was 
determined. 
The commercial ELISAs assayed against the cohort showed high specificity 
(94%-98%), however the sensitivities were low, with MEDAC MOMP being the 
lowest (2%) and ANILabsystems the highest (14%). The MEDAC infertile assay had 
a sensitivity of 11% and had higher positive predictive values (71%) in detecting 
participants with TFI compared to other commercial ELISAs. Although, MIF CT
(MIF C. trachomatis) had the highest sensitivity compared to commercial assays 
(27%) in detecting TFI in women, the specificity was lower than other assays (89%). 
Furthermore, its positive predictive value (PPV) was also lower than other assays. 
Amongst individual peptides assays, HSP60-E2 (cut off value=0.522; 
sensitivity=7%; specificity=96%) and 443-N2 (cut off value=0.539; specificity=9%; 
sensitivity=98%) showed better diagnostic performance as compared to peptide 11 
(cut off value=0.411; sensitivity =4%; specificity=94%) in identifying TFI 
participants from non-TFI participants. Combination of peptide 11 (=0.686) with 
either HSP60-E2 (absorbance threshold =0.559) or 443-N2 (absorbance threshold 
=0.5715) yielded a sensitivity of 27% and a specificity of 95% in differentiating TFI 
participants from non-TFI infertile participants (p=0.006). The combination of all 
three peptides, peptide 11 (absorbance threshold =0.216), HSP60-E2 (absorbance 
threshold =0.106) and 443-N2 (absorbance threshold =0.4025); and combination of 
peptide 11 (absorbance threshold =0.216) and 443-N2 (absorbance threshold 
=0.4025) showed equal sensitivity and specificity in identifying TFI participants. The 
positive predictive value was 100% in combination assays, which shows that all the 
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samples that tested positive were positive. Although, double combination of any of 
the following peptides, peptide 11, HP60-E2 and 443-N2, yielded higher sensitivity, 
triple combination of all three peptides yielded higher specificity and could 
significantly differentiate TFI participants from Non-TFI participants (p<0.004). 
Therefore, it was considered a potential candidate for QUT Chlamydia infertility test. 
The double and triple peptide combination assays had the highest sensitivity 
and specificity compared to all commercial serological assays, including MIF. The 
best performing commercial assay, MEDAC Infertile had only 11% sensitivity and 
96% specificity, whereas triple combination assays had much higher sensitivity 
(16%) and specificity (100%), and could effectively differentiate infertile participants 
with TFI from those without TFI (p=0.004). The odds ratio was adjusted for factors 
such as birth year, smoking, BMI and history of alcohol consumption using multiple 
logistic regression analysis. The decrease in odds ratio after the adjustments suggest 
that one of these factors could be a possible confounder for the analysis and may 
influence the outcome of all the peptide assays.
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Table 4.3: The diagnostic performance of individual and combination of peptides in a multi-well assay format and commercial 
serological assays in identifying infertile participants with TFI from those infertile participants without TFI [Evaluation 1 on 
development cohort]. 
TFI Positive (n=45) Non-TFI (n=52)
Assay
True 
positives
False 
negatives
False 
positives
True 
negatives
aSensitivit
y (95% ci)
bSpecificit
y (95% ci)
Positive 
predictive 
value 
(95% CI)
Negative 
predictive 
value
(95% CI)
Chi 
Squared P 
value 
(unadjuste
d)
Odds 
Ratio 
(95% CI)
cAdjusted 
odds ratio 
(95% CI)
MEDAC Infertile 5 39 2 45
0.11 
(0.04-
0.25)
0.96 
(0.85-
0.99)
0.71 
(0.29-
0.96)
0.54 
(0.42-
0.65) 0.203
2.88 
(0.53-
15.71)
1.9 (0.31-
12)
ANILabsystems 6 38 3 44
0.14 
(0.05-
0.27)
0.94 
(0.82-
0.99)
0.67 (0.3-
0.93)
0.54 
(0.42-
0.65) 0.247
2.32 
(0.54-9.9)
2.8 (0.5-
16)
MEDACMOMP 
>1.2 1 43 1 46
0.02 (0-
0.12)
0.98 
(0.89-1)
0.5 (0.01-
0.99)
0.52 
(0.41-
0.62) 0.962
1.07 
(0.06-
17.64)
0.56 
(0.027-
12)
MIF C. trachomatis 11 33 5 42
0.25 
(0.13-0.4)
0.89 
(0.77-
0.96)
0.69 
(0.41-
0.89)
0.56 
(0.44-
0.67) 0.072
2.8 (0.89-
8.85)
3.9 (0.95-
16)
MIF C. psittaci 4 40 1 46
0.09 
(0.03-
0.22)
0.98 
(0.89-1)
0.8 (0.28-
0.99)
0.53 
(0.42-
0.64) 0.145
4.6 (0.49-
42.86)
3.4 (0.33-
35)
MIF C. 
pneumoniae 12 32 16 31
0.27 
(0.15-
0.43)
0.66 
(0.51-
0.79)
0.43 
(0.24-
0.63)
0.49 
(0.36-
0.62) 0.484
0.73 (0.3-
1.78)
0.61 
(0.23-1.6)
Peptide 11 t0.411 2 43 3 49 0.05 0.94 0.4 (0.05- 0.53 0.701 0.7 (0.11- 0.7 
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(0.01-
0.15)
(0.84-
0.99)
0.85) (0.43-
0.64)
4.39) (0.093-
5.3)
HSP60E2 t0.522 3 42 2 50
0.07 
(0.01-
0.18)
0.96 
(0.87-1)
0.6 (0.15-
0.95)
0.54 
(0.44-
0.65) 0.592
1.65 
(0.26-
10.35)
2.5 (0.36-
17)
443N2 t0.539 4 41 1 51
0.09 
(0.02-
0.21)
0.98 (0.9-
1)
0.8 (0.28-
0.99)
0.55 
(0.45-
0.66) 0.145
4.6 (0.49-
42.86)
5.7 (0.45-
73)
Double 
combination of 
either peptides: 
Peptide 11t0.686 
or HSP60E2 
t0.559 or 443N2 t
0.5715 3 38 4 52
0.27 
(0.06-
0.61)
0.95 
(0.89-
0.99)
0.43 (0.1-
0.82)
0.91 
(0.83-
0.96) 0.203
2.88 
(0.53-
15.71)
3.3 (0.5-
21)
Triple combination:
Peptide 11 t 0.216 
and HSP60E2 t
0.106 and 443N2 t
0.4025 7 38 0 52
0.16 
(0.06-
0.29) 1 (0.9-1) 1 (0.47-1)
0.58 
(0.47-
0.68) 0.004
Inf (NaN-
Inf)
4.1e+07 
(0-Inf)
Double 
combination:_
Peptide 11 t 0.216 
and 443N2 t0.4025 7 38 0 52
0.16 
(0.06-
0.29) 1 (0.9-1) 1 (0.47-1)
0.58 
(0.47-
0.68) 0.004
Inf (NaN-
Inf)
4.1e+07 
(0-Inf)
a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence 
intervals in parenthesis, c The analysis also accounts for variables such as BMI and smoking status.
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Evaluation 2 (evaluation with cut-off): QUT Chlamydia infertility test can 
identify participants with chlamydial TFI from other cohorts
The second evaluation aimed to determine if any of the assays under 
development here had high specificity for women with C. trachomatis-related 
infertility and not detect fertile women, or women who have a recent or current CT 
infection with no reported fertility problems. Therefore through evaluation 2, the 
diagnostic performance of peptide ELISA in identifying participants with C. 
trachomatis-related infertility was assessed and compared with other commercial 
serological assays. Since, the MIF is considered the gold standard, it was used to 
define participants as C. trachomatis–related tubal infertility based on their 
serological status. MIF and confirmed tubal infertility was used to characterize 
participants into CT TFI positive cohort (n=11) and Negative cohort (comprises of 
infertile women with non-TFI, acute CT infections and fertile controls) (n=251) 
(Table 4.4). Participant sera that tested equivocal in the commercial serological 
assays were excluded from analysis. Therefore, 17 participants were excluded from 
ANILabsystems and 3 participants from MIF analysis. MEDAC infertile assay had 
the highest sensitivity (36%) compared to other commercial serological assays such 
as ANILabsystems and MEDAC MOMP. Although, its specificity was low (86%), 
the positive predictive (10% vs 5%) and the negative predictive value (97% vs 96%) 
was higher than other commercial assays. Additionally, it could effectively identify 
C. trachomatis-related TFI participants from negative cohort (p=0.04). 
Multiple peptides had greater sensitivity and specificity in detecting C. 
trachomatis related infertile participants from negative cohort compared to individual 
peptides. Double peptide combinations (peptide 11 with either Hsp60-E2 or 443-N2 
and peptide 11 and 443-N2) and triple peptide combinations (peptide 11, HSP60-E2 
and 443-N2) had a sensitivity of 27%, while their specificity ranged from 93%-94%. 
Although the assays had low positive predictive values (18%-43%), the combination 
assays generally had fewer false positives as they had high negative predictive values 
of 97%. This suggests that out of 227 samples tested, 97% of the samples that tested 
negative in the assay were truly negative. This suggests that the peptide assay test 
were highly specific to C. trachomatis-related infertility. 
The peptide combination assay also demonstrated greater diagnostic 
performance in identifying women with C. trachomatis –related TFI compared to the 
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best performing commercial assay, MEDAC infertile. Although, MEDAC infertile 
assay had higher sensitivity than peptide combination assays (36% vs 27%), the 
specificity (96%-97% vs 86%), PPV (14%-18% vs 10%) and the odds ratio (4.85-
6.35 vs 3.41) were higher for the peptide combination assays (p=0.004). Additionally, 
Women with CT TFI were significantly more likely to be positive in the peptide 
combination assays than the leading commercial ELISA MEDAC infertile. Although, 
the diagnostic sensitivities and specificities were comparable between both double 
and triple peptide combination assays, the triple peptide combination assay (peptide 
11, HSP60-E2 and 443-N2) showed greater odds ratio and level of significance in 
identifying participants with C. trachomatis-related infertility (p=0.004). 
Additionally, the triple peptide combination assays were also adept in identifying 
participants with TFI from those without TFI with the highest specificity (100%) 
compared to all other assays. Hence, this triple peptide was selected as the QUT 
Chlamydia infertility test and its performance was further validated in a secondary 
validation group. 
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Table 4.4: The diagnostic performance of individual and combination of peptides in a multi-well assay format and commercial 
serological assays in identifying CT TFI cohort (n=11) from negative cohort (n=251)[Evaluation 2 on development cohort].
CT TFI cohort (n=11) Negative cohort (n=251)
Assay
True 
positives
False 
negatives
False 
positives
True 
negatives
aSensitivity 
(95% CI)
Specificity 
(95% CI)
bPositive 
predictive 
value (95% 
CI)
Negative 
predictive 
value (95% 
CI)
Chi 
Squared P 
value 
(unadjusted
)
Odds Ratio 
(95% CI)
MEDAC 
Infertile 4 7 36 215
0.36 (0.11-
0.69)
0.86 (0.81-
0.9)
0.1 (0.03-
0.24)
0.97 (0.94-
0.99) 0.047
3.41 (0.95-
12.25)
ANIlabsystems 3 8 62 172
0.27 (0.06-
0.61)
0.74 (0.67-
0.79)
0.05 (0.01-
0.13)
0.96 (0.91-
0.98) 0.955
1.04 (0.27-
4.05)
MEDACMOMP 
>1.2 1 10 24 227
0.09 (0-
0.41)
0.9 (0.86-
0.94) 0.04 (0-0.2)
0.96 (0.92-
0.98) 0.959
0.95 (0.12-
7.71)
MIF C. 
trachomatis 11 0 84 164 1 (0.62-1)
0.66 (0.6-
0.72)
0.12 (0.06-
0.2) 1 (0.97-1) <0.001
Inf (NaN-
Inf)
MIF C. 
pneumoniae 7 4 110 138
0.64 (0.31-
0.89)
0.56 (0.49-
0.62)
0.06 (0.02-
0.12)
0.97 (0.93-
0.99) 0.209
2.2 (0.63-
7.69)
MIF C. psittaci 4 7 4 244
0.36 (0.11-
0.69)
0.98 (0.96-
1)
0.5 (0.16-
0.84)
0.97 (0.94-
0.99) <0.001
34.86 
(7.21-
168.63)
Peptide 11 
t0.411 1 10 27 207
0.09 (0-
0.41)
0.88 (0.84-
0.92)
0.04 (0-
0.18)
0.95 (0.92-
0.98) 0.802
0.77 (0.09-
6.2)
HSP60E2 t
0.522 1 10 14 220
0.09 (0-
0.41)
0.94 (0.9-
0.97)
0.07 (0-
0.32)
0.96 (0.92-
0.98) 0.72
1.47 (0.18-
12.2)
443N2 t0.539 1 10 11 223
0.09 (0-
0.41)
0.95 (0.92-
0.98)
0.08 (0-
0.38)
0.96 (0.92-
0.98) 0.465
2.18 (0.26-
18.59)
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Double 
combination of 
either peptides:
Peptide 11 
t0.686 or 
HSP60E2 
t0.559 or 
443N2t0.5715 3 8 14 237
0.27 (0.06-
0.61)
0.94 (0.91-
0.97)
0.18 (0.04-
0.43)
0.97 (0.94-
0.99) 0.004
6.35 (1.52-
26.59)
Triple 
combination: 
Peptide 11 t
0.216 and 
HSP60E2t0.106 
and 
443N2t0.4025 3 8 13 221
0.27 (0.06-
0.61)
0.94 (0.91-
0.97)
0.19 (0.04-
0.46)
0.97 (0.93-
0.98) 0.004
6.35 (1.52-
26.59)
Double 
combination: 
Peptide 11 t
0.216 and 
443N2 t0.4025 3 8 14 220
0.27 (0.06-
0.61)
0.94 (0.9-
0.97)
0.18 (0.04-
0.43)
0.96 (0.93-
0.98) 0.006
5.9 (1.42-
24.55)
a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence 
intervals in parenthesis
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The diagnostic performance of variants of peptide 11 is comparable to 
individual peptides, but does not outperform QUT Chlamydia infertility test 
in identifying women with tubal pathology and C. trachomatis-related 
infertility
The ability to use a more soluble format of peptide 11 was an important factor 
for consideration as the process to dissolve the peptide 11 was labour intensive 
leading to concerns about possible future manufacture process. This difficulty is 
likely due to the high hydrophobicity of peptide 11 (58% hydrophobicity, 25% 
hydrophilic). Hence, several peptide variants were designed attempting to bias the 
selection towards the hydrophilic amino acid residues while maintaining the antigenic 
epitope (ADTRGILVV, SPA). The variants included DTRGI, TRGILVV, 
ILVVAVEAGSPA and ILLVVAVEAGSP. Table 4.5 showed that the sensitivity of 
peptide variants TRGILVV (sensitivity =5%; specificity =93%) and 
ILVVAVEAGSPA (sensitivity=7%; specificity=96%) were comparable to that of 
peptide 11 and HSP60-E2 in identifying infertile women with tubal pathology.
Peptide variants in combination with peptide 11 and HSP60-E2 increased the 
sensitivity and specificity to 7% and 96%, which was higher than individual peptides; 
but were lower than the QUT chlamydia infertility test (sensitivity=16%; 
specificity=100%).
The peptide variants, individually and in combination with HSP60-E2 and 443-
N2, were tested on CT TFI cohort and negative cohort to determine its diagnostic 
performance in identifying women with C. trachomatis-related infertility. While 
neither individual peptide variants nor combination assays were able to identify 
women with CT TFI from the negative cohort, the combination of these peptides with 
HSP60-E2 and 443-N2, the specificity was improved while the sensitivity was 
maintained at 9% (Table 4.6). The positive predictive value of these individual 
peptide variants and their combination (20%) were higher than peptide 11 (3%), 
HSP60-E2 (6%) and 443-N2 (8%) and was comparable to QUT chlamydia infertility 
test (18%). Additionally, The odds ratio of combination assays of peptide 11 variant 
TRGILVV and ILVVAVEGSPA were comparable to that of QUT Chlamydia
infertility test. Thus, peptide variants of peptide 11 are likely candidates for a CT TFI 
diagnostic that can be further optimized for improved performance in the future. 
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Table 4.5 The diagnostic performance of peptide 11 variants in individual assays and in combination with HSP60 and 443-N2 in 
identifying women with tubal factor infertility from infertile women without tubal pathology were estimated.
TFI positive (n=41) Non-TFI (n=46)
P11 variant Assay
True 
positives
False 
negatives
False 
positives
True 
negatives
aSensitivity 
(95% CI)
aSpecificity 
(95% CI)
bPositive
predictive 
value (95% 
CI)
bNegative 
predictive 
value (95% 
CI)
Odds ratio 
(95% CI)
Chi 
Squared P 
value 
(unadjusted
)
cAdjuste
d odds 
ratio 
(95% 
CI)
Peptide 11 t0.411 2 43 3 49
0.05 (0.01-
0.15)
0.94 (0.84-
0.99)
0.4 (0.05-
0.85)
0.53 
(0.43-
0.64)
.7 (0.11-
4.39) 0.701
0.7 
(0.093-
5.3)
DTRGIt0.311
1 40 2 44
0.02 (0-
0.13)
0.96 (0.85-
0.99)
0.33 (0.01-
0.91)
0.52 (0.41-
0.63)
0.55 (0.05-
6.3) 0.626
0.57 
(0.036-
8.9)
DTRGI. t0 and HSP60E2 
t0.444 and 443N2 t
0.4025 3 41 2 45
0.07 (0.01-
0.19)
0.96 (0.85-
0.99)
0.6 (0.15-
0.95)
0.52 (0.41-
0.63)
1.65 (0.26-
10.35) 0.592
3 (0.42-
22)
TRGILVVt 0.3265
2 39 3 43
0.05 (0.01-
0.17)
0.93 (0.82-
0.99)
0.4 (0.05-
0.85)
0.52 (0.41-
0.64)
0.74 (0.12-
4.63) 0.742
1.2 
(0.17-
8.5)
TRGILVV. tand 
HSP60E2 t0.444 and 
443N2 t 0.4025 3 41 2 45
0.07 (0.01-
0.19)
0.96 (0.85-
0.99)
0.6 (0.15-
0.95)
0.52 (0.41-
0.63)
1.65 (0.26-
10.35) 0.592
3 (0.42-
22)
ILVVAVEAGSPAt
0.4825 3 38 2 44
0.07 (0.02-
0.2)
0.96 (0.85-
0.99)
0.6 (0.15-
0.95)
0.54 (0.42-
0.65)
1.74 (0.28-
10.95) 0.553
2.3 
(0.29-
18)
ILVVAVEAGSPA. t 0 
and HSP60E2 t0.444 and 
443N2 t 0.4025 3 41 2 45
0.07 (0.01-
0.19)
0.96 (0.85-
0.99)
0.6 (0.15-
0.95)
0.52 (0.41-
0.63)
1.65 (0.26-
10.35) 0.592
3 (0.42-
22)
ILVVAVEAGSP t0.676
1 40 3 43
0.02 (0-
0.13)
0.93 (0.82-
0.99)
0.25 (0.01-
0.81)
0.52 (0.41-
0.63)
0.36 (0.04-
3.59) 0.364
0.35 
(0.032-
3.8)
ILVVAVEAGSPt0 and 
HSP60E2 t 0.444 and 
443N2 t0.4025 3 41 2 45
0.07 (0.01-
0.19)
0.96 (0.85-
0.99)
0.6 (0.15-
0.95)
0.52 (0.41-
0.63)
1.65 (0.26-
10.35) 0.592
3 (0.42-
22)
a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence intervals in 
parenthesis, c The analysis also accounts for variables such as BMI and smoking status.
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Table 4.6: The diagnostic performance of peptide 11 variants individually and in combination with HSP60 and 443-N2 in identifying 
women with C. trachomatis-related tubal factor infertility from women non-TFI infertile women who are seronegative for C. trachomatis
infection (for individual peptides (n=82)) and Negative cohort (for combination assays (n=244).
a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence intervals in parenthesis
CT TFI 
positive (n=11)
Negative 
cohort (n=244)
Assay
True 
positiv
e
False 
negativ
es
False 
positiv
es
True 
negativ
es
Sensitivit
y (95% 
CI)
Specificity 
(95% CI)
Positive 
predictive 
value (95% 
CI)
Negative 
predictive value 
(95% CI)
Odds Ratio 
(95% CI)
Chi 
Squared P 
value 
(unadjuste
d)
Peptide 11 t0.411 1 10 27 207
0.0
9
(0-0.41)
0.88 (0.84-
0.92) 0.04 (0-0.18) 0.95 (0.92-0.98) 0.77 (0.09-6.2) 0.802
DTRGI t0.311 0 11 4 78 0 (0-0.38) 0.95 (0.88-0.99) 0 (0-0.72) 0.88 (0.79-0.94) 0 (0-NaN) 0.454
DTRGIt0 and HSP60E2 t0.444 and 443N2 t
0.4025
1 10 4 240 0.09 (0-0.41) 0.98 (0.96-1)
0.2 (0.01-
0.72) 0.96 (0.93-0.98) 6 (0.61-58.71) 0.081
TRGILVVt 0.3265 1 10 4 78 0.09 (0-0.41)
0.95 (0.88-
0.99)
0.2 (0.01-
0.72) 0.89 (0.8-0.94) 1.95 (0.2-19.22) 0.561
TRGILVVt0 and HSP60E2 t 0.444 and 443N2 
>= 0.4025
1 10 4 240 0.09 (0-0.41) 0.98 (0.96-1)
0.2 (0.01-
0.72) 0.96 (0.93-0.98) 6 (0.61-58.71) 0.081
ILVVAVEAGSPA t0.4825 1 10 4 78 0.09 (0-0.41)
0.95 (0.88-
0.99)
0.2 (0.01-
0.72) 0.89 (0.8-0.94) 1.95 (0.2-19.22) 0.561
ILVVAVEAGSPAt0 and HSP60E2 t0.444 and 
443N2 t0.4025 1 10 4 240
0.09 (0-
0.41) 0.98 (0.96-1)
0.2 (0.01-
0.72) 0.96 (0.93-0.98) 6 (0.61-58.71) 0.081
ILVVAVEAGSP t0.676 0 11 4 78 0 (0-0.38) 0.95 (0.88-0.99) 0 (0-0.72) 0.88 (0.79-0.94) 0 (0-NaN) 0.454
ILVVAVEAGSP. t0 and HSP60E2t0.444 and 
443N2 t0.4025 1 10 4 240
0.09 (0-
0.41) 0.98 (0.96-1)
0.2 (0.01-
0.72) 0.96 (0.93-0.98) 6 (0.61-58.71) 0.081
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QUT Chlamydia infertility test does not correlate with commercial 
serological assays in detecting C. trachomatis-related infertility in women in 
the development cohort
In order to determine if the same participants are being detected by the different 
serological tests a concordance analysis was conducted. Table 4.7 illustrated that all 
MOMP peptide based commercial serological assays including MEDAC Infertile 
assay, ANILabsystems, MEDAC MOMP showed great concordance with each other 
and with MIF CT (p<0.05). However, these assays also showed significant 
concordance with MIF CP (C. pneumoniae) and MIF CS (C. psittaci) (p<0.05). This 
suggests that there is a potential for cross-reactivity between other chlamydial species 
in commercial serological assay, which compromises the specificity of the assay. 
Thereby, possibly increasing the rate of false positive tests for these assays. 
As for QUT Chlamydia infertility test, the assay showed concordance with all 
peptide combination assays and individual peptides such as HSP60-E2 and 443N2. 
Although, the assay did not show concordance with any other commercial serological 
assays, it exhibited high correlation with MIF CS (p=0.032). Since, none of the 
individual peptides showed correlation to MIF CS, and MIF CS had exhibited its 
ability to differentiate CT TFI cohort from negative cohort (Table 4.4) and also 
correlates with MIF CT (p=0.002), it could be inferred that MIF CS may recognize 
cross-reacting antibodies with C. trachomatis. 
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Table 4.7: Concordance between commercial serological assays and In-house peptide ELISA in identifying C. trachomatis related tubal 
infertility in women in the development cohort 
MED
ACIn
fertil
e
ANIl
absys
tems
MED
ACM
OMP
MIF.
CT
MIF.
CP
MIF.
CS
Pepti
de.11
HSP
60E2
443N
2
Double 
combo 
(either)
Peptide
.11_or
_HSP6
0e2_or
_443n2
QUT 
Chla
mydia 
inferti
lity 
test
Do
ubl
e 
co
mbi
nati
on: 
pep
tide 
11 
and 
443
N2
Peptide
11.var.
DTRGI
DTR
GI + 
HSP6
0E2 + 
443-
N2
Pep
tide.
11.v
ar.T
RGI
LV
V
TRGIL
VV + 
HSP60
E2 
+443N
2 
Pepti
de 
11.va
r.ILV
VAV
EAG
SPA
ILVVAV
EAGSP
A+HSP6
0E2+443
N2
Peptide
.11.var.
ILVVA
VEAG
SP
ILVVA
VEAG
SP+
_HSP6
0e2_+4
43n2
MEDACInfertile
a<0.0
01
<0.00
1
<0.0
01
<0.0
01 0.01
<0.0
01 0.065 0.094 0.494 0.077 0.327
0.3
95 0.531 0.768 0.35 0.768 0.481 0.768 0.531 0.768
ANIlabsystems
<0.00
1
<0.00
1
<0.0
01
<0.0
01 0.145 0.019 0.475 0.99 0.902 0.982 0.304
0.3
96 0.478 0.504
0.49
3 0.504 0.493 0.504 0.478 0.504
MEDACMOMP
<0.00
1
<0.00
1
<0.0
01
<0.0
01 0.047 0.007 0.453 0.595 0.249 0.121 0.747
0.8
14 0.709 0.467
0.67
5 0.467 0.675 0.467 0.709 0.467
MIF.CT
<0.00
1
<0.00
1
<0.0
01
<0.0
01 0.004 0.002 0.227 0.358 0.714 0.119 0.15
0.2
24 0.351 0.449
0.86
5 0.449 0.865 0.449 0.351 0.449
MIF.CP 0.01 0.145 0.047 0.004
<0.0
01 0.015 0.572 0.732 0.009 0.111 0.064
0.0
43 0.856 0.245
0.57
9 0.245 0.141 0.245 0.191 0.245
MIF.CS
<0.00
1 0.019 0.007 0.002 0.015
<0.0
01 0.228 0.491 0.282 0.002 0.032
0.0
41 0.626 0.03
0.13
6 0.03 0.584 0.03 0.626 0.03
Peptide.11 0.065 0.475 0.453 0.227 0.572 0.228
<0.0
01 0.106 0.561 0.001 0.106
0.1
37 <0.001 0.437
0.58
4 0.437 0.584 0.437 0.626 0.437
HSP60E2 0.094 0.99 0.595 0.358 0.732 0.491 0.106
<0.0
01 0.008 <0.001
<0.00
1
<0.
001 0.075
<0.00
1
<0.
001 <0.001 0.584 <0.001 0.075 <0.001
443N2 0.494 0.902 0.249 0.714 0.009 0.282 0.561 0.008
<0.0
01 <0.001
<0.00
1
<0.
001 0.626
<0.00
1
0.13
6 <0.001 0.136 <0.001 0.075 <0.001
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Double combo 
(either)
Peptide.11_or_HSP
60e2_or_443n2 0.077 0.982 0.121 0.119 0.111 0.002 0.001
<0.0
01
<0.0
01 <0.001
<0.00
1
<0.
001 0.176 0.003
<0.
001 0.003 0.277 0.003 0.176 0.003
Triple combination 0.327 0.304 0.747 0.15 0.064 0.032 0.106
<0.0
01
<0.0
01 <0.001
<0.00
1
<0.
001 0.56
<0.00
1
0.27
7 <0.001 0.512 <0.001 0.176 <0.001
Double 
combination: 
peptide 11 and 
443N2 0.395 0.396 0.814 0.224 0.043 0.041 0.137
<0.0
01
<0.0
01 <0.001
<0.00
1
<0.
001 0.56
<0.00
1
0.27
7 <0.001 0.512 <0.001 0.176 <0.001
Peptide.11.var.DTR
GI 0.531 0.478 0.709 0.351 0.856 0.626
<0.0
01 0.075 0.626 0.176 0.56
0.5
6 <0.001 0.626
0.07
5 0.626 0.626 0.626 0.665 0.626
DTRGI + HSP60E2 
+ 443-N2 0.768 0.504 0.467 0.449 0.245 0.03 0.437
<0.0
01
<0.0
01 0.003
<0.00
1
<0.
001 0.626
<0.00
1
<0.
001 <0.001 0.136 <0.001 0.075 <0.001
Peptide.11.var.TRG
ILVV 0.35 0.493 0.675 0.865 0.579 0.136 0.584
<0.0
01 0.136 <0.001 0.277
0.2
77 0.075
<0.00
1
<0.
001 <0.001
<0.00
1 <0.001 0.626 <0.001
TRGILVV + 
HSP60E2 +443N2 0.768 0.504 0.467 0.449 0.245 0.03 0.437
<0.0
01
<0.0
01 0.003
<0.00
1
<0.
001 0.626
<0.00
1
<0.
001 <0.001 0.136 <0.001 0.075 <0.001
Peptide.11.var.ILV
VAVEAGSPA 0.481 0.493 0.675 0.865 0.141 0.584 0.584 0.584 0.136 0.277 0.512
0.5
12 0.626 0.136
<0.
001 0.136
<0.00
1 0.136 0.075 0.136
ILVVAVEAGSPA
+HSP60E2+443N2 0.768 0.504 0.467 0.449 0.245 0.03 0.437
<0.0
01
<0.0
01 0.003
<0.00
1
<0.
001 0.626
<0.00
1
<0.
001 <0.001 0.136 <0.001 0.075 <0.001
Peptide.11.var.ILV
VAVEAGSP 0.531 0.478 0.709 0.351 0.191 0.626 0.626 0.075 0.075 0.176 0.176
0.1
76 0.665 0.075
0.62
6 0.075 0.075 0.075 <0.001 0.075
ILVVAVEAGSP+
_HSP60e2_+443n2 0.768 0.504 0.467 0.449 0.245 0.03 0.437
<0.0
01
<0.0
01 0.003
<0.00
1
<0.
001 0.626
<0.00
1
<0.
001 <0.001 0.136 <0.001 0.075 <0.001
aCorrelation and concordance between serological assay defined by level of significance (p<0.05). 
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Women predicted to have C. trachomatis-related infertility in the QUT 
Chlamydia infertility test are equally likely to conceive by IVF as other 
infertility and therefore it is valid to recommend progression to IVF 
Tubal factor infertility and previous IVF success rates were evaluated as 
prognostic indicators of successful infertility treatment in Table 4.8. Women with 
Tubal factor infertility had a lower success rate for IVF in this study, as the number 
of live births in infertile women without tubal pathology was significantly higher than 
that reported from women with tubal factor infertility (p=0.032, 24 vs 13). The odds 
ratio also suggested that non-TFI women were twice as likely to have a live birth than 
women with TFI after IVF treatment. Thus, compared to previous successful live 
birth and pregnancy outcome in an IVF procedure (p>0.05), tubal status of women 
proved to be a negative prognostic indicator of IVF outcome (p=0.032; AOR (95% 
CI)=3.9 (1.4-11). 
Table 4.9 showed that none of the C. trachomatis serological assays including 
the QUT Chlamydia infertility test, MEDAC infertile assay, MEDAC MOMP, MIF 
CT and peptide 11 variant assays could effectively differentiate participants with 
successful IVF outcome from those who did not achieve a successful IVF outcome
(p>0.05). Thus, the inability of the QUT Chlamydia infertility test to differentiate 
participants based on IVF outcomes suggests that participants positive for C. 
trachomatis-related infertility in this assay were as likely to achieve a successful IVF 
outcome as those infertile C. trachomatis seronegative participants. The sensitivity to 
detect positive live births and pregnancy rates were generally low (3%-5%) in both 
the peptide ELISAs and commercial serological assays (MEDAC infertile and 
MEDAC MOMP). Contrary to other commercial serological assays, ANILabsystems 
was able to effectively predict the IVF outcome (p=0.04). If a participant tested 
positive in this assay, they were 2.5 times more likely to have a successful IVF 
outcome. The analysis (Figure 4.3) also showed that the number of IVF cycles taken 
to achieve live birth or pregnancy rates were not statistically significantly between 
women with C. trachomatis-related TFI and women with other forms of infertility. 
This indicates that IVF treatments are as likely to be successful for women with C. 
trachomatis-related infertility as women with other forms of infertility.
.
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Table 4.8:Prediction of IVF outcome (Live birth) based on the tubal status of infertile participants, history of live births and pregnancy 
in previous IVF cycles.
Factor (+/-) Live 
birth, 
factor 
+
Live 
birth, 
factor 
-
No live 
birth, 
factor +
No live 
birth, 
factor -
Sensiti
vity 
(95% 
CI)
Specifi
city 
(95% 
CI)
Positive 
predictive 
value (95% 
CI)
Negative 
predictive 
value (95% 
CI)
Odds 
Ratio 
(95% 
CI)
Chi Squared 
P value 
(unadjusted
)
Adjusted 
Odds Ratio 
(95% CI)
Tubal status 
(Non-TFI (n= 
52)/ TFI (n=45)
24 13 18 26 0.65 
(0.47-
0.8)
0.59 
(0.43-
0.74)
0.57 (0.41-
0.72)
0.67 (0.5-
0.81)
2.67 
(1.08-
6.58)
0.032 3.9 (1.4-
11)
Previous live
birth outcome 
(TRUE / 
FALSE)
7 30 6 38 0.19 
(0.08-
0.35)
0.86 
(0.73-
0.95)
0.54 (0.25-
0.81)
0.56 (0.43-
0.68)
1.48 
(0.45-
4.86)
0.519 1.6 (0.44-
5.6)
Previous 
pregnancy 
outcome (TRUE 
/ FALSE)
8 29 12 32 0.22 
(0.1-
0.38)
0.73 
(0.57-
0.85)
0.4 (0.19-
0.64)
0.52 (0.39-
0.65)
0.74 
(0.26-
2.05)
0.557 0.71 (0.24-
2.2)
a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence 
intervals in parenthesis, c The analysis also accounts for variables such as BMI and smoking status.
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Table 4.9: The sensitivity and specificity of commercial serological assays and In-house peptide ELISA to predict IVF outcome in 
infertile women (n=97) in the development cohort
No. of women with 
successful live 
births/ 
pregnancies
(n=44)
No. of women with 
failed live births/ 
pregnancies 
(n=47)
Assay
True 
positive
s
False 
negatives
False 
positives
True 
negatives
aSensitivity 
(95% CI)
aSpecificity 
(95% CI)
bPositive 
predictive 
value 
(95% CI)
bNegative 
predictive 
value (95% 
CI)
Chi 
Square
d P 
value 
(unadju
sted)
Odds 
Ratio 
(95% 
CI)
cAdjusted 
odds ratio 
(95% CI)
MEDAC Infertile 5 39 2 45
0.11 
(0.04-0.25)
0.96 
(0.85-0.99)
0.71 (0.29-
0.96)
0.54 (0.42-
0.65) 0.528
0.57 
(0.1-
3.31) 1.9 (0.31-12)
ANILabsystems 6 38 3 44
0.14 
(0.05-0.27)
0.94 
(0.82-0.99)
0.67 (0.3-
0.93)
0.54 (0.42-
0.65) 0.04
4.9 
(0.95-
25.26) 2.8 (0.5-16)
MEDAC MOMP >1.2 1 43 1 46
0.02 
(0-0.12)
0.98 
(0.89-1)
0.5 (0.01-
0.99)
0.52 (0.41-
0.62) 0.273
Inf 
(NaN-
Inf)
0.56 (0.027-
12)
MIF C. trachomatis 6 31 6 38
0.16
(0.06-0.32)
0.86 
(0.73-0.95)
0.5 (0.21-
0.79)
0.55 (0.43-
0.67) 0.745
1.23 
(0.36-
4.18)
0.57 (0.12-
2.8)
MIF C. pneumoniae 15 22 10 34
0.41
(0.25-0.58)
0.77 
(0.62-0.89)
0.6 (0.39-
0.79)
0.61 (0.47-
0.74) 0.084
2.32 
(0.88- 1.9 (0.68-5.5)
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6.07)
Peptide 11 t0.411 3 34 2 42
0.08 
(0.02-0.22)
0.95 
(0.85-0.99)
0.6 (0.15-
0.95)
0.55 (0.43-
0.67) 0.507
1.2 
(0.16-
8.96) 2 (0.24-17)
HSP60E2 t 0.522 2 35 2 42
0.05 
(0.01-0.18)
0.95 
(0.85-0.99)
0.5 (0.07-
0.93)
0.55 (0.43-
0.66) 0.859
1.85 
(0.29-
11.73) 1.4 (0.15-12)
443N2 t0.539 1 36 4 40
0.03 
(0-0.14)
0.91 
(0.78-0.97)
0.2 (0.01-
0.72)
0.53 (0.41-
0.64) 0.234
1.2 
(0.16-
8.96)
0.29 (0.021-
4.1)
Double combination 
(either peptides):
Peptide 11t0.686 or 
HSP60E2 t0.559 or 
443N2 t 0.5715 2 35 5 39
0.05 
(0.01-0.18)
0.89 
(0.75-0.96)
0.29 (0.04-
0.71)
0.53 (0.41-
0.64) 0.342
0.28 
(0.03-
2.6)
0.33 (0.045-
2.4)
QUT Chlamydia infertility 
test 2 35 5 39
0.05 
(0.01-0.18)
0.89 
(0.75-0.96)
0.29 (0.04-
0.71)
0.53 (0.41-
0.64) 0.342
0.45 
(0.08-
2.45)
0.32 (0.048-
2.2)
Double combination:
Peptide 11 t 0.216 and 
443N2 t 0.4025 2 35 5 39
0.05 
(0.01-0.18)
0.89 
(0.75-0.96)
0.29 (0.04-
0.71)
0.53 (0.41-
0.64) 0.342
0.45 
(0.08-
2.45)
0.32 (0.048-
2.2)
Peptide 11 variant 
(DTRGI) t0.311 2 35 1 39
0.05
(0.01-0.18)
0.98 
(0.87-1)
0.67 (0.09-
0.99)
0.53 (0.41-
0.64) 0.51
2.23 
(0.19-
25.66) 1.8 (0.13-26)
Peptide.11.variant..DTRGI
. t0 and HSP60E2 t 0.444 
and 443N2 t 0.4025 1 36 3 41
0.03 
(0-0.14)
0.93
(0.81-0.99)
0.25 (0.01-
0.81)
0.53 (0.42-
0.65) 0.394
0.38 
(0.04-
3.81)
0.5 (0.042-
6.1)
Peptide 11 variant 3 34 2 38 0.08 0.95 0.6 (0.15- 0.53 (0.41- 0.58 1.68 1.8 (0.23-13)
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(TRGILVV) t 0.3265 (0.02-0.22) (0.83-0.99) 0.95) 0.65) (0.26-
10.64)
Peptide.11.variant..TRGIL
VV. t 0 and HSP60E2 t
0.444 and 443N2 t0.4025 1 36 3 41
0.03 
(0-0.14)
0.93 
(0.81-0.99)
0.25 (0.01-
0.81)
0.53 (0.42-
0.65) 0.394
0.38 
(0.04-
3.81)
0.5 (0.042-
6.1)
Peptide 11 variant 
(ILVVAVEAGSPA) 
t0.4825 2 35 2 38
0.05 
(0.01-0.18)
0.95 
(0.83-0.99)
0.5 (0.07-
0.93)
0.52 (0.4-
0.64) 0.936
1.09 
(0.15-
8.13)
0.99 (0.11-
9.3)
Peptide.11.variant..ILVVA
VEAGSPA. t 0 and 
HSP60E2 t 0.444 and 
443N2 t 0.4025 1 36 3 41
0.03 
(0-0.14)
0.93 
(0.81-0.99)
0.25 (0.01-
0.81)
0.53 (0.42-
0.65) 0.394
0.38 
(0.04-
3.81)
0.5 (0.042-
6.1)
Peptide 11 variant 
(ILVVAVEAGSP) t
0.676 0 37 2 38
0 
(0-0.14)
0.95 
(0.83-0.99) 0 (0-0.91)
0.51 (0.39-
0.62) 0.168
0 (0-
NaN)
5.7e-08 (0-
Inf)
Peptide.11.variant..ILVVA
VEAGSP. t 0 and 
HSP60E2 t0.444 and 
443N2 t 0.4025 1 36 3 41
0.03 
(0-0.14)
0.93 
(0.81-0.99)
0.25 (0.01-
0.81)
0.53 (0.42-
0.65) 0.394
0.38 
(0.04-
3.81)
0.5 (0.042-
6.1)
a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence 
intervals in parenthesis, c The analysis also accounts for variables such as BMI and smoking status.
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Figure 4.3: The association of number of cycles to achieve an IVF outcome in infertile women with C. trachomatis commercial and 
peptide ELISAs 
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Inter and intra assay variability 
The inter and intra assay variability was estimated for QUT Chlamydia
infertility test by assaying against 6 samples from each cohort; CT TFI cohort, CT 
negative infertile participants with no tubal pathology, participants with acute C. 
trachomatis infections, healthy fertile controls. The variability was measured across 
three replicates and over six days. Table 4.10 showed that the intra assay variability 
for peptide 11, HSP60-E2 and 443-N2 were 0.07, 0.069 and 0.074 respectively. The 
inter assay variability for peptide 11, HSP60-E2 and 443-N20 were 0.13, 0.139 and 
0.136, respectively. Since the coefficient of variation of both inter and intra assay 
variability was less than 15%, the peptide ELISAs yielded reproducible results, 
therefore QUT Chlamydia infertility test that includes a combination of all three 
assays would be reproducible and robust. 
Table 4.10: The inter and intra assay variability in 24 samples over the span of 6 
days for peptide ELISAs that constitute QUT Chlamydia infertility test
Assay Intra assay
variability (n=24) (%CV)
Inter assay
variability (%CV) (n=6)
Peptide 11 0.07 0.13
HSP60-E2 0.069 0.139
443-N2 0.074 0.136
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4.3.3 Testing of QUT Chlamydia infertility test as a diagnostic test on infertile 
participants recruited from an IVF clinic (Validation cohort)
The QUT Chlamydia infertility test was tested on 73 infertile participants 
recruited from an IVF clinic (Brisbane, Australia). The diagnostic performance of the 
assay in identifying tubal pathology and C. trachomatis-related infertility was 
evaluated and compared against commercial serological assays. 
QUT Chlamydia infertility test and commercial serological assays could not 
differentiate women with TFI from non-TFI infertile women in the 
validation cohort
The QUT Chlamydia infertility test was tested against another development 
cohort consisting of women recruited from another IVF clinic to validate its 
performance. The assay was tested against 19 infertile women with tubal pathology 
and 54 infertile women with no tubal pathology. Participant sera that tested equivocal 
for C. trachomatis infection in the commercial serological assays were excluded from 
the analyses. Among participants who tested equivocal, 2 participants were excluded 
from MEDAC Infertile and MEDAC MOMP, 3 participants from ANILabsystems 
and one participant from MEDACHSP60. Table 4.11 showed that while none of the 
commercial serological assays yielded significant differences between women with 
TFI and non-TFI women, MIF CT showed the highest sensitivity (26%) and positive 
predictive value (38%) compared to all other assays for identifying tubal pathology in 
women. Although, the MEDAC infertile assay and QUT Chlamydia infertility test 
showed significant difference in identifying women with C. trachomatis-related 
infertility from C. trachomatis-negative non-TFI women in the development cohort, 
the assays could not detect a single true positive in the validation cohort, but had high 
negative predictive value (72%). However, only peptide 11 showed a sensitivity of 
11% and a specificity of 81% (not significant) in detecting C. trachomatis-related 
tubal factor infertility in women. The overall low diagnostic performance of 
serological assays in this cohort could be attributed to its limited sample size and that
the tubal pathology in this cohort might not be a consequence of C. trachomatis
infections. 
Chapter 4: Development and evaluation of a novel multi-antigen peptide ELISA for the diagnosis of C. trachomatis-related infertility in women 117
Table 4.11: The validation of the diagnostic performance of QUT Chlamydia infertility test in identifying women with TFI (n=19) from 
infertile women not associated with TFI (n=54) in the validation cohort
TFI positive 
(n=19)
Non-TFI 
(n=54)
Assay
True 
positi
ve 
False 
negati
ve 
False 
positiv
e 
True 
negati
ve 
Sensitivit
y (95% 
ci)
Specificit
y (95% 
CI)
Positive 
predictive value 
(95% CI)
Negative 
predictive value 
(95% CI)
Odds 
Ratio 
(95% CI)
Chi Squared P 
value 
(unadjusted)
MEDAC Infertile 0 19 2 50 0 (0-0.25)
0.96 
(0.87-1) 0 (0-0.91) 0.72 (0.6-0.83) 0 (0-NaN) 0.386
MEDACMOMP 1 18 3 49
0.05 (0-
0.26)
0.94 
(0.84-
0.99) 0.25 (0.01-0.81) 0.73 (0.61-0.83)
0.91 
(0.09-9.3) 0.935
MEDACHSP60 3 16 6 47
0.16 
(0.03-0.4)
0.89 
(0.77-
0.96) 0.33 (0.07-0.7) 0.75 (0.62-0.85)
1.47 
(0.33-
6.57) 0.613
ANIlabsystems 3 15 6 45
0.17 
(0.04-
0.41)
0.88 
(0.76-
0.96) 0.33 (0.07-0.7) 0.75 (0.62-0.85)
1.5 (0.33-
6.75) 0.595
MIF.CT 5 14 8 46
0.26 
(0.09-
0.51)
0.85 
(0.73-
0.93) 0.38 (0.14-0.68) 0.77 (0.64-0.87)
2.05 
(0.58-
7.29) 0.26
MIF.CP 9 10 28 26
0.47 
(0.24-
0.71)
0.48 
(0.34-
0.62) 0.24 (0.12-0.41) 0.72 (0.55-0.86)
0.84 
(0.29-
2.38) 0.737
MIF.CS 1 18 1 53
0.05 (0-
0.26)
0.98 (0.9-
1) 0.5 (0.01-0.99) 0.75 (0.63-0.84)
2.94 
(0.17-
49.54) 0.433
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PEPTIDE11 2 17 10 44
0.11 
(0.01-
0.33)
0.81 
(0.69-
0.91) 0.17 (0.02-0.48) 0.72 (0.59-0.83)
0.52 (0.1-
2.61) 0.419
HSP60E2 0 19 3 51 0 (0-0.25)
0.94 
(0.85-
0.99) 0 (0-0.81) 0.73 (0.61-0.83) 0 (0-NaN) 0.294
443N2 0 19 4 50 0 (0-0.25)
0.93 
(0.82-
0.98) 0 (0-0.72) 0.72 (0.6-0.83) 0 (0-NaN) 0.222
Double combination 
(either peptides) 0 19 6 48 0 (0-0.25)
0.89 
(0.77-
0.96) 0 (0-0.58) 0.72 (0.59-0.82) 0 (0-NaN) 0.129
QUT Chlamydia
infertility test 0 19 6 48 0 (0-0.25)
0.89 
(0.77-
0.96) 0 (0-0.58) 0.72 (0.59-0.82) 0 (0-NaN) 0.129
Double combination 
(Peptide11 and 
443N2) 0 19 6 48 0 (0-0.25)
0.89 
(0.77-
0.96) 0 (0-0.58) 0.72 (0.59-0.82) 0 (0-NaN) 0.129
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QUT Chlamydia infertility test and commercial serological assays could not 
differentiate women with tubal pathology or unknown etiology from women 
with neither tubal pathology nor unknown etiology 
The QUT Chlamydia infertility test was tested against women with tubal 
pathology or unknown etiology (n=42) against women with other forms of infertility 
(neither tubal nor unknown etiology) (n=31) (Table 4.12). Several participants were 
excluded from the study if they tested equivocal for C. trachomatis infection in the 
commercial serological assays. Therefore, only 29 participants were included in 
MEDAC Infertile, MEDACMOMP and ANILabsystems, while 30 participants were 
included in MEDACHSP60. While none of the commercial serological assays or In-
house peptide ELISAs including QUT Chlamydia infertility test yielded significant 
difference in identifying women with either tubal pathology or unknown etiology, 
MEDAC cHSP60 had the highest sensitivity (17%) amongst commercial assays. 19% 
(8/42) of participants with tubal pathology/unknown etiology were positive in MIF, 
while only 2% (1/42) and 4% (2/42) of the participants were detected by MEDAC 
Infertile and QUT Chlamydia infertility assay (sensitivity =5%; specificity =87%).
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Table 4.12: The validation of the diagnostic performance of QUT Chlamydia infertility test in identifying women with women with 
unknown etiology or tubal pathology (n=42) from infertile with no tubal pathology/unknown etiology (n=31) in the validation cohort
Assay
Unknown or 
Tubal 
pathology / 
assay +
Unknown or 
Tubal 
pathology / 
assay -
Pathology 
neither 
Tubal or 
Unknown / 
assay +
Pathology 
neither 
Tubal or 
Unknown / 
assay -
Sensitivity 
(95% CI)
Specificity 
(95% CI)
Positive 
predictive 
value (95% 
CI)
Negative 
predictive 
value (95% 
CI)
Odds Ratio 
(95% CI)
Chi Squared 
P value 
(unadjusted)
MEDACInf
ertile 1 41 1 28
0.02 (0-
0.13)
0.97 (0.82-
1)
0.5 (0.01-
0.99)
0.41 (0.29-
0.53)
0.68 (0.04-
11.38) 0.789
MEDACM
OMP 3 39 1 28
0.07 (0.01-
0.19)
0.97 (0.82-
1)
0.75 (0.19-
0.99)
0.42 (0.3-
0.54)
2.15 (0.21-
21.8) 0.507
MEDACHS
P60 7 35 2 28
0.17 (0.07-
0.31)
0.93 (0.78-
0.99)
0.78 (0.4-
0.97)
0.44 (0.32-
0.58)
2.8 (0.54-
14.55) 0.206
ANILabsyst
ems 6 34 3 26
0.15 (0.06-
0.3)
0.9 (0.73-
0.98)
0.67 (0.3-
0.93)
0.43 (0.31-
0.57)
1.53 (0.35-
6.7) 0.571
MIF.CT 8 34 5 26
0.19 (0.09-
0.34)
0.84 (0.66-
0.95)
0.62 (0.32-
0.86)
0.43 (0.31-
0.57)
1.22 (0.36-
4.18) 0.747
MIF.CP 21 21 16 15
0.5 (0.34-
0.66)
0.48 (0.3-
0.67)
0.57 (0.39-
0.73)
0.42 (0.26-
0.59)
0.94 (0.37-
2.37) 0.892
MIF.CS 1 41 1 30
0.02 (0-
0.13)
0.97 (0.83-
1)
0.5 (0.01-
0.99)
0.42 (0.31-
0.55)
0.73 (0.04-
12.17) 0.827
PEPTIDE11 6 36 6 25
0.14 (0.05-
0.29)
0.81 (0.63-
0.93)
0.5 (0.21-
0.79)
0.41 (0.29-
0.54)
0.69 (0.2-
2.4) 0.564
HSP60E2 2 40 1 30
0.05 (0.01-
0.16)
0.97 (0.83-
1)
0.67 (0.09-
0.99)
0.43 (0.31-
0.55)
1.5 (0.13-
17.33) 0.744
443N2 2 40 2 29
0.05 (0.01-
0.16)
0.94 (0.79-
0.99)
0.5 (0.07-
0.93)
0.42 (0.3-
0.55)
0.72 (0.1-
5.45) 0.754
Double 
combination 3 39 3 28 0.07 (0.01- 0.9 (0.74- 0.5 (0.12- 0.42 (0.3- 0.72 (0.13- 0.697
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(either 
peptides)
0.19) 0.98) 0.88) 0.54) 3.82)
QUT 
Chlamydia
infertility test 2 40 4 27
0.05 (0.01-
0.16)
0.87 (0.7-
0.96)
0.33 (0.04-
0.78)
0.4 (0.28-
0.53)
0.34 (0.06-
1.97) 0.211
Double 
combination 
(Peptide11 
and 443N2) 2 40 4 27
0.05 (0.01-
0.16)
0.87 (0.7-
0.96)
0.33 (0.04-
0.78)
0.4 (0.28-
0.53)
0.34 (0.06-
1.97) 0.211
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Concordance of QUT Chlamydia infertility test with commercial assays
The concordance between QUT Chlamydia infertility test and commercial 
serological assays in detecting tubal pathology were compared in this cohort (Table 
4.13). MIF CT correlated with MOMP based serological assays, MEDAC Infertile 
and ANILabsystems (p<0.001). Although, QUT Chlamydia infertility showed no 
concordance with all commercial serological assays, it showed high concordance 
with MIF CS (p<0.001). As all the peptides in the QUT Chlamydia infertility assay 
are specific only to C. trachomatis (as confirmed by BLAST), the concordance to 
MIF CS could be due to possible cross-reactivity between C. psittaci and C. 
trachomatis.
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Table 4.13: Concordance of QUT Chlamydia infertility test with commercial and In-house peptide ELISAs in the validation cohort
MEDAC
MOMP
MEDAC
HSP60
AN
ILa
b
MIF.
CT
MIF.
CP
MIF.
CS
PEPT
IDE1
1
HSP
60E2
443N
2
Double 
combo 
(either)
QUT 
Chlamydia
infertility test
Double combo: 
peptide 11 and 
443N2
MEDACMOMP <0.001 0.021
<0.
001
<0.0
01
0.93
1 0.726 0.378
0.66
5 0.615 0.532 0.532 0.532
MEDACHSP60 0.021 <0.001
0.0
31
0.20
3
0.24
7 0.588 0.151
0.50
4 0.437 0.334 0.334 0.334
ANILab <0.001 0.031
<0.
001
<0.0
01
0.22
5 0.578 0.581
0.49
3 0.425 0.321 0.321 0.321
MIF.CT <0.001 0.203
<0.
001
<0.0
01
0.38
8 0.504 0.124
0.47
3 0.338 0.939 0.234 0.234
MIF.CP 0.931 0.247
0.2
25
0.38
8
<0.0
01 0.984 0.226
0.08
1 0.317 0.095 0.414 0.414
MIF.CS 0.726 0.588
0.5
78
0.50
4
0.98
4
<0.00
1 0.194
0.76
7 0.73 0.668 0.029 0.029
PEPTIDE11 0.378 0.151
0.5
81
0.12
4
0.22
6 0.194
<0.00
1
<0.0
01 0.062 0.001 0.001 0.001
HSP60E2 0.665 0.504
0.4
93
0.47
3
0.08
1 0.767
<0.00
1
<0.0
01 0.03 <0.001 0.106 0.106
443N2 0.615 0.437
0.4
25
0.33
8
0.31
7 0.73 0.062 0.03
<0.00
1 <0.001 <0.001 <0.001
Double combo. (Either 
peptides) 0.532 0.334
0.3
21
0.93
9
0.09
5 0.668 0.001
<0.0
01
<0.00
1 <0.001 <0.001 <0.001
QUT Chlamydia
infertility test 0.532 0.334
0.3
21
0.23
4
0.41
4 0.029 0.001
0.10
6
<0.00
1 <0.001 <0.001 <0.001
Double combo: 
peptide 11 and 443N2 0.532 0.334
0.3
21
0.23
4
0.41
4 0.029 0.001
0.10
6
<0.00
1 <0.001 <0.001 <0.001
Chapter 4: Development and evaluation of a novel multi-antigen peptide ELISA for the diagnosis of C. 
trachomatis-related infertility in women 124
Women predicted to have C. trachomatis-related infertility in QUT 
Chlamydia infertility test is as likely to conceive with IVF as women with 
other forms of infertility 
The specificity and sensitivity of QUT Chlamydia infertility test to predict IVF 
outcome was assessed in Table 4.14. A total of 63 infertile women who have 
undergone IVF were included in this study. Serum samples of participants that tested 
equivocal for C trachomatis infection in commercial were excluded in the study. 
Therefore only 61 participants were included in the MEDACMOMP and MEDAC 
Infertile analysis, while only 59 participants were included in the ANILabsystems 
analysis. The QUT Chlamydia infertility assay could not effectively predict the IVF 
outcome (p>0.05). MIF was the only serological assay that could effectively predict 
live birth outcome after an IVF cycle (p=0.034). Despite showing significant 
difference, MIF CT showed very low sensitivity and specificity. This shows that 
women who are positive for C. trachomatis-related infertility in QUT Chlamydia
infertility test have equal likelihood of live birth or pregnancy via IVF as women with 
other forms of infertility. Since the women in this group were currently undergoing 
IVF, their final outcome is not yet known.
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Table 4.14: The sensitivity and specificity of commercial serological assays and QUT Chlamydia infertility test to predict IVF outcome in 
infertile women (n=63) in the validation cohort
Assay
Live birth / 
assay +
Live birth / 
assay -
No live 
birth / 
assay +
No live 
birth / 
assay -
aSensitivity 
(95% CI)
aSpecificity 
(95% CI)
bPositive 
predictive 
value (95% 
CI)
bNegative 
predictive 
value (95% 
CI)
Odds Ratio 
(95% CI)
cChi 
Squared P 
value 
(unadjusted
)
MEDAC Infertile 0 30 2 30 0 (0-0.17)
0.94 (0.79-
0.99) 0 (0-0.91)
0.5 (0.37-
0.63) 0 (0-NaN) 0.164
MEDACMOMP 1 29 3 29
0.03 (0-
0.17)
0.91 (0.75-
0.98)
0.25 (0.01-
0.81)
0.5 (0.37-
0.63)
0.33 (0.03-
3.4) 0.333
MEDACHSP60 2 29 5 27
0.06 (0.01-
0.21)
0.84 (0.67-
0.95)
0.29 (0.04-
0.71)
0.48 (0.35-
0.62)
0.37 (0.07-
2.08) 0.247
ANILabystems 3 25 6 25
0.11 (0.02-
0.28)
0.81 (0.63-
0.93)
0.33 (0.07-
0.7)
0.5 (0.36-
0.64)
0.5 (0.11-
2.22) 0.357
MIF.CT 3 28 10 22
0.1 (0.02-
0.26)
0.69 (0.5-
0.84)
0.23 (0.05-
0.54)
0.44 (0.3-
0.59)
0.24 (0.06-
0.96) 0.034
MIF.CP 14 17 20 12
0.45 (0.27-
0.64)
0.38 (0.21-
0.56)
0.41 (0.25-
0.59)
0.41 (0.24-
0.61)
0.49 (0.18-
1.35) 0.167
MIF.CS 1 30 1 31
0.03 (0-
0.17)
0.97 (0.84-
1)
0.5 (0.01-
0.99)
0.51 (0.38-
0.64)
1.03 (0.06-
17.28) 0.982
PEPTIDE11 7 24 4 28
0.23 (0.1-
0.41)
0.88 (0.71-
0.96)
0.64 (0.31-
0.89)
0.54 (0.39-
0.68)
2.04 (0.53-
7.83) 0.292
HSP60-E2 2 29 1 31
0.06 (0.01-
0.21)
0.97 (0.84-
1)
0.67 (0.09-
0.99)
0.52 (0.38-
0.65)
2.14 (0.18-
24.86) 0.535
443-N2 3 28 0 32
0.1 (0.02-
0.26) 1 (0.84-1) 1 (0.19-1)
0.53 (0.4-
0.66)
Inf (NaN-
Inf) 0.071
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a Specificity and Sensitivity: Range is 0-1, 95% confidence intervals in parenthesis; b Positive predictive value and negative predictive value: range 0-1, 95% confidence 
intervals in parenthesis, c The analysis also accounts for variables such as BMI and smoking status.
Double combo 
(either peptides) 4 27 1 31
0.13 (0.04-
0.3)
0.97 (0.84-
1)
0.8 (0.28-
0.99)
0.53 (0.4-
0.67)
4.59 (0.48-
43.63) 0.151
QUT Chlamydia
infertility test 4 27 1 31
0.13 (0.04-
0.3)
0.97 (0.84-
1)
0.8 (0.28-
0.99)
0.53 (0.4-
0.67)
4.59 (0.48-
43.63) 0.151
Double combo 
assay (peptide 11 
and 443N2) 4 27 1 31
0.13 (0.04-
0.3)
0.97 (0.84-
1)
0.8 (0.28-
0.99)
0.53 (0.4-
0.67)
4.59 (0.48-
43.63) 0.151
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4.4 DISCUSSION 
The QUT Chlamydia infertility test exhibited superior specificity and sensitivity 
compared to the current commercially available serological assays in diagnosing 
women with tubal pathology and C. trachomatis-related tubal infertility. The assay 
was developed based on the peptides that were identified in Stansfield et al. [411]. 
The peptides included Peptide 11, HSP60-E2 and 443-N2 that were derived from a 
wide range of antigens that were also known to be immunodominant in women with 
C. trachomatis-related tubal infertility. The initial proof of concept peptide ELISA 
based on peptide 11 had a specificity of 95% and a sensitivity of 47% in identifying 
women with C. trachomatis-related infertility [411]. In order to improve the 
sensitivity of the peptide 11 ELISA, a novel peptide ELISA was designed by 
combining peptide 11 with other peptides. Like peptide 11, they were specific only to 
C. trachomatis and did not show cross-reactivity with other chlamydial species (by 
BLAST). 
A range of methods and conditions were evaluated on a small- scale assay to 
triage the conditions for the large-scale tests. While all peptide assays including 
individual and combination assay formats identified women with C. trachomatis
related infertility (p<0.01), peptide combinations in multi-well format were selected 
for assay design due to its superior diagnostic performance (sensitivity=100%; 
specificity =78%-89%). 
In this study, the definition of tubal infertility and inclusion (unilateral or 
bilateral tubal occlusion) and exclusion criteria in recruiting participants for 
development and validation cohort are consistent with previous studies [362, 377, 
410]. The cohort definitions and experiment design applied in this study is similar to 
that of Bax et al. [377], who also evaluated the performance of two commercial 
ELISAs against MIF in identifying participants with tubal pathology in women with 
infertility (confirmed by laparoscopy). This was followed by evaluation of diagnostic 
performance of the commercial ELISAs in identifying C. trachomatis-related 
infertility in participants with MIF as the gold standard [377]. The study reported that 
MEDACMOMP ELISA had high specificity and could potentially be good alternative 
to MIF. 
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For large scale-evaluation of the diagnostic performance of peptide assays, the 
target groups included infertile women with tubal pathology (confirmed by 
laparoscopy) (evaluation 1) and women with C. trachomatis-related infertility 
(evaluation 2). Since MIF was considered the gold standard and used widely in CAT 
[374, 400, 404], it was used to define the infection status of the cohorts. The group 
included women with C. trachomatis- related TFI and the negative cohort included 
non-TFI infertile women seronegative and seropositive for C. trachomatis infections 
by MIF CT. Therefore, the assays were developed to be specific only to women with 
tubal infertility, and who were seropositive for C. trachomatis. 
The absorbance threshold and the corresponding diagnostic performance were 
evaluated on women with CT TFI (n=11) and negative cohort (infertile seronegative 
for C. trachomatis infection and tubal pathology; n=80) (Table 4.2). The absorbance 
threshold that yielded highest sensitivity and specificity in both individual and peptide 
combination assays were applied in evaluation 1 and evaluation 2. In evaluation 1, the 
ability of peptide assays to identify women with tubal pathology (n=45) from infertile 
women without tubal pathology (n=47) was determined. The diagnostic performances 
of peptide assay formats (individual and combination) were compared commercial 
serological assays, including MIF CT. Although MIF CT had the highest sensitivity 
(25%) in identifying tubal infertility in women as compared to commercial and In-
house peptide ELISAs, its specificity was the lowest (89%) (Table 4.3). This is 
consistent with findings of Dabekausen et al. [403] that showed that participants with 
TFI had a 9.1 times likelihood of testing positive in MIF than participants without 
TFI. The low sensitivity of MIF suggests that C. trachomatis infections may not 
account for all tubal pathology in women in this cohort. Therefore, overall sensitivity 
would be lower for all assays in this cohort. Additionally, the assay usually detects 
women with past CT infections regardless of infertility, thus compromising its 
specificity. Compared to commercial serological assays and peptide ELISAs, only 
double combination of peptides (peptide 11 and 443-N2) and triple combination of 
peptides (peptide 11, Hsp60-E2 and 443-N2) were able to significantly differentiate 
women with TFI from infertile women with non-TFI (p=0.004). In addition, the 
sensitivity (16%) and specificity (100%) of the peptide combination assays were 
higher than MEDAC infertile (sensitivity=11%; specificity =96%) and 
ANILabsystems IgG ELISA (sensitivity=14%; specificity=94%) in identifying 
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women with tubal pathology. BMI and smoking status have been implicated in female 
infertility in several studies [222-224]. Studies have shown a positive correlation of 
smoking and BMI, and their compounded effects on female infertility [222]. Thus, the 
odds ratio was adjusted for factors such as BMI and smoking status, which through 
step-wise logistic regression analysis were found to be associated with tubal 
infertility.
While the diagnostic performance of peptide ELISAs in identifying tubal 
pathology was evaluated in Evaluation 1, the diagnostic performance of the assays in 
identifying C. trachomatis-related infertility in women were evaluated in evaluation 2 
(Table 4.4). MEDAC infertile assay and the peptide combination assays were the only 
serological assays that could significantly differentiate women with C. trachomatis-
related infertility (CT TFI cohort) (n=11) from negative cohort (CT negative women 
without tubal infertility, women with acute infections, fertile women) (n=251) 
(p<0.001). MEDAC Infertile assay had the highest sensitivity (36%) in identifying 
women with C. trachomatis-related TFI compared to commercial serological assays. 
All three peptide combination assays had a sensitivity of (27%) and specificity (94%). 
Based on the evaluation 1 and evaluation 2, the triple combination assay (peptide 11, 
HSP60-E2 and 443-N2) showed the highest sensitivity (27%) and specificity (94%) 
and hence chosen as the QUT Chlamydia infertility test. Although the sensitivity of 
QUT Chlamydia infertility test was lower than MEDAC infertile assay, the positive 
predictive value of the assay was (18%-19%) were higher, which suggests that 19% 
women who tested positive in the QUT Chlamydia infertility test were true positive 
for C. trachomatis-related TFI as compared to 10% women who tested positive in 
MEDAC infertile assay. Thus, it could detect a higher proportion of participants with 
TFI that were missed by MEDAC Infertile assay. Additionally, the high specificity 
and negative predictive value (NPV) of the assay would ensure low false positive rate. 
The high NPV (96%-97%) obtained in all ELISAs in the study is consistent with 
previous reports, which report a NPV of 85%-90% for CAT [362, 410, 437].
Therefore, these characteristics make QUT Chlamydia infertility test a suitable 
diagnostic for detection of C. trachomatis tubal factor infertility and IVF could be 
recommended without any additional diagnosis for women positive in the assay. 
This superior diagnostic performance of QUT Chlamydia infertility test as 
compared to commercial serological assays suggests that combined peptides from 
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cytosolic proteins HSP60, outer membrane protein CT443 and a periplasmic protein 
HtrA showed greater antibody reactivity to women with C. trachomatis-related TFI 
than traditional protein antigens such as MOMP. Multi-well formats have been 
evaluated in the development of peptide ELISA combining CT226, CT795 and 
CT694, wherein triple combination of peptides yielded higher sensitivity but the 
specificity was compromised when compared to double combinations [389]. Bas et al.
[367] also showed that the combination of HSP60 and PGP3 improved the sensitivity 
(76%) and specificity (77%) of the assay to detect acute C. trachomatis infections as 
compared to HSP60 (sensitivity =62%; specificity =80%) and PGP3 
(sensitivity=53%; specificity =80%) used alone. Genome wide identification of 
antigens identified HSP60 and CT443 to be preferentially recognized by TFI 
participants (n=33), and reported that proteins in combination yielded higher 
sensitivity than when used alone in identifying women with tubal infertility compared 
to non-TFI infertile controls (n=23) [385]. Additionally, Budrys et al. [387] reported 
that peptide fragments of CT443 had better diagnostic value in identifying tubal 
infertility in women than full-length CT443 proteins. This shows that epitopes on 
peptides are show greater antibody reactivity than epitopes in full- length proteins. 
This highlights the antigenicity of the linear B-cell epitopes identified through 
bioinformatics analysis. Linear B-cell epitopes have been previously identified in 
MOMP [429, 439], which identified MOMP377-386 (TRLIDERAAH) to be 
immunogenic and a potential vaccine and a diagnostic candidate [429].
Several variants of peptide 11 were designed that were selected in order to
improve its solubility. The diagnostic performance of peptide variants in identifying 
women with tubal pathology and C. trachomatis-related infertility were assessed. 
Some peptide variants were detected to have slightly improved performance than 
peptide 11 in detecting tubal pathology in women (Table 4.5). However, the 
diagnostic performance did not differ between peptide 11 and its variants when C. 
trachomatis-related infertility was considered the positive group (Table 4.6). 
It was interesting to note that although MEDAC Infertile and QUT Chlamydia
infertility test were able to identify C. trachomatis-related TFI in women with high 
sensitivity and specificity, however, there was no concordance between the two 
assays (p>0.05) (Table 4.7). All commercial serological assays had significant
concordance with MIF CS and MIF CP. This suggests that the commercial serological 
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assays have a high rate of cross-reactivity between C. pneumoniae and C. psittaci. 
Land et al. [410] reported that with the exception of MEDAC MOMP all serological 
assays such as MIF, ANILabsystems showed significant cross-reactivity with C. 
pneumoniae in 315 subfertile women. C. pneumoniae has not been reported to 
contribute to tubal pathology [440], but high prevalence of serological positive people 
the population are thought to lead to false positive results in MIF CT [373]. Contrary 
to commercial serological assays, individual peptide ELISAs did not correlate with 
MIF CP and MIF CS, thus highlighting the specificity of the peptides to C. 
trachomatis alone. However, peptide combination assays including double 
combination of either peptides (p=0.002), double combination of peptide 11 and 443-
N2 (p=0.041), triple combination (p=0.032) showed high correlation with MIF CS. 
Since the peptide combination assays were controlled for high specificity, it resulted 
in a higher rate of true negatives while fewer true positives were identified. The low 
prevalence of MIF CS indicated a high rate of true negatives, which accounts for the 
correlation in the diagnostic performance between both MIF CS and the peptide 
combination assays.
The participants in the development cohort included women who underwent 
treatment at IVF clinics. The factors associated with IVF outcome was evaluated in 
Table 4.8. Amongst other factors such as previous history of live birth and pregnancy 
in previous IVF treatments, tubal pathology in women significantly correlated with 
IVF outcome (p=0.032). Infertile women without tubal pathology were 3.9 times 
more likely to have a successful IVF outcome (pregnancy/ live birth) compared to 
women with tubal pathology. The analysis was adjusted for variables such as BMI 
and smoking status, and the increase in the adjusted odds ratio suggest that one of 
these variables may also be a confounder to IVF outcome prediction. Since women 
with tubal infertility are more likely to have a successful IVF outcome, the likelihood 
of women predicted to have C. trachomatis-related infertility by QUT Chlamydia
infertility test in conceiving via IVF as women with other forms of infertility were 
represented in Table 4.9. 
With the exception of ANILabsystems, none of the serological assays including 
QUT Chlamydia infertility test were significantly different based on the IVF outcome 
or the number of cycles to achieve it in infertile women (Table 4.9). This could be due 
to the influence of confounding factors such as BMI and smoking status. Consistent 
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with the findings in this study, Tasdemir et al. [441] evaluated 51 couples undergoing 
IVF and embryo transfer treatment and reported that presence of C. trachomatis
antibodies did not alter the success rates of IVF-ET and achieved a pregnancy rate of 
32.7% as compared to participants seronegative for C. trachomatis (17.4%). Keltz et 
al. [185] also demonstrated that per-cycle pregnancy rate did not differ significantly 
in CT positive and CT negative infertile participants (n=1279). The study also showed 
that while pregnancy rates were lower in women with C. trachomatis induced 
infertility; it did not affect the IVF outcome. Among tubal factor infertility 
participants, cHSP60 seropositive participants had greater pregnancy rate than 
cHSP60 seronegative participants after oocyte pick-up (OR = 8.9, 95% CI = 2.3 to 
27.5) (n=195) [442]. Thus, it could be inferred that amongst all assisted reproductive 
technologies, IVF is most ideal and effective treatment strategy for women with C. 
trachomatis-related tubal pathology. Therefore, women positive in QUT Chlamydia
infertility could proceed directly to IVF without undergoing additional investigations. 
The reproducibility and robustness of QUT Chlamydia infertility test was 
validated by measuring inter and intra assay variability (Table 4.10). The coefficient 
of variation (%CV) was less than 15% in both assays; therefore QUT Chlamydia
infertility test was robust and reproducible. 
The diagnostic performance of the assay was validated on another cohort 
comprising of women retrospectively and prospectively recruited from a separate IVF 
clinic (n=73) (Table 4.11). Contrary to the development cohort, none of the 
serological assays including QUT Chlamydia infertility test effectively identified 
women with tubal pathology (n=19) (p>0.05). MIF CT had low sensitivity and 
specificity of 25% and 85% respectively. The inability of serological assays to detect 
tubal pathology could be due to the low prevalence of C. trachomatis-induced tubal 
pathology in the group. Group definitions may be the major factor influencing these 
results. Another explanation could be that this clinic may represent a distinct 
demographic of patients from the first, with some other aetiology being more 
commonly responsible for tubal fertility.
Keltz et al. [185] reported that women with tubal damage confirmed by 
laparoscopy and hysterosalpinography who are seropositive for C. trachomatis were 
less likely to conceive without IVF compared to women who were seronegative for 
the infection. The study also showed CAT positive women had significantly more 
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tubal damage on HSG (37.5% vs 10.1%; p=0.001) and laparoscopically confirmed 
tubal damage (85.7% vs 48.9%; p=0.002) than CAT negative participants. Therefore, 
HSG and laparoscopy may not detect all the tubal damage associated with C. 
trachomatis infection. Although not statistically significant, by including infertile 
participants with unknown etiology, the sensitivity was higher with QUT Chlamydia
infertility test as well as other serological assays (Table 4.12). Hence, in this study 
women with unknown infertility were also included, so as to determine if their 
infertility was associated with C. trachomatis infections. However, MIF CT showed 
reduced sensitivity (19%) but higher specificity in this cohort compared to women 
with tubal pathology alone (not significant). This suggests that MIF CT is more likely 
to detect tubal pathology than any other forms of infertility. The concordance between 
commercial assays and QUT Chlamydia infertility test in identifying tubal pathology 
was also assessed (Table 4.13). Similar to the development cohort results, the 
commercial assays showed great correlation with each other and not with QUT 
Chlamydia infertility assay and other peptide ELISAs. However, contrary to the 
development cohort results, the commercial assays did not show cross-reactivity with 
other species, while QUT Chlamydia infertility test showed concordance with MIF 
CS. Since very low number of positives were detected by QUT Chlamydia infertility 
test in this group as compared to commercial assays (such as ANILabsystems and 
MIF CT), it is likely that of the two samples detected, one sample could have shown 
cross-reactivity with C. psittaci. However, since the prevalence of C. trachomatis –
induced TFI has been estimated to be low in this cohort, a larger sample size would be 
needed to effectively independently validate the performance of QUT Chlamydia
infertility test. The prevalence rate of C. trachomatis-related TFI estimated by MIF in
the development cohort and validation cohort was 11.95% and 7.04% respectively, 
which was similar to previous literature (5.5% (n=1279)[185], 20.8% (n=1482)
[361]). However, high prevalence rate has also been reported by Bax et al. [377] of 
31.6% in 76 women with subfertility. Similar to the development cohort, the QUT 
Chlamydia infertility test could not predict the IVF outcome (Table 4.14). Since most 
of the women in this cohort have only begun their IVF treatment, their pregnancy 
outcomes are still unknown. Therefore, the analysis may not be relevant. 
QUT Chlamydia infertility test has demonstrated a high specificity in 
identifying women with tubal pathology (100%) and C. trachomatis-related infertility
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(94%). While, the assay significantly reduces the rate of false positives, making it an 
ideal early infertility investigative tool in fertility clinics, its sensitivity has been 
limited to 16% and 27% respectively. However, the low sensitivity means that a 
negative result in this test does not exclude the possibility of chlamydial tubal 
infertility. In addition, the multi peptide ELISA outperformed current commercial 
serological assays in identifying women with tubal pathology and chlamydial 
infertility. Despite the lack of validation in a separate IVF clinic, QUT Chlamydia
infertility is highly promising and could be developed into a specific test for 
chlamydial infertility in women. The assay validation could be further improved by 
considerably increasing the sample size of target cohort, in order to evaluate and 
enhance its diagnostic ability.
The highly specific QUT Chlamydia test can be applied through a two-step 
diagnostic pathway that could be routinely implemented during the infertility 
investigation of women presenting at the fertility clinic setting. Firstly, a MIF positive 
result could be used to indicate if further tubal investigation is needed or possible 
non-detectable tubal damage is present. If other infertility aetiologies were absent in 
the individual, then IVF would be recommended. Secondly, a highly specific ELISA, 
such as the multi-peptide test developed here, could be used to identify women who 
(if positive) are likely to have chlamydial tubal damage that might be best 
recommended to progress directly to IVF treatment. Since the study demonstrated 
equivalent IVF success rates from both fertility clinic cohorts for women who were 
positive in the serological tests compared to women who were negative. Thus, IVF 
treatment is a valid recommendation in the context of these serological results.
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are induced in mononuclear cells 
from women with C. trachomatis
related infertility
Chapter 5: CXCL10, CXCL11 and IL-1 are induced in mononuclear cells from women with C. trachomatis related 
infertility 136
5.1 INTRODUCTION
The progression of C. trachomatis infection from the lower genital tract to 
upper genital tract and its role in female infertility has been investigated using various 
in vitro [443-445], ex vivo [446-450], and mouse models [451-455]. These studies 
indicate that a pro-inflammatory response from the local tissue is likely a major 
contributor to the pathological outcome in some cases, while in others it has been 
associated with resolution of the infection.
In vitro studies have shown that infection with C. trachomatis in HeLa cells 
induced the expression of genes that regulate innate immunity [443] and Interleukin-8 
(IL-8) cytokine [444]. Buchholz et al. [444] further confirmed that IL-8 was produced 
as a result of bacterial protein synthesis at 15 hours post infection and transcription of 
IL-8 responses such AP-1, NFL6 and NFNB were also up regulated. Thus, the study 
illustrates that in in vitro, one of the early immune responses associated with C. 
trachomatis infection are IL-8 production and the genes associated with its 
transcription. Zhou et al. [445] further illustrated the signalling pathways regulating 
key pro-inflammatory immune genes that are associated with chlamydial pathology. 
The study showed that infection with a C. trachomatis pORF5 protein (secreted 
protein by pORF5 plasmid) in HeLa cells, induced the expression of genes such TNF-
D, IL-1E and IL-8 through p38/mitogen activated protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK)/MAP signaling pathways. In addition to 
IL-8, pro-inflammatory cytokine IL-6 was reported to be upregulated in a HeLa/THP-
1 co-culture model, and using a multiplexed cytometric bead array assay, the study 
reported a downregulation of IL-10, IL-12p70, and TNF-D [280].
Consistent with the findings in in vitro models, among ex vivo studies, infection 
with C. trachomatis serovar D on primary cells isolated from human fallopian tube 
showed that under hypoxic condition, IFN-J facilitated the development of persistent 
infections in the upper genital tract [447]. While the study reports the role of pro-
inflammatory cytokine in C. trachomatis-related tubal pathology, it also highlights the 
likely role of environmental conditions such as oxygen supply in reducing clearance 
of bacteria and development of pathology in the upper genital tract. Contrary to these 
findings, ex-vivo stimulation of PBMC and endometrial tissue of women with C. 
trachomatis showed an accumulation of IL-4 [449] and a polarization towards Type 2 
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immunity [448]. This was supported by genome-wide microarray analysis, which also 
revealed up-regulation of genes such as matrix metalloproteinase 10, GATA-3 
(transcription factor regulating Th2 differentiation), IL-4 as compared to IL-17 and 
IFN-J [448]. Several studies have elucidated the role of innate immunity in C. 
trachomatis –related pathology in the upper genital tract. Immumohistochemistry 
(IHC) on fallopian tubes of women with ectopic pregnancy (n=50) revealed 
expression of IL-6, IL-8 and its receptor CXCR1 [456]. Shaw et al. [267] showed an 
increased expression of prokineticin (PROK1) and its receptor PROKR1, a molecule 
that controls smooth muscle contractility and genes associated with intrauterine 
implantation, in fallopian tubes of women with a history of C. trachomatis infection
and ectopic pregnancy (n=14). The study further identified higher expressions of 
TLR2 and TLR4 in the fallopian tubes by IHC, and cell culture models further 
supported these results and showed that in addition to the innate molecules, NFNB 
was activated on C. trachomatis infection [267]. Higher expression of TLR2 and 
TLR4 were also evident in cervical monocytes obtained from women with fertility 
disorders who are positive for C. trachomatis infection (n=57) [263]. Interestingly, 
cytokine analysis of laparoscopic specimens of fallopian tube and cervical secretions 
of infertile women (n=37) revealed that the secretion of cytokines varied between 
different sites [285]. Most cytokines including IL-6, IL-2 and IL-12 levels were 
significantly much lower in the fallopian tubes of C. trachomatis positive infertile 
women compared to infertile women negative for C. trachomatis infection (p<0.05)
[285]. However, in the cervical secretions, the level of IFN-J, IL-10 and IL-12 were 
significantly higher in infertile women with C. trachomatis infection compared to 
infertile women negative for the infection (p <0.05) [285]. The presence of IL-10 and 
IFN-J in the cervical secretions of infertile participants indicates that genital mucosa 
produces both Th1/Th2 responses during C. trachomatis infection. 
The C. muridarum mouse model can replicate most pathologies associated with 
C. trachomatis in women, including ascension of infection and subsequent oviduct 
scarring, hydrosalpinx and infertility; hence it is considered a good experimental 
model for C. trachomatis [457]. Khamesipour et al. [450] illustrated that inoculation 
of C. trachomatis MoPn biovar in the ovarian bursa of C3H/ HeN and C57BL/6 mice 
resulted in salpingitis in both mice which correlated with high antibody response to 
cHSP60. The infection adversely affected the pregnancy outcome, with significantly 
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lower pregnancy rates in infected mice as compared to the control (p <0.05) (8% of 
C3H and 25% of C57BL/6). Murine models have shown that infection with C. 
trachomatis activates the development of CD8+T memory cells that elicit protection 
against pathology on secondary infection [453]. Gondek et al. [458] reported that 
secondary C. trachomatis infections in upper genital pathology induced by 
transcervical inoculation resulted in a 100-fold level of protection by CD4+T cells 
against the infection as compared to CD4+T cell naïve control. However, C. 
muriadarum immune mice that had undergone CD4+T cells depletion before 
secondary challenge did not exhibit any protective effect against the infection. Thus, 
this shows that, in addition to CD8+ T cells, CD4+T cell-specific cells skewed towards 
Th1 immunity elicit protective immunity in the upper genital tract against re-
infection. However, CD8 T-cell clones derived from infected mice showed that it 
contributed to immunopathology through production of IL-10, TNF-D and IL-13, 
which revived replication of C. muridarum in epithelial cells and subsequent scarring 
of tissues [457]. Nagarajan et al. [446] reported that infection of mouse macrophages 
and fibroblasts with C. trachomatis MoPn resulted in the production of IFN-E and IP-
10 (chemokine involved in T cell recruitment) in cells deficient in Toll like receptors, 
TLR2 and TLR4. The study showed that the production of the pro-inflammatory 
cytokines is not dependent on the TLRs, rather it adopts the MyD88 singalling 
pathway. Thus, it gives an insight into the innate immune markers associated with 
chlamydial pathology. Therefore, these studies indicate that a pro-inflammatory 
response from the local tissue is likely a major contributor to the pathological 
outcome.
Several studies have identified immune factors expressed from peripheral blood 
mononuclear cells from Chlamydia infected or infertile participants. The stimulation 
of PBMC from infertile women (n=133) with chlamydial 60kDa heat shock protein 
yielded higher production of IFN-J, IL-10 and IL-12 cytokines, while stimulation 
with EB antigen induced a weaker production of IL-10 cytokine [270]. This suggests 
that cHP60 plays an important role regulating Th1-Th2 balance and in the 
immunopathogenesis of chlamydial infection in the upper genital tract. In vitro
lymphocyte proliferation of PBMC with C. trachomatis 57-kDa HSP showed that the 
proportion of women with salpingitis (n=18) who exhibited antigen mediated 
lymphocyte proliferation were significantly higher than women with cervicitis (n=10), 
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recurrent miscarriages (n=5) and healthy fertile women (n=45) (p<0.001) [459] . This 
shows that C. trachomatis induces tubal pathology in the upper genital tract. Cytokine 
assay on PBMCs stimulated with cHSP60 revealed that the proportion of IFN-J to IL-
10 was significantly lower in women with PID and history of C. trachomatis infection 
(n=9; 0.006, P<0.01)) [273]. Thus, cHSP60 elicits a Th2 immune response in women 
with C. trachomatis- related PID. Similarly, stimulation of PBMCs from women with 
tubal factor infertility and a history of C. trachomatis infection (n=4) with chlamydial 
antigens CtTSp (Chlamydia trachomatis tail-specific protease) and CtHtrA showed 
higher production IL-6 and IL-10 [278]. In addition to cytokine and gene expression 
analysis, the influence of host gene polymorphisms were elucidated in Ohman et al.
[249]. The study reported that infertile women (n=34) with IL-10-0182 and 
IFNG+874 SNPs showed an abundance of IL-10 secretion in the PBMC compared to 
IFN-J on infection with C. trachomatis. Thus, host gene polymorphisms in IFN-J and 
IL-10 genes affect the susceptibility to TFI by influencing the cytokine profile and 
immune response to C. trachomatis infection. The PBMC studies reveal that both Th1 
and Th2 mediated immune responses are associated with C. trachomatis-related 
infertility in women. 
Diagnosis of women with chlamydial infertility is typically conducted using 
surgical or sonographic investigation for fallopian tubal blockage [460]. However, 
even in the absence of apparent tubal occlusion women who are seropositive for C. 
trachomatis are 50% less likely to conceive other than by IVF treatment [185]. 
However, serology, particularly the gold standard microimmunofluorescence, is not 
specific enough to be used as a diagnostic to proceed directly to IVF treatment [2]. It 
is estimated that 5.5% of IVF patients have chlamydial infertility (due to positive 
Chlamydia serology) in the USA [185]. However, in spite of the prevalence of this 
condition we still only have limited understanding of the underlying disease 
mechanism that results in pathology.
In this study, gene expression of 88 innate and adaptive genes (excluding 5 
house-keeping genes) and 10 secreted cytokines were measured from PBMC from 
infertile female participants who are undergoing or had recently undergone IVF 
treatment were isolated and cultured ex vivo in the presence of C. trachomatis. The 
immune response was measured in order to help understand the possible disease 
processes that have occurred from women with a history of C. trachomatis infection. 
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5.2 MATERIALS AND METHODS
5.2.1 Patient recruitment 
Whole blood and sera was collected from fully consented voluntary participants 
attending an IVF hospital (Brisbane, Australia). 31 women with infertility (requiring 
IVF treatment with multiple etiologies) (UC Health Ethics approval 1314, QUT
Human Research Ethics approval 1300000505) participated in the study. The bloods 
were processed and the PBMC were isolated the same day it was collected. The sera 
were stored at -80qC. Chlamydia Microimmunofluorescence (MIF) IgG (Focus 
Diagnostics, USA) assay (described in detail in section 3.4.4.3.) was conducted on the 
participant sera to determine the C. trachomatis infection history status.
5.2.2 C. trachomatis strain D and F strain culture 
C. trachomatis D (ATCC VR-885) and F strain (ATCC VR-346) were cultured 
in McCoy cells. Confluent cells were infected with the strains and incubated at 37qC 
for 44 hours. Following infection, the strains were semi-purified (described in section 
3.3.1.). To prepare a mixture of C. trachomatis D and F strains, the cultures were 
mixed together (equal ratio of EBs) and purified using density gradient centrifugation 
(29% v/v urografin Ultravist® (Bayer, USA)) (described in detail in Materials and 
methods 3.3.2.), and stored in sucrose phosphate buffer at -80qC.
5.2.3 PBMC proliferation and stimulation 
Peripheral blood mononuclear cells (PBMC) were isolated and purified as 
described in the section 3.6. They were cultured in 48-well cell culture plates at a 
1x106 cells/well. The PBMCs were stimulated at a MOI of 5 with 4 antigens; purified 
C. trachomatis serovar F (ATCC VR-346), purified C. trachomatis D and F mix 
(50:50 elementary bodies (EBs)), phytohemaglutinin (PHA) (positive control) and 
media (negative control). The cells were incubated for 15 hours at 37qC. After 
incubation, the cells were centrifuged at 800 ug, and the supernatant was collected.
The pelleted cells were resuspended in 1mL of RNA cell protect® reagent (Qiagen, 
Victoria, Australia) for gene expression analysis. The plates are placed in -80qC until 
further use. 
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6.1.1. History of C. trachomatis infection
The presence of past C. trachomatis infection in women with TFI was 
determined using microimmunofluorescence (MIF) (Focus Diagnostics, USA) on 
patient sera. Those patients that were rendered positive by MIF were considered as C. 
trachomatis-positive. The method has been detailed in section 3.4.4.3.
6.1.2. Expression of innate and adaptive immune genes using RT -qPCR array
The expressions of innate and adaptive immune genes that are associated with 
C. trachomatis-related infertility in women were analysed using the Qiagen RT2
Profiler PCR array. 
5.2.4 RNA isolation from PBMC
The RNA from PBMC was extracted using the RNeasy micro kit (Qiagen, 
Victoria, Australia). The cell protectant agent was removed from the cells by
centrifuging at 3000 ug for 5 minutes at 4qC. The cells were resuspended in 350PL of 
RLT lysis buffer and the RNA was extracted as per manufacturer’s instructions. The 
concentration and purity of RNA was determined by measuring the absorbance at 
260nm and 280 nm using a NanoDrop spectrophotometer (Thermofischer, USA). The 
absorbance ratios of A260/280 >2 and A230/260 >1.2 were indicative of pure RNA. An 
on-column Dnase (Qiagen, Australia) digestion for 10 minutes at room temperature 
was conducted to remove genomic DNA. The RNA was eluted into nuclease-free 
water and stored at -80qC until use.
5.2.5 cDNA synthesis
The total RNA was reverse-transcribed to cDNA using the Qiagen First Strand 
synthesis (Qiagen, Victoria, Australia). The kit includes a genomic DNA elimination 
buffer, random hexamers and oligo dT primers for reverse transcription. The RNA 
was added to the reverse transcription mix, and incubated 42qC for 15 minutes 
followed by 95qC for 5 minutes. 6PL of the resulting mixture (1:10 dilution) was used 
directly in the RT-PCR profiler array. 
5.2.6 Expression of genes using RT-PCR profiler array 
The expression of innate and adaptive immune genes were determined using 
Qiagen RT2 Profiler PCR arrays which contains preset primers for 88 genes. The 
expression levels of all genes were normalized to 5 reference genes (ACTB, B2M, 
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GAPDH, HPRT1, RPLP0) as per manufacturer’s instructions. The RT-PCR profiler 
array involves a combination of real-time PCR performance and ability of 
microarrays to detect multiple gene expressions. The kit includes a RT2 SYBR Green 
mastermix and the 384-well plates are embedded with several controls such as 
Genomic DNA control, Reverse transcription and positive PCR controls. The arrays 
were run on the Applied Biosystems ABI7900HT PCR systems. The reaction was 
initiated at 95qC for 10 minutes, followed by 40 cycles of 15s at 95qC and 1 minute at 
60qC. The fold change between C. trachomatis-positive infertile women and C. 
trachomatis-negative infertile women were determined using 2-''Ct method [461]. 
5.2.7 Cytokine ELISAs
The level of IFN-J, IL-12, IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17 and TNF-
D were measured from the supernatants using cytokine ELISA kits (Elisakit.com, 
Melbourne, Australia) as per manufacturer’s instructions. 
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5.3 RESULTS 
5.3.1 Classification of women into cohorts based on C. trachomatis serology and 
gynecological history 
Participants were classified as C. trachomatis-positive infertile women using 
Chlamydia MIF IgG assay (four out of 31 were MIF positive and considered positive 
for C. trachomatis-related infertility). All participants were women undergoing or 
recently had IVF treatment for infertility (Table 5.1). The type of infertility was 
diagnosed using laparoscopy and the participants were characterized as positive for 
tubal infertility if they had tubal occlusion, damage or salpingitis. The participants 
who were seronegative to C. trachomatis infection were characterized as C. 
trachomatis-negative (n=27). The innate and adaptive immune responses associated 
with chlamydial infertility was analysed using cytokine ELISAs and qRT-PCR 
analysis. The immune responses induced by C. trachomatis D and F strain treatments 
within the same group were compared to the cells stimulated by media (negative 
control).
The gynecological history and demographic status of participants are outlined in 
Table 5.1. The average age of women in the C. trachomatis-positive infertile group 
was 39.5 years while the average age of women in the C. trachomatis-negative group 
was 36.8 years. In C. trachomatis-positive infertile group (n=4), 75% had tubal 
infertility accompanied by other gynecological disorders such salpingitis (n=1) PID 
(n=1) and tubal adhesion (n=2). The IVF outcome based on number of successful or 
failed live births or pregnancies after IVF treatment were reported for both C. 
trachomatis-positive infertile women and C. trachomatis-negative infertile women 
(Table 5.1). Among C. trachomatis-positive participants who underwent IVF, 75% 
were nulliparous in the past and 50% attained a successful IVF outcome. 
In the C. trachomatis-negative infertile group (n=27), 18.5% of the women had 
tubal infertility (n=5), accompanied by gynecological disorders and surgeries such as 
PID (n=1), salpinigitis (n=1), ovary removal (n=2), tubal obstruction (n=2), 
endometriosis (n=2) and polycystic ovarian syndrome (n=1). Amongst non-tubal C. 
trachomatis-negative infertile women, 33.3% (n=9) had for unknown etiology, 18.5% 
(n=5) had endometriosis (n=2). 22.2% (n=6) of the participants had polycystic 
ovarian syndrome and only one person had ectopic pregnancy and non-tubal ovary 
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removal. 77% of C. trachomatis-negative infertile women were nulliparous and about 
62% achieved a successful IVF outcome. 
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Table 5.1: Demographic and gynecological history of study participants
C. trachomatis
serology status by 
MIF
Mean 
Age 
(years) 
Type of infertility
*ectopic (n=)
*tubal(n=)
IVF outcome (live 
birth/pregnancy)
*success(n=)
*failure (n=)
Gravidas past 
*nulliparous(n=)
*multiparous (n=)
Gravidas at the 
time of
collection
(n=)
C. trachomatis-
positive infertile 
women (n=4)
39.5 Tubal (n=3) [PID (n=1); salpingitis (n=1); 
tubal adhesion (n=2)]
Unknown etiology (n=1)
Success (n=2)
Failure (n=2)
Nulliparous (n=3)
Multiparous (n=1)
0
C. trachomatis-
negative infertile 
women (n=27)
36.8 Tubal (n=5)[ovary removal (n=2); PID 
(n=1); salpingitis (n=1); tubal obstruct 
(n=2); PCOS (n=1), Endometriosis (n=2)]
Ectopic pregnancy (n=1)
Polycystic ovarian syndrome (PCOS) 
(n=6)
Endometriosis (n=5) [PID=(n=2)]
Unknown etiology (n=9)[PCOS (n=2)]
Non-tubal ovary removal (n=1)
Success (n=17)
Failure (n=10)
Nulliparous (n=21)
Multiparous (n=6)
n=7
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5.3.2 The level of IL-1E was significantly higher in women with C. trachomatis-
related infertility than in women with other forms of infertility 
The level of secreted cytokines produced by stimulated PBMCs isolated from C. 
trachomatis- positive infertile and C. trachomatis-negative infertile women was 
analysed in Figure 5.1. In response to C. trachomatis D and F EBs, high levels of IL-8 
(617.5pg/mL versus 602.5pg/mL) and TNF-D (111 pg/mL versus 71.73pg/mL) were 
secreted in PBMCs isolated from C. trachomatis-positive infertile women and C. 
trachomatis-negative infertile women. However, only IL-1E (96.42pg/mL versus 
41.42pg/mL) production in the PBMCs of C. trachomatis-positive infertile women 
was significantly higher than the levels in the PBMCs of C. trachomatis-negative 
women (p<0.05). Within the C. trachomatis-positive infertile women, the levels of 
IL-8 (617.5pg/mL and 515pg/mL), TNF-D (111pg/mL and 7.557pg/mL) and IL-1E
(96.42 pg/mL vs 7.76pg/mL) were significantly higher in the PBMC stimulated with 
C. trachomatis D and F strains compared to the negative control (Media; unstimulated 
PBMC) (Figure 5.2). Therefore, the secreted cytokines observed in the PBMC of C. 
trachomatis-positive infertile provides insight into the immune markers associated 
with C. trachomatis-related infertility.  
5.3.3 CXCL10, CXCL11 and HLA-A were significantly up-regulated in women 
with C. trachomatis-related infertility than in women with other forms of 
infertility 
Expression of 88 innate and adaptive immune genes in the stimulated PBMCs
of C. trachomatis-positive infertile and C. trachomatis-negative infertile women were
analysed using a RT-PCR array. The expression of each gene was normalized to 
reference genes and the fold change in gene expression between C. trachomatis
infertile women and women with infertility for other reasons tested (2-''Ct). Three 
genes showed increased expression levels (not significant; p > 0.05) in C. 
trachomatis-positive infertile women (n=4) compared to C. trachomatis-negative 
infertile women (n=27) (Table 5.2). The chemokines CXCL10 (5.48-fold) and 
CXCL11 (2.31-fold), and human leukocyte antigen HLA-A (2.22-fold) showed the 
most notable differences between the two participant groups (these were not 
significantly different, possibly due to the small sample size of women with C. 
trachomatis-related infertility).
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Figure 5.1: The graph shows the concentration of cytokines detected in the 
stimulated PBMCs (C. trachomatis D and F strains) of C. trachomatis- positive 
infertile women and C. trachomatis-negative infertile women .
C. trachomatis-positive infertile women (n=4) and C. trachomatis-negative infertile 
women (n=27) were compared. * indicates p<0.05. 
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Figure 5.2: The graph shows the concentration of cytokines detected in the 
stimulated PBMCs (C. trachomatis D and F strains) and unstimulated PBMCs 
(Media; negative control) of C. trachomatis- positive infertile women.
The PBMCs stimulated with C. trachomatis D and F EBs (n=4) was compared 
with the unstimulated PBMCs (media only) (n=4). * indicates p<0.05
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Table 5.2: Gene expression (2-''Ct) for PBMCs from C. trachomatis-positive infertile women compared to C. trachomatis-negative 
infertile women
Gene symbol Gene function [462] Fold change (C. 
trachomatis-positive
infertile vs C. 
trachomatis-negative
infertile)*
P value 
CXCL10 CXC motif ligand 10 or interferon gamma inducible protein 10 (IP10)- stimulation of T 
cells, natural killer cells and monocytes
5.480 0.0557889
CXCL11 Induced by IFN-J, a chemotactic for T cells 2.319 0.0717008
HLA-A Human leucocyte antigen presents peptides from endoplasmic reticulum lumen 2.224 0.0796689
MX1 Gene encodes guanosine triphosphate metabolizing protein that is induced by type I and 
type II interferons.
2.044 0.15578
TNF Tumour necrosis factor regulates cell proliferation, differentiation, apoptosis, lipid 
coagulation and metabolism. 
1.689 0.374361
HLA-E Human leucocyte antigen belongs to class I heavy chain that binds to a subset of peptides 
derived from leader peptides of other class I peptides
1.317 0.590575
C3 Complement component 3 1.190 0.471629
NFKBIA Nuclear factor of Kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 1.105 0.867405
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inhibits NFK-E/REL complexes that are involved in inflammatory responses
IRF3 Interferon regulatory transcription factor (IRF) 0.185 0.97611
IL1B Interleukin 1 induces cytokine inflammatory response and regulates a variety of cellular 
activities, including cell proliferation, differentiation, and apoptosis
1.08 0.980821
CCL5 Chemokine, chemoattractant for blood monocytes, eosinophils and memory T helper 
cells
1.055 0.806007
STAT3 Mediates the expression of a variety of genes in response to cell stimuli, cell growth and 
apoptosis
1.010 0.979167
IL8 Chemoattractant, and a potent angiogenic factor. 0.995 0.657476
FASLG Member of the tumor necrosis factor superfamily FAS/FASLG signalling pathway is 
essential for immune system regulation, including activation-induced cell death (AICD) 
of T cells and cytotoxic T lymphocyte induced cell death.
0.988 0.961924
DDX58 DEAD box proteins, putative RNA helicases 0.962 0.816789
STAT1 Signal transducer and activator of transcription (STAT1) is vital for cell viability in 
response to different pathogens and cell stimuli
0.926 0.96934
MYD88 Cytosolic adapter protein; central role in the innate and adaptive immune response. 0.913 0.870936
IFNAR1 Receptor for interferons alpha and beta 0.912 0.829671
CD14 Surface antigen expressed on monocytes/macrophages; mediates the innate immune 
response to bacterial lipopolysaccharide. 
0.875 0.886719
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IL1A Interleukin 1 cytokine family; pleiotropic cytokine involved in various inflammatory 
processes, immune responses, and hematopoiesis
0.854 0.974281
STAT4 Signal transducer and activator of transcription; essential in regulating the differentiation 
of T helper cells and for mediating responses to IL12 in lymphocytes
0.831 0.906692
CSF2 Colony stimulating factor 2; production, differentiation and function of granulocytes and 
macrophages
0.818 0.972042
IL23A Subunit of the cytokine interleukin 23 (IL23). Activate the transcription activator 
STAT4, and stimulate the production of interferon-gamma (IFNJ).
0.782 0.746775
NFKB1 Transcription regulator activated by intra- and extra-cellular stimuli such as cytokines, 
ultraviolet irradiation, oxidant-free radicals, and bacterial or viral products.
0.744 0.537021
ICAM1 Intercellular adhesion molecule 1 cell surface glycoprotein; typically expressed on 
endothelial cells and cells of the immune system.
0.710 0.988701
CD40 Member of the TNF-receptor superfamily; receptor on antigen-presenting cells. memory 
B cell development, T cell-dependent immunoglobulin class switching, and germinal 
centre formation.
0.689 0.708097
CXCR3 G protein-coupled receptor with selectivity for three chemokines, termed CXCL9/Mig 
(monokine induced by interferon-g), CXCL10/IP10 (interferonJ-inducible 10 kDa 
protein) and CXCL11/I-TAC (interferon-inducible T cell a-chemoattractant). 
0.629 0.524409
IL6 Cytokine that functions in inflammation and the maturation of B cells 0.622 0.862861
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TBX21 T-box genes encode transcription factors that regulate developmental processes. 0.591 0.556515
CASP1 Cysteine-aspartic acid protease (caspase) family; apoptosis. 0.580 0.708687
CD80 Membrane receptor; induces T-cell proliferation and cytokine production. 0.578 0.923101
IRF7 IRF7 encodes interferon regulatory factor 7 (IRF); role in the transcriptional activation of 
virus-inducible cellular genes.
0.546 0.500677
STAT6 Exert IL4 mediated biological responses that induce the expression of BCL2L1/BCL-xL, 
which is responsible for the anti-apoptotic activity of IL4
0.532 0.01862
IFNG Type II interferon family 0.519 0.741645
IFNGR1 This gene (IFNGR1) encodes the ligand-binding chain (alpha) of the gamma interferon 
receptor. 
0.515 0.253977
MAPK1 MAP kinases, also known as extracellular signal-regulated kinases (ERKs); involved in a 
wide variety of cellular processes such as proliferation, differentiation, transcription 
regulation and development.
0.448 0.928017
ITGAM This gene encodes the integrin alpha M chain. 0.441 0.797051
IFNA1 Produced by macrophages and has antiviral activity 0.4068 0.621741
CD8A The CD8 antigen is a cell surface glycoprotein found on cytotoxic T lymphocytes. 
Mediates efficient immune cell-cell interactions 
0.403 0.874176
IFNB1 Production of Interferon E 0.394 0.606598
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TRAF6 TNF receptor associated factor (TRAF) protein family; mediate signal transduction 0.392 0.8323
NOD1 NOD (nucleotide-binding oligomerization domain) family; cytosolic protein, 0.374 0.857525
CXCR5 This gene encodes a multi-pass membrane protein that belongs to the CXC chemokine 
receptor family; binds to B-lymphocyte chemoattractant (BLC).
0.359 0.678219
CD4 Membrane glycoprotein of T lymphocytes; interacts with major histocompatibility 
complex class II antigens.
0.340 0.700329
CD86 Expressed by antigen-presenting cells; is the ligand for two proteins at the cell surface of 
T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4
0.323 0.549186
MAPK8 MAP kinases; involved in a wide variety of cellular processes such as proliferation, 
differentiation, transcription regulation and development.
0.310 0.591922
CCL2 Chemokine displays chemotactic activity for monocytes and basophils 0.294 0.601704
IL10 Cytokine pleiotropic effects in immunoregulation and inflammation. 0.292 0.539064
TICAM1 Adaptor protein containing a Toll/interleukin-1 receptor (TIR) homology domain, 
mediates signal-transduction components and protein-protein interactions between the 
Toll-like receptors (TLRs).
0.271 0.651261
JAK2 Janus kinase 2 involved in a cytokine receptor signalling pathways; is required for 
responses to gamma interferon.
0.257 0.291592
LYZ Lysozyme, targets bacterial cell wall peptidoglycan 0.257 0.72527
TLR3 Toll-like receptor (TLR) family; pathogen recognition and activation of innate 0.2541 0.722248
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immunity.
IL2 Proliferation of T and B lymphocytes 0.225 0.712847
CCR6 Beta chemokine receptor family; preferentially expressed by immature dendritic cells 
and memory T cells.
0.211 0.573793
TLR7 Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition 
and activation of innate immunity
0.204 0.416802
IRAK1 Interleukin-1 receptor-associated kinase 1; partially responsible for IL1-induced 
upregulation of the transcription factor NF-kappa B.
0.198 0.637532
CD40LG Surface of T cells; regulates B cell function by engaging CD40 0.191 0.866972
SLC11A1 Solute carrier family 11 (proton-coupled divalent metal ion transporters) family divalent 
transition metal transporter 
0.183 0.574461
FOXP3 Member of forkhead/winged-helix family of transcriptional regulator 0.162 0.614845
NLRP3 Upstream activator of NF-kappaB signaling, and it plays a role in the regulation of 
inflammation, the immune response, and apoptosis.
0.159 0.604511
TLR2 Member of the Toll-like receptor (TLR) family; fundamental role in pathogen 
recognition and activation of innate immunity
0.143 0.172989
CCR5 Beta chemokine receptor family, 0.142 0.39416
IL18 Proinflammatory cytokine; augments natural killer cell activity and stimulates interferon 
gamma production in T-helper type I cells.
0.138 0.639216
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IL1R1 Cytokine receptor interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor 
antagonist
0.117 0.579764
TLR1 Plays a fundamental role in pathogen recognition and activation of innate immunity 0.098 0.544638
TLR4 Lipopolysaccharide (LPS) found in most Gram-negative bacteria induces signal 
transduction events
0.098 0.532769
LY96 Protein associates with toll-like receptor 4 on the cell surface and confers responsiveness 
to lipopolysaccyaride (LPS)
0.089 0.675998
NOD2 Nod1/Apaf-1 family; primarily expressed in the peripheral blood leukocytes; role in the 
immune response to intracellular bacterial lipopolysaccharides (LPS)
0.088 0.653912
TLR8 Predominantly expressed in lung and peripheral blood leukocytes 0.086 0.569824
TLR6 Receptor functionally interacts with toll-like receptor 2 to mediate cellular response to 
bacterial lipoproteins
0.081 0.552111
RAG1 Involved in activation of immunoglobulin V-D-J recombination and recognition of the 
DNA substrate
0.081 0.658209
IL5 Interleukin 5 cytokine acts as a growth and differentiation factor for both B cells and 
eosinophils
0.080 0.626102
GATA3 GATA family of transcription factors; endothelial cell biology. 0.080 0.663112
IL17A Proinflammatory cytokine produced by activated T cells; regulates the activities of 
mitogen-activated protein kinases and NF-kappaB 
0.078 0.655239
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TLR5 Receptor mobilizes the nuclear factor NF-NB; inflammatory gene regulation 0.076 0.632839
CXCL13 Chemokine; promotes the migration of B lymphocytes 0.075 0.642325
IL4 Interleukin 4; pleiotropic cytokine produced by activated T cells 0.073 0.648235
MBL2 Soluble mannose-binding lectin found in serum; innate immune 0.073 0.651894
APCS Glycoprotein; 0.072 0.637162
TLR9 Toll-like receptor (TLR) family; role in pathogen recognition and activation of innate 
immunity
0.072 0.636229
CRP Host defence related functions; recognize foreign pathogens 0.071 0.651894
IL22 Interleukin-22 (IL-22); host defence at mucosal surfaces [463] 0.045 0.646686
IL13 Immunoregulatory cytokine; B-cell maturation 0.041 0.646695
MPO Myeloperoxidase (MPO). 0.037 0.611395
CCR4 G-protein-coupled receptor family; receptor for the CC chemokine 0.036 0.688041
TYK2 Tyrosine kinase Janus kinases (JAKs) protein families; interferon signalling pathways. 0.034 0.671997
CCR8 Beta chemokine receptor family; G protein-coupled receptors; important for migration of 
various cell types into the inflammatory sites.
0.015
RORC DNA-binding transcription factor; inhibits the expression of Fas ligand and IL2. 0.081 0.640822
*'CT was obtained by normalizing the level of expression of gene of interest to the expression level of housekeeping genes (HKG) ('CT= CTGOI - CTAVG HKG). Fold 
change in gene expression (2-''CT) was determined by dividing the normalized expression of gene of interest of the experimental sample by the normalized expression of 
the same gene of interest in the control sample; where ''CT= 'CT (C. trachomatis-positive infertile sample)- 'CT (C. trachomatis-negative infertile sample
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5.4 DISCUSSION
The cytokines secreted in response to CT stimulation and expression of 
immune genes in peripheral blood mononuclear cells were tested to provide 
information into the immune pathway modulated by C. trachomatis in women with
chlamydia-related infertility. Within 15 hours of co-culture with C. trachomatis, 
three immune genes, HLA-A (2.224-fold), CXCL10 (5.480- fold) and CXCL11 
(2.31-fold) were expressed at greater than 2 fold higher levels in C. trachomatis-
positive infertile women compared to C. trachomatis-negative infertile women (not 
significant). Amongst secreted cytokines, IL-1E was significantly up-regulated in 
women with C. trachomatis-related infertility compared to infertile women 
seronegative for C. trachomatis (p<0.05). The PBMCs were stimulated with a mix of 
two well characterized and common C. trachomatis strains, rather than a single 
strain, although these may not have been the same as the strain that originally 
infected the participants to cause the infertility. Serovar F is one of the most 
prevalent C. trachomatis strains in Australia [124]. Serovar D was reportedly found 
to be predominant in women with PCR confirmed C. trachomatis infection and 
elicited the highest mean IgG response (Mean IgG titre of 200) compared to other 
serovars such as such as serovas B, C and I [293]. Genotyping of C. trachomatis
from endocervical specimens of infertile Mexican women (n=152) who were positive 
for C. trachomatis infection (n=24), revealed that serovar F was the most prevalent 
serovar (54.2%), as compared to other serovars (serovars K, E, LGV, D, H, Ia) [464]. 
These two strains will not cover all of the relevant diversity of C. trachomatis, but 
were used to provide more diversity in the simulating antigen mix than a single 
strain. 
In this study, the expression of HLA-class I molecule, ecncoded by the HLA-A 
gene was upregulated in women with C. trachomatis-related infertility (not 
significant). Infection by C. trachomatis is likely to trigger a range of immune 
responses as a result of antigen binding human leukocyte antigens (HLA) molecules. 
Although several studies have established strong association between HLA class II 
molecules and their genotypes in women with chlamydial infertility [172, 465], HLA 
class I molecules and alleles have also been reported to in increasing the 
susceptibility to tubal pathology and infertility caused by C. trachomatis infections 
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[466, 467]. Kimani et al. [466] reported that HLA-A31 allele was a significant risk 
factor for C. trachomatis PID (OR (95%CI): 3.9(1.04-14.5); p=0.04; n=23) in a 
longitudinal study of urban female sex worker in Kenya (n=23 PID cases). 
Additionally, HLA-A2 was reported to elicit cytotoxic T lymphocyte responses to C. 
trachomatis MOMP in peripheral blood of patients infected by C. trachomatis [467]. 
Therefore, the upregulation of HLA-A genes in women with C. trachomatis-related 
infertility indicate that functional CD8+ T cytotoxic lymphocytes may play a role in 
chlamydial pathology.
The study also showed an increased expression of two chemokines, CXCL10 
(IP-10) and CXCL11 (IFN-inducible T cell D-chemoattractant or i-TAC) in PBMCs 
fromwomen with C. trachomatis-related infertility compared to PBMCs from
infertile women seronegative for C. trachomatis. Chemokines are small pro-
inflammatory molecules that induce migration of leucocytes [468]. The role of 
CXCL10 in protective immunity against chlamydial infections has been implicated 
in several studies [469-475]. The cytokine response to C. trachomatis in endocervical 
epithelium showed that there was a reduction of CXCL10 in polarized polA2EN 
epithelial cells [470]. CXCL10 recruits CXCR3 and CCR5 positive leukocytes such 
as T cells and natural killer cells to the site of infection and regulates IFN-J-
mediated resolution of C. trachomatis [470]. The reduced levels of CXCL10 indicate 
that endocervial epithelial cells could subvert the chemokine, which prevents the 
migration of IFN-J producing T cells to the site of infection, thus leading to 
pathology [470]. The C. muridarum model has also been used to investigate the role 
of CXCL10 in protective immunity against C. trachomatis infections [469]. The 
study showed that the levels of CXCL10 was highest 21 days post infection and 
declined after 42 days which corresponded with resolution of the disease. 
Additionally, previous studies using mouse models have shown that CXCL10 is 
predominantly expressed in upper genital tract infection and mediate protection 
through Th1 or pro-inflammatory immunity [469, 473, 476]. Similar to CXCL10, 
CXCL11 is also induced by IFN-J, which recruit CCR3, and is exclusively 
associated with Th1 responses [477].Wan et al. [478] showed that CXCL11 gene 
expression levels were higher in the secretory phase of endocervical epithelial cells 
on infection with C. trachomatis, thus indicating the potential role of hormones in 
modulating immune system. Thus, the upregulation of both CXCL10 and CXL11 in 
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the mononuclear cells of women with chlamydial infertility are indicative of Th1 
mediated immune-responses against C. trachomatis infection. 
Whilst a trend towards an increase in mRNA levels were observed for IL-1E
and TNF-D (not significant), ELISAs detection of the secreted protein showed that 
secreted IL-1E levels were significantly higher in PBMC isolated from women with 
C. trachomatis-related infertility as compared to PBMCs from C. trachomatis
seronegative infertile women (p<0.05). Consistent with the findings of Hvid et al.
[266], this study also shows that IL-1E is the pro-inflammatory cytokine induced by 
C. trachomatis infection, and an important contributor to pathology during C. 
trachomatis infections. Here the IL-1E was detected from primary ex vivo culture of 
PBMC rather than reproductive tract epithelia (as in Hvid et al., [266]), suggesting 
that both the innate epithelial response and innate mononuclear response from some 
women in response to C. trachomatis infection is pro-inflammatory and involves IL-
1E. TNF-D, a pro-inflammatory multifunctional cytokine that triggers a variety of 
immune responses on infection, also regulates production of several cytokines by 
activating various components of cellular signal transduction that has detrimental 
effect on the genital tract [479, 480]. 
Murine models have previously established the role of CD8+T cells mediated 
upper genital tract pathology via production on TNF-D by examining the oviduct 
pathology in TNF-D deficient mice [481] and OT-1 transgenic mice (CD8+T respond 
only to Ova 257-264 peptide, and not C. trachomatis- specific antigens) [482]
transgenic mice. In cervical mononuclear cells isolated from infertile women (n=70) 
stimulated with cHSP60 and cHSP10, an increase in the production of TNF-D
suggests that it maybe involved in the immunopathological condition associated with 
infertility [303]. Both IL-1E and TNF-D are potent inducers of IL-8 [479], hence high 
levels of the cytokine were observed in the supernatants of women with C. 
trachomatis-related infertility. 
The serology and gynaecology status of the participants recruited from IVF 
clinics showed that patients who were positive for chlamydial serology were 
predominantly positive for tubal pathology (75%) as compared to those who were 
negative for chlamydial serology (18.5%). C. trachomatis specific IgG antibodies in 
sera are indicative of chlamydial infertility as it was reported to be higher in women 
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with tubal factor infertility (41.4%; n=33) [165]. Analysis of follicular liquid of 253 
IVF patients revealed that cHSP60 antibodies were predominant in infertile women 
with tubal occlusion (69.5%), and it was also predominant in 74.1% of women 
whose embryo implantation failed during IVF [184]. Sharara et al. [483] showed that 
the presence of elevated serum C. trachomatis IgG in infertile women undergoing 
gamete intra-fallopian transfer cycles significantly lowered the implantation rate 
(7.1% in C. trachomatis-positive group vs 16.5% in negative C. trachomatis-
negative group) and increased the early pregnancy loss (33.3% in C. trachomatis-
positive vs 14.6% in C. trachomatis-negative group). In this study, 75% of women 
with C. trachomatis –related infertility were nulliparous compared to 62% of infertile 
seronegative for C. trachomatis. This is consistent with the findings of Coppus et al.
[484] that showed that positive C. trachomatis IgG serology in women with tubal 
pathology (n=1882) was associated with 33% lower conception rate. Thus, CXCL10, 
CXCL11, HLA-A and IL-1E maybe associated with the pathology in the upper 
genital tract that lead to severe tubal damage and lower pregnancy rate in women 
with C. trachomatis-related infertility. 
The limitations of our study include a small sample size that might account for 
the lack of significance between the groups for many factors. By restricting the 
stimulation to 15 hours, we were able to effectively identify early mononuclear 
cellular responses that are associated with C. trachomatis-related infertility in 
women. The observed differences in responses here for women with C. trachomatis-
related infertility compared to women with other causes of infertility supports the 
model that some women launch a more pronounced pro-inflammatory response to 
the infection and thus develop more serious pathology and disease sequelae and these 
responses may reflect the original response to the infection in the local tissue. 
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6.1 INTRODUCTION
Chlamydia (C.) trachomatis is one of the most common bacterial sexually 
transmitted infections in the world [102]. Due to the asymptomatic nature of the 
disease, the infection is frequently undiagnosed, resulting in the development of 
serious sequelae such as pelvic inflammatory disease, ectopic pregnancy and tubal 
infertility in women [485, 486]. Clinical infertility or subfertility is defined as the 
inability to become pregnant after 12 months of unprotected intercourse [374]. The 
lack of adequate diagnosis and timely treatment of the disease has allowed this 
infection to reach endemic levels in developing countries [487]. 
The prevalence rate (estimated by PCR) ranges from 1.5% to 5% in the 
developed affluent countries [488, 489] while it is significantly higher, ranging from 
3.7% to 15% in the developing world [490, 491]. In the United States, between the 
years 1999 and 2000, a cross-sectional population assessment of C. trachomatis
infection in 20,836 people aged 14-39 years estimated that the overall prevalence as 
1.6% [492]. However, in the years 2007-2008, an increase in the prevalence rate to 
2.2% was reported in 2667 women aged between 14- 39 years [492]. A similar 
prevalence rate of 2.0% was recorded among pregnant women aged 15-24 years 
recruited from prenatal clinics in the United States between the years 2004-2009 
[493]. The prevalence rate in Europe was similar to that reported in United States. 
For instance, a prevalence rate of 2.2% was reported in in German adolescents 
(n=1136 girls) using a nucleic acid amplification test (strand displacement 
amplification)[494]. A prevalence rate similar to Germany was reported in Ireland, 
where the prevalence of C. trachomatis infection in women recruited from antenatal 
clinics was 3.7% using polymerase chain reaction (PCR) (n=945)[495]. Conversely, 
a high prevalence rate of 7.3% (estimated by PCR) was reported in a cross-sectional 
population based study of adolescent girls in Norway, and the study further reported 
that girls were twice as more likely to be infected as boys (95% CI 5.3-9.7 vs 2.3-6) 
[496]. Similarly, a cross-sectional population based sero-surveillance study in 
Netherlands showed that seroprevalence of C. trachomatis infection in women aged 
15-39 years was 10% [497]. Davies et al. [111] reported that in 307 sex workers 
recruited from Genito- Urinary Medicine (London), the rate of PID in women with 
recent chlamydial infection was 27.4 per 100 person-years as compared to the 11.2 in 
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women with previous chlamydial infection as estimated by direct 
immunofluorescence.
In developing countries such as Nigeria, the overall prevalence rate of 
asymptomatic C. trachomatis infection estimated by PCR in 132 infertile women 
attending Gynaecological clinic was 20.5% as opposed to 10.4% in the UK and other 
developed countries [125, 126]. Out of 125 patients attending infertility and STD 
clinics in Nigeria, the prevalence rate was 8.7% in the fertility clinic (estimated by 
Chlamydia Rapid test, an immunoassay technique that detects C. trachomatis from 
swab or urine) and 10.7% in an STD clinic [128]. Using PCR, a similar prevalence 
rate to Nigeria of 18.6% also reported amongst infertile women (n=264) in India 
[498]. A higher prevalence rate of 52.8% (n=106) was reported in infertile women 
attending fertility clinics in the Manaus-Amazon (Brazil) using PCR [348]. The 
higher incidence of C. trachomatis infection has been reported in developing 
countries could be accounted by lack of regular screening strategies or untimely 
treatment of the infection, resulting in recurrent re-infection and transmission of the 
infection. Table 6.1 lists the prevalence of C. trachomatis infections in developed 
and developing countries. 
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Table 6.1:The prevalence of C. trachomatis infections in developed and developing countries
Country Study setting (number of women) Prevalence Testing method Reference
USA Population-based assessment 
(n=2667)
2.2% PCR [492]
USA Prenatal clinics (n=166) 2% PCR [493]
Germany Adolescent girls (n=1136) 2.2% PCR [494]
Ireland Antenatal clinics (n=945) 3.7% PCR [495]
Norway Adolescent girls (n=800) 7.3% PCR [496]
Netherlands Population sero-surveillance 
study
10% CAT [497]
India Gynaecology outpatient clinic 
(n=593)
23% PCR [487]
Italy STD outpatient clinic (n=43) 18.6% PCR [489]
Kenya Antenatal clinic (n=300) 6% Chlamydia Rapid Test [490]
Egypt IVF clinics 40% PCR and CAT [499]
Nigeria Population based prospective 
study (n=286)
29.4% CAT [500]
Haiti Women’s health clinic (n=303) 11.9% PCR [501]
Spain Cross-sectional population study 
(n=277)
4% PCR [502]
Suva Antenatal clinics (n=440) 50% CAT [503]
Iran Obstetrics and Gynaecology 
clinics (n=255)
2.4% PCR [504]
Samoa Antenatal clinics (n=299) 26.8% PCR [505]
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Sullivan et al. [506] previously estimated the prevalence rate of C. trachomatis
infection in Samoa to be 30.9%, based on pregnant women (mean age =26 years)
attending antenatal clinics between the years 1999 and 2000 (n = 427). The 
prevalence of sexually transmitted infections in pregnant women from antenatal 
clinics was also studied by Cliffe et al. [505] between the years 2004 and 2005 who 
reported that amongst all STIs such as Gonorrhoea and Syphilis, chlamydial 
prevalence (n=299) was the highest in women of all ages (26.8%) who were 
recruited from antenatal clinics. However, this group may not represent the general 
or at risk members of the population and consequently, an accurate estimate of the 
prevalence remains unknown. The high incidence of C. trachomatis infection may 
imply a high probability of increased risk of sequelae such as infertility in Samoan 
women. 
Serological assays have been used to detect anti-chlamydial antibodies during 
the infertility investigation in women as a method to predict women with tubal factor 
or chlamydial infertility [359, 377]. There are several serological tests that could be 
used to detect C. trachomatis infection. The Microimmunofluorescence (MIF) test 
developed by Wang and Grayston [366] showed a high sensitivity and it is still 
considered the serologic “gold standard”. However, it is labour intensive and highly 
subjective [2]. This has accounted for poor interpretation of MIF results that has led
to conclusions about its poor specificity. Enzyme linked immunosorbent assay 
(ELISA), overcomes the problems posed by MIF with high specificity to C. 
trachomatis as it is based on recombinant chlamydial antigens [371]. Since 
Chlamydia IgG antibodies in serum are associated with tubal pathology, ELISAs
have been introduced as non-invasive screening for implementation during the initial 
fertility investigation in some countries [365, 400]. For instance, Muvunyi et al.
[359] demonstrated that three commercial ELISA kits, ANILabsystems IgG, Vircell 
IgG and ANILabsystems IgA had a high specificity of 84%, 86%, 95% respectively 
and a positive predictive values of 73%, 76% and 81% respectively, in detecting 
tubal pathology (n=312). Thomas et al. [400] estimated that in participants with 
infertility (n=57), an IgG titer greater than 1 in 32 was effective identifying those 
with tubal damage. 
While IgG titres are indicative of past infection, positive chlamydial IgA titres 
indicate active ongoing infection [357]. Serum IgA antibodies have a half-life of 
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about 5-7 days; hence they are useful markers of active chlamydial infections [507]. 
A number of commercial ELISAs are available to detect C. trachomatis infections.
They are often based on variable domains of MOMP synthetic peptide specific to C. 
trachomatis [371]. MOMP makes up to 60% of the outer membrane protein content 
and contains species- specific and serotype- specific epitopes [390, 393, 410, 437]. 
Several studies have implicated strong serological responses to cHsp60 (Heat Shock 
Protein60) and cHsp10 in women with subfertility [304, 508-510]. Therefore, several 
commercial kits utilise cHSP60 protein or peptide as the antigen to detect persistent 
infection or past infection. In a meta-analysis of published evaluations of various 
assays, Broeze and co-workers identified that micro immune-fluorescence (MIF) 
(various companies) was the most sensitive, but relatively low in specificity. In the 
same study, the MEDAC and ANIlabsystems ELISAsystems enzyme linked 
immunosorbent assays (ELISA) appeared to be the most specific, although less 
sensitive than MIF [365] to diagnose women with uni or bi-lateral tubal damage 
detected by surgical or sonographic technologies. These commercial tests are based 
on whole Chlamydia (MIF), or antigens (typically the major outer membrane protein 
(MOMP) and/or cHSP60). Numerous studies have reported a correlation with 
Chlamydia antibody testing (CAT) against MOMP and/or cHSP60 with diagnosed 
tubal infertility [365]. However, a proportion of women with infertility and who are 
serologically positive by CAT are absent of detectable tubal blockage or adhesions, 
but still require IVF to conceive [365].
Nucleic acid amplification tests are highly accurate techniques that are widely 
used in C. trachomatis diagnosis [318]. They detect chlamydial nucleic acids, 
transcripts from genital specimens, and non-invasive samples such urine specimens 
and self -obtained vaginal swabs, and are highly sensitive [318]. The evaluation of 
the sensitivity and specificity of NAAT techniques such as strand displacement 
amplification (SDA), PCR and Abbott ligase reaction (LCR) to C. trachomatis
showed that the three techniques performed similarly with regards to sensitivity and 
specificity [326]. However, when compared to the performance of 
enzymeimmunoassay, the detection rate for PCR was 62% higher than that of ELISA 
[327].Although it cannot be used to detect past infections, its superior sensitivity and 
specificity allows efficient diagnosis of active C. trachomatis infection [511]. In 
fertility studies, several reports on women with infertility have shown that PCR 
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prevalence rate of C. trachomatis may be lower than seroprevalence rate which 
indicates that markers of past chlamydial infections are important in determining 
chlamydial infertility as infertile women may not longer have the infection [512-
514]. 
In developing countries, very little is known about C. trachomatis and 
infertility. In Rwanda, 67.8% of sub-fertile women attending a fertility clinic were 
found to have tubal pathology by hysterosalpinography, and of these 38 (20.5%) 
were also found to have C. trachomatis serum antibodies using the ANILabsystems 
IgG ELISA for C. trachomatis infertility [365]. In India, 55% of women with 
secondary infertility had C. trachomatis IgG antibodies, and of these 63.6% had 
confirmed tubal occlusion [406]. In Ghana, women reporting infertility were more 
likely to have C. trachomatis IgG antibodies (odds ratio 2.1) compared to fertile 
women in a case-control study design that included 439 women (39% vs. 19%) 
[514]. Additionally in Alexandria, Egypt, higher titers of anti-Chlamydia IgG 
antibodies were significantly more likely in women with TFI and ectopic pregnancy 
compared to fertile or healthy pregnant controls [515]. These studies suggest that in 
fertility clinic studies within developing countries, C. trachomatis infertility is more 
common than that reported in developed countries. 
In the current study, a sero-epidemiological analysis on a Samoan population 
of women was conducted using existing commercial serological kits to evaluate both, 
the prevalence of, and the epidemiological risk factors associated with infertility 
caused by C. trachomatis. 
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6.2 MATERIALS AND METHODS
6.2.1 Epidemiological and serological assignment of groups 
The following figure (Fig 6.1) summarises the assignment and characterization 
of Samoan women using clinical history and serological techniques. It includes the 
number of samples analysed in the study and the tests conducted on the samples on 
the sexually active women in Samoa. The inclusion criteria were that participants 
were (1) sexually active (2) do not use contraceptives (3) have stayed a minimum of 
one year in the village, and (4) they should not have undergone any gynaecological 
surgeries that would render them infertile or unable to reproduce. 
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Figure 6.1: Schematic representation of the cross-sectional study design and 
analysis including the epidemiological assignment of cohorts and the serological 
assays.
The cross-sectional study included 239 female participants between the ages 18-29. 
Based on the patient data sheet, patients with incomplete data or unknown status 
were excluded from data analysis and the participants that satisfied the inclusion 
criteria were categorized as self-reported fertile (n=152) and self-reported infertile
(n=87).
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6.2.2. Cross-sectional participant recruitment in Samoan population
Study design and sample size estimation
The study design and sampling for this study has already been published in 
Walsh et al. [516]. This was a cross-sectional study set on the island of Samoa, 
which comprises of two main islands, Savaii and Upolu, and six smaller outer 
islands. Samoa is divided into four regions, the Apia Urban Area (63 villages), Upolu 
(111 villages), North-West Upolu (54 villages), and Savai’i (102 villages). Based on 
the Samoa demographic and health survey of 2009 [517], 47% of women were 
sexually active, of which 30% were assumed to meet the inclusion criteria and could 
participate in the study. The estimated C. trachomatis prevalence was 30% [505],
and in order to obtain 95% confidence interval from 26.8 to 33.2%, 800 participants 
needed to be recruited through cluster sampling method. The cluster sampling 
method included grouping the villages into 16 clusters and the samples were 
collected randomly using a sampling interval number. This yielded a total of 48 
villages, with each cluster encompassing between 1 and six villages. This cluster 
design would ensure that a minimum of 125 participants be recruited, with 50 
participants recruited from each cluster [516]. Due to the subsequent damage caused 
by the cyclone that hit in 2011, seven villages were excluded from the study. For the 
41 selected villages, the Ministry of Women, Community and Social Development 
provided the contact details of Sui o le Malo or Sui tama’ita’i o le Nu’u 
(representative of the village women’s committee) for each village. 249 sexually 
active women from the ages of 18-29 years were recruited from 41 villages. The 
approval was obtained from National University of Samoa Research Ethics 
Committee, the Oceania University of Medicine, The Samoan Ministry of Health and 
the Lower South Regional Ethics Committee in New Zealand (LRS/10/11/059). The 
approval for the study was also obtained from Queensland University of Technology 
Human Research Ethics Committee (approval number 1100000276). 
Collection of demographic and epidemiological information
Participants provided informed written consent, and completed an interview-
led questionnaire addressing their reproductive history, sexual, lifestyle and medical 
(general health, current levels of smoking, drinking, exercise, BMI) and demographic 
information (age, marital status, educational level, own and partner’s occupation). 
Table 8.4.in the appendix lists the demographic and epidemiological information of 
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the participants. The questionnaire responses were used to assign women to 
‘infertile’ (or otherwise ‘fertile’) groups based on reporting at least 12 months of 
unprotected intercourse without conceiving a pregnancy. Based on the questionnaire, 
women were classified as self-reported infertile if they reported that they have been 
trying to get pregnant, and they have been doing so for more than a year . Women 
who have indicated no problems in getting pregnant and have taken less than 1 year 
to do so were categorized as fertile. The recruitment was conducted in schools, 
churches and community halls in larger villages, and local Women’s committee 
members house was used in smaller villages. A nurse was appointed to record all the 
responses of the participants and the participants who tested positive for C. 
trachomatis were given 1000 mg of azithromycin. Their partners or recent sexual 
contact were also provided with 1000mg of azithromycin. 
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6.2.3. Diagnosis of Chlamydia trachomatis infection using NAAT
After completing their questionnaire, the first catch urine specimen and blood 
(processed to obtain sera) samples were collected from these patients. All 
questionnaires and urine specimens were de-identified labelled with the participant’s 
unique study code, and the urine specimens were analysed locally with BD 
ProbeTech Chlamydia Amplified DNA assay according to manufacture’s 
recommendations (Becton, Dickson, Franklin Lake, New Jersey, USA) as previously 
reported [516]. Urine specimens were transported to the laboratory at the end of each 
village visit. Any sample showing inhibition in the test was repeated twice and 
reported as inhibited if the tests continued to fail. 
6.2.4. Serological diagnosis of C. trachomatis infection 
The participant sera were tested for C. trachomatis antibodies using three 
commercial tests; Chlamydia trachomatis-IgG ELISA-plus MEDAC (peptides from 
MOMP protein) and cHSP60-IgG ELISA MEDAC (cHSP60 protein). The kits were 
used according to the manufacturer’s instructions. According to the MEDAC 
manufacturer-provided instructions, samples positive in both MEDAC IgG C. 
trachomatis pELISA and cHSP60 IgG ELISA indicate a high risk of developing C. 
trachomatis induced tubal factor infertility (MEDAC Infertile). ANILabsystems C. 
trachomatis IgG ELISA based on synthetic peptides from C. trachomatis -specific 
variable domain of MOMP (major outer membrane protein), identified women with 
C. trachomatis PCR diagnosed infection and infertility with a sensitivity and 
specificity of 84% and 91% respectively (n=303) [365]. C. trachomatis IgA pELISA 
MEDAC which is also based on the immunodominant region of MOMP peptide
measures the level of IgA antibodies which is an indication of current infection.
Mouton et al. showed that MEDAC IgA pELISA had a sensitivity of 53.3% and 
specificity of 90.2% in identifying women with tubal factor pathology (n=15)[437]. 
According to the manufacturer’s instructions, samples positive for MEDAC IgG p-
ELISA and C. trachomatis IgA pELISA MEDAC are definite positive for C. 
trachomatis infection. However, if they were positive only in MEDAC IgA assay, 
then the participant has a possibility of early stages of infection.
Chapter 6: Sero- epidemiological assessment of C. trachomatis infection and infertility in Samoan women 173
6.2.5. Statistical analysis
Serological assays were conducted on all serological specimens collected 
during this study and analysed against epidemiological and PCR data. All statistics 
were calculated in R statistical environment (3.0.3) using the ‘EpiR (0.9-57) and 
‘metafor’ package (1.9-2) for calculation and presentation of odds ratios (forest 
plots) and embedded routines for generalized linear models for logistic regression
[413]. Odds ratios (OR) were calculated with restricted maximum likelihood 
estimates of error.
6.3. RESULTS
6.3.1. Epidemiological and demographic factors associated with infertility 
Table 6.2 lists the epidemiological and demographic factors that are associated 
with infertility. The factors that significantly associated to infertility were age, 
alcohol (frequency of drinking beer and spirits) and relationship status (p<0.05). The 
BMI of 10 women (5 infertile) were not reported. Hence, the BMI of only 82 women 
were included. Younger women between the 18-24 years, who were single, with no 
children and did not consume alcohol, were more likely to be infertile than fertile. 
The likelihood of developing infertility was four times higher in women who were 
between the ages of 18-24 years as compared to women who between the ages of 25-
29 years (OR=4.22, 95% CI=2.27-7.84), and in women who were single as compared 
to married/de-facto/separated/widowed (OR=4.00, 95% CI=2.2342-7.1613). 
Although not significant, women who were unemployed were five times more likely 
to develop infertility as compared to women who were employed (OR=5.32, 95% 
CI= 2.3-12.4).
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Table 6.2:The effect of epidemiological and demographic factors on infertility 
using chi-square tests 
Infertility vs Fertility Number 
of 
infertile 
women
Chi 
square 
value
P 
value 
OR (95% CI)
Age
18-24 years
25-29 years
70
17
22.453 <0.01 4.22 (2.2786-
7.8431)
BMI
Underweight 
Normal weight
Over weight
Obese 
0
14
37
31
3.216 0.36
-
-
1.3974 (0.686-
2.8458)
1.567 (0.75-3.26)
Problems becoming 
pregnant
No
Yes
1
1
0.155 0.694 -
1.76 (0.107-28.7)
Age of first sex
19years or older
18 years or lesser
55
32 0.255 0.614
0.8679 (0.5-1.50)
Number of sex partners
1 sex partner
2 sex partners
3 or more sex partners
54
20
13
4.629 0.099
1.77 (1.03-3.03)
Paid work
No
Yes
66
21
3.502 0.061 5.32 (2.3-12.4)
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6.3.2. A high proportion of women reporting infertility by an epidemiological 
questionnaire were serologically predicted to have chlamydial infertility
There were 239 participants in the study, and 152 of these were identified as 
being fertile. The remaining 87 women were defined as infertile. The commercial 
assays that are specifically developed to detect women with C. trachomatis infertility
(MEDAC Infertile, ANILabsystems ELISA) or women with C. trachomatis infection 
history (MEDAC MOMP, MEDAC cHSP60), or current infection (MEDAC IgA) 
were used to investigate the participant’s serological responses. 
Figure 6.2. illustrates the correlation between the diagnostic tests; PCR, 
MEDAC infertile, MEDAC MOMP, MEDAC IgA and ANILabsystems ELISA. A 
total of 9 participants were positive in all five assays including PCR. 4 participants 
tested positive only in ANILabsystems IgG ELISA, while 19 participants were 
uniquely recognized by MEDAC cHSP60 IgG ELISA. PCR, MEDAC IgA ELISA 
and MEDAC MOMP ELISA were able to identify only 5, 2 and 1 participant 
respectively. 11 participants showed co-positivity between all three IgG serological 
assays, while 16 participants showed positivity in all three IgG serological and PCR.
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Figure 6.2: Venn diagram representing concordance of positive results for PCR 
status, MEDAC Infertile and ANILabsystems ELISA, MEDAC cHSP60 and 
MEDAC IgA serology
112 participant results, excluding 127 participants who were unequivocal or 
beyond the detection range of the assay, were analysed for positive results in 
either/both or all ANILabsystems ELISA, MEDAC Infertile, MEDAC MOMP, 
MEDAC cHSP60, MEDAC IgA or current infection (PCR) tests. 9 of the 112
women testing ANILabsystems ELISA, MEDAC MOMP, MEDAC cHSP60, 
MEDAC IgA and MEDAC Infertile positive demonstrated current infection. 
Table 6.3 summarizes the ability of commercial serological assays to 
differentiate self-reported infertility in women from the fertile women in the 
population. Participant sera that tested equivocal or whose absorbance values lay 
beyond the upper and lower limit range of positive and negative controls were 
excluded from analysis. Therefore, out of 239 participants in the study, MEDAC 
infertile assay comprised of 163 participants, while 205 participants were included in 
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MEDAC MOMP. 182 participants, 218 participants and 192 participants were 
included in MEDAC cHSP60 IgG ELISA, MEDAC IgA ELISA and ANILabsystems 
IgG ELISA respectively. With 38 infertile participants in MEDAC MOMP assay 
(61.2%; OR (95%CI): 1.94 (1.09, 3.46), the assay showed significant association 
with infertility (p=0.024) and were almost twice as more likely to be infertile than 
fertile. Although not significant, participants who tested positive in MEDAC infertile 
assay and ANILabsystems were 1.7 and 1.75 times more likely to be infertile than 
fertile, respectively.
Among 85 participants positive by PCR (Figure 6.2.B), 34 women (were
seropositive in MEDAC Infertile and was significantly associated with the PCR 
status (p<0.01; OR=4.36, 95% CI= 2.19-8.68). In addition to MEDAC Infertile, all 
serological assays including MEDAC MOMP, MEDAC IgA and ANILabsystems 
IgG could significantly differentiate participants with acute C. trachomatis infections 
from those without (p<0.01). Amongst the serological assays, ANILabsystems IgG 
ELISA had the highest odds ratio, with PCR positive participants testing positive in 
ANILabsystems 6 times more than women who are PCR negative (OR=6.68, 95% 
CI=3.46-12.93). 
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Table 6.3: Correlation of Chlamydia antibodies detected by commercial serological assays with fertility status 
Infertile Fertile
Assay (+/-) Assay + Assay - Assay + Assay - Odds Ratio (95% CI) P value
MEDAC Infertile (+/-) 26 36 30 71 1.71 [0.88, 3.31] 0.11
MEDAC MOMP (+/-) 38 37 45 85 1.94 [1.09, 3.46] 0.024
MEDAC cHSP60 (+/-) 40 30 64 48 1.00 [0.55, 1.83] 1
MEDAC IgA (+/-) 11 69 12 126 1.67 [0.7, 3.99] 0.242
ANILab (+/-) 40 32 50 70 1.75 [0.97, 3.16] 0.062
MEDAC C. 
pneumoniae (+/-)
77 4 107 28 5.04 [1.70, 14.95] 0.002
Table 6.4:Correlation of Chlamydia antibodies detecting by commercial serological assays with current infection status as determined by 
PCR
Chlamydia + Chlamydia -
Assay (+/-) Assay + Assay - Assay + Assay - Odds Ratio (95% CI) P value
MEDAC Infertile (+/-) 34 28 22 79 4.36 [2.19. 8.68] <0.001
MEDAC MOMP (+/-) 46 27 37 95 4.37 [2.38, 8.04] <0.001
MEDAC cHSP60 (+/-) 52 19 52 59 3.11 [1.63, 5.91] <0.001
MEDAC IgA (+/-) 14 66 9 129 3.04 [1.25, 7.39] 0.011
ANILab (+/-) 53 18 37 84 6.68 [3.46, 12.93] <0.001
MEDAC C. 
pneumoniae (+/-)
71 8 113 24 1.88 [0.8, 4.43] 0.141
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6.3.1. Chlamydia pneumoniae serology correlates with infertility in this 
population
The prevalence of antibodies to C. pneumoniae in this population was high at 
85.1% (184/216 participants). However, it was surprising that antibodies to C. 
pneumoniae were found to be significantly more likely to be detected in women with 
infertility (p=0.002; OR 5.04, 95% CI: 1.7–14.95) (Fig 6.3A). This was not a false 
positive detection of antibodies against C. trachomatis in the C. pneumoniae assay 
because a current infection (C. trachomatis PCR positive result) and a positive result 
in C. pneumoniae serological assay did not correlate (of the 216 positive, only 71 
(35.6%) with the PCR positive result (Pearson’s chi-square test, p=0.141).
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6.4. DISCUSSION
A cross-sectional sero-epidemiological study of sexually active Samoan 
women between the ages of 18-29 years was undertaken to determine the overall 
prevalence of C. trachomatis infection and the risk of developing chlamydial
infertility. In addition to estimating the risk of chlamydial infertility using serology, 
the epidemiological and demographic factors associated with chlamydial infertility 
were determined. 
The high prevalence rate (35.6%) of C. trachomatis infection, as diagnosed by 
PCR, in the Samoan population indicates that the infection may be endemic. High 
prevalence of C. trachomatis in Samoa has been reported previously. In 2005, 
Sullivan et al. [506] reported a prevalence rate of 30.8% in 452 pregnant women 
attending antenatal clinics in Samoa using PCR. Similarly in 2008, Cliffe et al. [505], 
reported prevalence rate of 26.1% for 1618 pregnant women recruited from antenatal 
clinics. However, because these studies only evaluated women who attended 
antenatal clinics for the first time, the prevalence could be expected to be much 
higher in the population of sexually active women in Samoa. In other developing 
countries such as Kenya and Cameroon, the prevalence rate was estimated based on 
sexually active urban women recruited in antenatal clinics and student volunteers 
respectively. A cross-sectional study was conducted in Kenya, where vaginal swabs 
from sexually active women aged 18-45 years were tested by PCR and the 
prevalence was estimated to be 6% (95%CI: 3.31%-8.69%) [490]. Using Direct 
fluorescence assay (DFA) and PCR on cervical and urethral swabs, the prevalence 
rate was estimated to be 3.96% (95% CI: 2.61%-5.93%) in Cameroon [491]. In 
Bangladesh, the prevalence of C. trachomatis was estimated based on 110 sexually 
active women and 40 sex workers between the ages of 15-35 years. The prevalence 
was determined from endocervical swab specimens from the participants through 
PCR and/or immunochromatography and was estimated to be 27% in local female 
populations and 58% in female sex workers [519]. This suggests that the prevalence 
of C. trachomatis infections in Samoa is relatively higher than some other 
developing countries, thus drawing attention to the immediate need to implement 
effective diagnosis and control of the disease. 
The prevalence of approximately 50% C. trachomatis serum antibody positive 
results (MEDAC Infertile 52.5%, MEDAC MOMP 55.3%, MEDAC cHSP60 
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42.02%, ANILabsystems ELISA 50.9%) for infertile women was high in this 
population compared to that reported in developed countries. It is not unexpected that 
the infertility assays did not correlate significantly with the infertile group, as there 
are multiple reasons for infertility. In addition, these assays were developed in 
Western countries, where the prevalence of C. trachomatis infections was much 
lower than Samoa. Most studies where a significant association is found is when the 
tubal factor infertility is the specified outcome. Consistent with the findings in this 
study, Agholor et al. [134] reported that the prevalence of serum antibodies to C. 
trachomatis in women with ectopic pregnancy in Nigeria was 48% (98 ectopic 
pregnant women) compared to 16.3% in women with normal intrauterine pregnancy. 
Although the study did report a significant difference in the prevalence of chlamydial
antibodies between women with ectopic pregnancy and fertile controls, the absence 
of C. trachomatis antibodies in 52% of women with ectopic pregnancy highlights 
that Chlamydia infection may play a less than significant role in the aetiology of the 
ectopic pregnancy in this population. In this population there is a limited knowledge 
of other fertility factors, as this was a village based survey study in the absence of 
any gynecological investigations that would normally be conducted in a fertility 
clinic. This lack of gynecological data is a limitation of the study. It is important to 
note that this study is also limited by the number of villages that were included as 
sites to recruit participants, however, the age range and sexual behavior used for 
inclusion criteria are highly relevant for women likely to be seeking pregnancy. The 
important observation is that by any of the assays it appears that approximately half 
of the women who are identified as infertile in this population have evidence of C. 
trachomatis infertility. This is higher than most studies report; even those conducted 
in fertility clinics, but are consistent with a fertility clinic study in India that found a 
similar prevalence [406]. This is likely a reflection of the absence of routine 
screening and treatment for C. trachomatis infections in this population. This may 
support that the widespread implementation of screening programs in several 
developed countries is effectively reducing the sequelae such as infertility. 
Whilst a higher proportion of infertile participants were positive compared to 
fertile participants in most serological assays, only MEDAC MOMP showed 
significant association to infertility (43.6%; P<0.05) (Table 6.3.). Mouton et al. [437]
showed that C. trachomatis specific IgG was reported in 41-57% of women with 
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tubal factor infertility (n=85), and MEDAC MOMP detected women with infertility 
with a sensitivity of 55.3% and a specificity of 75.5%. Similar to the results obtained 
in this study, MEDAC MOMP detected C. trachomatis specific IgG in 39.1% (n=23) 
of women with tubal pathology as compared to 10.4% of infertile women with 
ovulation dysfunction and idiopathic infertility (n=48) [105]. Consistent with the 
findings in Jeremiah et al. [520], the absorbance values that correspond to anti-
chlamydial antibodies in MEDAC MOMP showed a significant difference between 
women with chlamydial infertility from those without. Additionally, they were able 
to distinguish women with current C. trachomatis infection than those without. 
Whilst not recommended by the manufacturer for the test used here, many studies 
use cHSP60 antibodies as a test for chlamydial infertility. In this population, 40 of 
the 70 infertile women were positive in this test; however, this was not significantly 
higher than in the infertile compared with the fertile group. Nevertheless, the high 
prevalence of cHSP60 antibodies in this population suggests that chronic infections 
or sequelae are high in this population. A possible limitation is that the serological 
results may be influenced by a higher number of repeat infections given the high 
prevalence of infection in this population. However, the prevalence of antibodies to 
C. trachomatis was reported to be lesser in women with repeat infections than in 
women with primary infections. This was elucidated in van den Broek et al. [357], 
which reported that the prevalence of IgG was 78% in primary infection and 23% in 
recurrent infection. Similarly, the prevalence of IgA was 52% in women with 
primary infection and 37% in women with recurrent infection.
All IgG serological assays, including MEDAC MOMP, MEDAC cHSP60, 
ANILabsystem ELISA and MEDAC IgA, showed significant association with PCR 
status (p<0.01) (Table 6.4). The IgA antibody response to C. trachomatis infection 
and its correlation with PCR positivity (active infection) in the Samoan population 
confirms that C. trachomatis infection elicits humoral response. This is consistent 
with the findings of van der Broek [357], where in 94% of participants who were 
positive for C. trachomatis infection by PCR were also seropositive in MEDAC 
MOMP. In this study, amongst those women who were positive for PCR confirmed 
C. trachomatis infection, 8.03% (9/112) were also seropositive in MEDAC MOMP, 
ANILabsystems IgG ELISA, MEDAC IgA ELISA and MEDAC cHSP60 IgG 
ELISA. Using PCR alone, C. trachomatis infections was detected in 47.1% (41/87) 
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of infertile participants, while 33.3% (16/48) of infertile participants with PCR 
confirmed C. trachomatis infection also showed seropositivity in IgG serological 
assays [357]. The study also highlighted that the presence of IgA antibodies to C. 
trachomatis in the vaginal mucosa of women (PCR negative for C. trachomatis
infection), might indicate an ongoing Chlamydia infection. This also indicated a
chronic low-grade immune response in the upper genital tract [357]. Therefore, 
humoral response is detectable in women following chlamydial infection. Consistent 
with the results obtained in the study, Abdella et al. [499] estimated that the 
prevalence of chlamydial infertility in Egyptian women as 40% (n=50) by both PCR 
and ELISA. Using PCR alone, current infection was detected in 6% women, and C. 
trachomatis specific IgG antibodies were detected in 38.9% of women with primary 
infertility (n=36) and 28.6% of women with secondary infertility (n=14). Marashi et 
al. [347] reported that in Iran, the C. trachomatis prevalence estimated from 
endocervical swabs using indirect immunofluorescence was 22.6% for infertile 
women (n=150) and 4.5% for fertile healthy controls (n=200). PCR analysis of 
endocervical swabs on the same cohorts estimated the prevalence rate to be 32% in 
infertile women and 8.7% in fertile healthy controls [347]. Therefore, while PCR can 
be used to determine with current infections, serological assays are instrumental in 
identifying women with past C. trachomatis infections. 
The demographic and epidemiological factors associated with infertility 
included age, alcohol and relationship status. In this study, younger women between 
ages of 18-24 years were at a higher risk of developing infertility than women 
between the ages of 25-29 years (OR: 4.22; 95% CI = 2.27-7.84) (Table 6.2). 
Contrary to the findings in this study, majority of the studies conducted on women 
with C. trachomatis-related infertility or ectopic pregnancy showed that the mean 
age was above 28 years [134, 348, 520, 521]. Mueller et al. [522] estimated that a 
higher proportion of women between the ages of 25-29 years had a history of 
inflammatory disease as compared to women less than 25 years and greater than 30 
years (38.8%; n=129). A similar result was determined by Iris et al., [523] in which 
the mean age of infertile women with primary infertility was determined as 31.2r 3.8 
years. Savolainen et al. [524] reported that over a period of 16 years (1999-2006) the 
mean age of patients with fertility complications was 25.1 years.
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The increased prevalence observed could be explained by various factors. The 
reports of Samoa demographic and health survey, 2009 by Ministry of Health (Apia, 
Samoa) [517] showed that 55% of younger women between the ages of 15-29 years 
do not use contraceptives due to the lack of knowledge of method or source of the 
method and 59% of women are opposed to the use of contraceptives. Due to low 
condom usage rates in Samoa, there is an increasing incidence in adolescent 
pregnancy rates [517]. Additionally, only 11% of married women and 12% of never 
married women between the ages of 15-29 self-reported being likely to refuse having 
sexual intercourse with a man who has STI, the rest were supportive of having sexual 
intercourse with their partner knowing that they have an STI [517].
IgA antibodies in sera is an indication of current infection [165, 357], and 
consistent with the literature, the serum IgA was significantly associated with PCR 
status (p=0.011). Additionally, 17.5% participants who were serum IgA positive, 
were three times more likely to test positive for C. trachomatis infection in PCR as 
compared to participants who were serum IgA negative (OR=3.04, 95% CI= 1.24-
7.39). van der Broek [357] reported that 33% (n=24) of women seropositive for 
serum IgA were also positive in PCR testing, and serum IgA had a sensitivity of 32% 
and a specificity of 95% in detecting women with active infection. In this study 
MEDAC IgA antibodies were prevalent in 13.75% of women with infertility and 
were unable to differentiate women with infertility from those without. Consistent 
with this study, Muvunyi et al. [359] reported a higher prevalence of 14% (n=14) in 
women with acute infections than women with subfertility (7.8%, n=303) a 
specificity and sensitivity of 93% (95%CI= 91-95) and 14% (95%CI: 3.00-44.00) 
respectively. However, contrary to results obtained in this study, C. trachomatis
specific IgA levels were reported to be higher in women with TFI and persistent 
chlamydial infection (83.3%), and were further able to discriminate between 
participants with TFI from those with spontaneous miscarriage [165]. Komoda et al.
[528], showed that in 52 women clinically diagnosed with cervicitis/ and or PID, 
very low levels of C. trachomatis specific serum IgA was observed using a synthetic 
peptide- based ELISA test. However, it is present at early stages of infection and the 
IgA positivity rate decreased from 82.7% at the first testing to zero after 200 days
[528]. Hence, it is important to conduct additional tests such as PCR to confirm C. 
trachomatis infection. Serum IgG levels generally show greater association with 
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PCR status as evident in several studies [357, 365]. The low IgA levels were also 
reflected in the earliest studies conducted in Samoa by Ushijima et al. [529], where 
antibody testing using microplate Fluorescent antibody method reported that amongst 
192 adolescents recruited from health centres, 39% were C. trachomatis IgG 
positive, while only 10% were IgA positive. 
C. pneumoniae is a common respiratory infection associated with community 
acquired pneumonia and has been associated with systemic dissemination and 
chronic diseases such as atherosclerosis and Alzheimer’s disease [530]. Serology to 
C. pneumoniae is highly prevalent in many populations with 50–70% prevalence 
reported [531]. More recently, 57% seropositivity was reported in Australia in 
women attending sexual health or fertility clinics, suggesting the previously reported 
50–70% range is relevant [373]. However, there were no reports of the prevalence of 
C. pneumoniae serology in Samoa, therefore, this test was included in the serological 
assays conducted on this population. In this study, C. pneumoniae was significantly 
associated with infertility (p=0.002) but it did not correlate with the C. trachomatis
PCR result (p=0.141). Serology to C. pneumoniae has been previously significantly 
correlated with various diseases [530], but not infertility. One possible explanation 
for high sero-prevalence to C. pneumoniae in infertile population is that the infertile 
women here have tissue lesions or adhesions in the fallopian tube that may form a 
reservoir for the pathogen (similar to the lesions in the other chronic diseases, 
although this has never been reported) and therefore these participants more 
frequently have a positive serological response to the pathogen. Additionally, the 
antigens associated with pathogenesis may be highly conserved between C. 
trachomatis and C. pneumoniae. Another concern for the high prevalence of C. 
trachomatis in the Samoan population was that the commercial serological assays 
were possibly showing cross-reactivity with ocular C. trachomatis strains. Ocular C. 
trachomatis strains have been reported to be endemic in the Pacific Islands [532]. 
However, a study by Lees et al. [532] reported that among 200 participants who 
attended the clinic in 2011 and 2012, and 150 participants who attended in 2013, 
none of them were positive for trachoma. The study was conducted from 2009 to 
2013 and investigated eye diseases in patients attending Ophthalmology outreach 
clinics in Pacific islands, Fiju, Kiribati, Papua New Guinea, Samoa, Solomon 
Islands, Tonga, Vanuatu. Thus, the prevalence of trachoma is extremely low and it is 
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unlikely that it would interfere with the serological diagnosis of genital C. 
trachomatis infections.
In summary, the high prevalence of C. trachomatis infections in Samoa could 
be leading to increased preventable infertility in this population. Women need to be 
educated about safe-sex practices and made aware of the symptoms and diagnosis of 
C. trachomatis infections. Public health strategies such as implementation of routine 
testing and treatment for the infection could reduce the disease burden from 
infertility and could also reduce the other morbidities (PID and ectopic pregnancy) 
within this population.
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C. trachomatis infections are one of the major causes of tubal pathology in 
women, and tubal pathology accounts for up to 35% of all causes of infertility [416]. 
Since infertility treatments are financially as well as psychologically costly, it poses a 
significant burden on health care systems and individuals. Laparoscopy and 
hysterosalpinography, which cost up to AUD $4500, are currently used for 
diagnosing C. trachomatis-related tubal factor infertility. These are costly and have 
limited availability in developing countries [423]. Additionally, the invasive nature 
of the technique increases the risk of surgical complication [421]. These 
shortcomings have the potential to be overcome by a sensitive and specific 
serological diagnosis of C. trachomatis tubal infertility, a technique that is non-
invasive, easy, cost-effective [362, 403, 404]. However, none of the current 
serological diagnostic assays have been adopted for routine implementation during 
infertility investigation in fertility clinics owing to their lack of specificity, possibly 
due to cross-reactivity between other chlamydial species and lack of sensitivity 
[533]. 
Through this study, the QUT Chlamydia infertility test was developed that had 
the highest specificity of 94% and a sensitivity of 27% in identifying women with C. 
trachomatis-related TFI when compared to current commercial serological assays. 
The QUT Chlamydia infertility test comprised of three peptides; peptide 11, HSP60-
E2 and 443-N2 that were derived from antigens that are immuno-dominant in women 
with C. trachomatis induced TFI. Novel antigens for diagnosis of C. trachomatis
associated infertility in women have been identified previously, most commonly, 
through proteomic analysis via two- dimensional electrophoresis and mass 
spectrometry [353, 426, 427], and proteome array using glutathione fusion proteins 
[386, 387]. However in this study, the peptides used in the development of the assay 
were identified through in silico analysis based on their antigenicity and specificity 
to C. trachomatis (BLAST E value for C. trachomatis in HSP60-E2 and CT443 
peptides are 0.0003 and 0.005 respectively) [411]. Frikha-Gargouri et al. [534]
identified an OmcB antigen through in silico analysis, and although it showed 72.7% 
concordance with MIF and a specificity of 94.3% in detecting C. trachomatis
antibodies in participants positive in MIF, its sensitivity was very low at 23.9% 
(n=24). 
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Although, The QUT chlamydia infertility test had the highest specificity 
(100%) in identifying women with tubal pathology, its sensitivity was lower than 
MIF (16% vs 27%) (Table 4.3). However, MIF had the lowest specificity (89%) in 
detecting women with TFI (n=45). Bax et al. [377] also reported that compared to 
MEDAC MOMP, MIF had the highest sensitivity (63.6% vs 36.4%) but a lower 
specificity (81% vs 85.7%) in detecting tubal pathology (n=76). Consistent with the 
findings in the study, the sensitivity, specificity, PPV and NPV of commercial MIF 
(MIF FOCUS and MIF ANILabsystems) and ELISA (ELISA ANILabsystes and 
ELISA Vircell) in identifying sub-fertile women with tubal damage compared to 
women without (n=104) were in the ranges of 15%-27%, 88%-93%, 53%-60% and 
62%-64% respectively [359]. Therefore, compared to the commercial assays in this 
study, and those assays in previously published literature, the QUT Chlamydia
infertility test had a much higher specificity (100%) and PPV (100%). Additionally, 
this assay could significantly differentiate women with tubal damage from women 
without tubal damage (P=0.004) unlike the commercial assays used in this study. 
Thus, the QUT Chlamydia infertility test could be a potential screening test for
identifying tubal pathology in infertile women. 
The QUT Chlamydia infertility assay also demonstrated the highest specificity 
(94%), sensitivity (27%) and PPV (19%) compared to other commercial serological 
assays in detecting women with C. trachomatis-related tubal factor infertility (n=11) 
from the negative cohort (n=251) (seronegative C. trachomatis women with no TFI, 
women with acute C. trachomatis infections and fertile women). Although the 
commercial ELISA, MEDAC infertile assay (combination of MEDAC MOMP and 
MEDAC cHSP60) had a higher sensitivity and could significantly differentiate CT 
TFI cohort from negative cohort, like the QUT Chlamydia test, its PPV (10%) was 
lower than the peptide assay. Consistent with the literature, the MEDAC infertile 
assay was the best performing assay (sensitivity=36%; specificity =86%) amongst all 
commercial assays [535]. Jones et al. [375] also reported that MEDAC MOMP had 
the highest specificity in diagnosing chlamydial infertility compared to five 
commercial ELISAs, including ANILabystems. 
The high diagnostic performance of the QUT Chlamydia infertility test could
be attributed to the use of non-traditional antigens in this assay, unlike commercial 
assay that are generally based on MOMP and HSP60. The combination of peptides 
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from the cytosolic protein HSP60 (HSP60-E2), a periplasmic protein HtrA (peptide 
11) and the outer membrane protein CT443 (443-N2) potentially increased the range 
of epitopes that would improve the antibody response in women with C. trachomatis-
related TFI. Several novel antigens specific to C. trachomatis-related TFI have been 
identified previously, however none of these antigens have been developed for a 
clinical setting. Whilst Rodgers et al. [385] identified antigens that were uniquely 
recognized by participants with C. trachomatis-related infertility and combination of 
antigens that could improve the sensitivity (67%) and specificity (100%) of detecting 
women with TFI (combination of four antigens HSP60, CT376, CT381 and CT798 
and combination of two antigens CT443 and CT381), it was a predictive model 
rather than a functional diagnostic. Budrys et al. [387] further evaluated the ability of 
these antigens to discriminate between different disease groups and reported that the 
combination of six antigens HSP60, CT376, CT557 and CT443 could differentiate 
women with TFI (n=24) from fertile women (n=25) (sensitivity =63%; 
specificity=100%). However, unlike QUT Chlamydia infertility test, it was unable to 
discriminate between women with TFI and women with acute infections. 
The QUT Chlamydia infertility assay did not show complete concordance with 
any of the commercial serological tests used in this assay to identify C. trachomatis-
related TFI in women (P>0.05). However, the commercial assays correlated with 
each other as they share a common antigen (MOMP), and even with MEDAC 
infertile correlated with MIF C. pneumoniae and MIF C. psittaci. This indicates that 
the commercial assays may have a high rate of cross-reactivity between C. 
pneumoniae and C. psittaci. Although, individual peptide assays did not correlate 
with MIF C. psittaci, QUT Chlamydia infertility test did. This could be due to the 
high specificity of the assay, which ensures effective identification of true negatives 
and elimination of false positives. Since, the prevalence of C. psittaci was very low 
in the population, the number of true negatives may coincide with that of the peptide 
assay. Thus, a concordance was observed between QUT Chlamydia infertility test 
and MIF CS. Freidank et al. [536] reported a high number of C. pneumoniae
antibodies in women with tubal infertility (53% in women with one occluded tube 
(n=30) and 75% in bilateral tubal occlusion (n=64)). However, it did not correlate to 
cHSP60 from C. trachomatis [384] and was reported not to be associated with tubal 
pathology but are likely to cause false positive results in MIF [373]. 
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The assay was validated on a separate group that only included infertile women 
who were recruited from a different IVF clinic (n=74). Contrary to the development 
cohort, none of the serological assays including QUT Chlamydia infertility test 
showed a statistically significant difference in identifying women with TFI from 
women with other forms of infertility (p>0.05) in the validation cohort. However, the 
inclusion of women with unexplained infertility resulted in an increase in sensitivity 
and specificity of all serological assays. Interestingly, MEDAC MOMP (sensitivity 
=7%, 97%), MEDAC cHSP60 (sensitivity= 17%, specificity =93%) and 
ANILabsystems (sensitivity =15%, specificity =90%) showed greater sensitivity and 
specificity than MEDAC infertile (sensitivity= 2%, specificity 97%) and QUT 
Chlamydia infertility test (sensitivity= 5%, specificity =87%) in identifying women 
with unknown infertility or pathology from infertile women without tubal pathology 
and known infertility. However, the differences were not significant (P>0.05). The 
poor performance of the serological assays on this group could have been due to the 
small sample size. The low overall prevalence of C. trachomatis in the validation 
cohort could also be due to the geographical location of the IVF clinic from where 
these participants were recruited. Since the participants for assay development and 
validation were recruited from separate IVF clinics situated at different geographical 
locations, the prevalence of C. trachomatis will differ between both groups. 
Although, C. trachomatis seropositivity is associated with decreased pregnancy 
rates in infertile women, the literature suggests that it does not influence the IVF 
outcome. Tasdemir et al. [441] and Claman et al. [442] reported that after an IVF 
cycle, TFI women who were seropositive for C. trachomatis had a higher pregnancy 
rate than infertile women who were seronegative for C. trachomatis. Keltz et al.
[185] also demonstrated that participants who were seropositive for C. trachomatis
were more likely to conceive with IVF treatment than other non-IVF treatments. 
Consistent with these findings, QUT Chlamydia infertility test also could not predict 
IVF outcome (pregnancy and live birth rates) in both test and validation cohorts. 
Therefore, women who are positive for chlamydial infertility as diagnosed by the 
QUT Chlamydia infertility test are as likely to conceive via IVF as those women 
with other forms of infertility. This is important for a diagnostic assay, as the 
clinician could recommend these women to proceed to IVF without additional 
treatments or diagnosis. The limitations of this study are that due to the small sample 
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size in the validation cohort, the assay performance could not be validated 
effectively. Since, the prevalence of chlamydial infertility was higher in the 
diagnostic cohort (11 %) compared to the validation cohort (7%), an increased 
sample size would also allow higher number of participants with tubal pathology 
associated with C. trachomatis,. Future studies should include the evaluation of QUT 
Chlamydia infertility test on larger numbers of infertile participants
Thus, QUT Chlamydia infertility test is highly specific for tubal pathology and 
can effectively differentiate women with C. trachomatis induced tubal infertility 
from non-TFI infertile women seronegative for C. trachomatis, women with acute C. 
trachomatis infections and healthy fertile women. The assay is cost effective, robust 
and easy to use. Additionally, women positive in the assay could be recommended 
treatment by IVF directly. These characteristics make QUT Chlamydia test an ideal 
diagnostic tool for early infertility investigation. The accessibility and ease of use 
would also be potentially useful in low-resource setting or in countries with high 
prevalence of C. trachomatis infections. 
While several techniques have been developed for the diagnosis of C. 
trachomatis-related infertility in women, the underlying mechanism leading to tubal 
factor infertility is yet to be understood. Cytokine analyses of peripheral blood 
mononuclear cells (PBMC) from infertile women have shown the involvement of 
both cytotoxic pathological response (Th1) [270] or a humoral antibody mediated 
response (Th2)[273]. In this study the expression of 88 innate and adaptive immune 
genes and the levels of 10 secreted cytokine from PBMC s were compared between 
infertile women seronegative for C. trachomatis (n=27) and infertile women 
seropositive for C. trachomatis (n=4). After 15 hours of stimulation with C.
trachomatis EBs, the genes that were predominant in PBMC of women with C. 
trachomatis-related infertility were CXCL10, CXCL11 and HLA-A, while the 
secreted cytokine was IL-1E. Although, HLA class II molecules have been reported 
to be associated with cHSP60 and enhance Th2-type immune responses in infertile 
women (n=53) [172], HLA-A2 was reported to elicit cytotoxic T lymphocyte 
responses to C. trachomatis MOMP in the peripheral blood of C. trachomatis
infected patients [467]. In a longitudinal study of urban female sex workers in Kenya 
(n=23), HLA-A31 was reported to be a significant risk factor C. trachomatis-related 
PID [466]. Proinflammatory chemokines, CXCL10 and CXCL 11 that induce 
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migration of leucocytes, were highly expressed in stimulated PBMCs from women 
with C. trachomatis-related infertility. Both chemokines play an important role in 
regulating the Th1 type immune pathway, as CXCL10 recruits CXCR3 and CCR5 
positive leukocytes such as T cells and natural killer cells to the site of infection 
[470] and upregulation of CXCL11 (IFN-inducible T cell D-chemoattractant or i-
TAC) leads to further infiltration of IFN-J secreting T cells resulting in a positive 
feedback loop [539]. Additionally, several studies have reported that CXCL10 is 
predominantly expressed during upper genital tract infection by C. trachomatis [469, 
473, 476]. Therefore, it could be inferred that Th1 type immune pathway is one of 
the early mononuclear immune responses associated with C. trachomatis pathology.
Amongst the secreted cytokines, IL-1E, IL-8 and TNF-D were predominantly 
secreted in PBMCs from women with C. trachomatis-related infertility, however 
only IL-1E showed significantly higher levels compared to infertile women 
seronegative for C. trachomatis PBMCs. The synergistic effects of secreted 
cytokines IL-1E, IL-8 and TNF-D have been elucidated in several studies [173, 479, 
480]. Though ex vivo fallopian tube studies, Hvid et al. [173] showed that addition of 
IL-1RA receptor antagonists, blocked IL-1E and IL-8 production preventing the 
pathology from chlamydial infection. This confirms that IL-1E along with IL-8 were 
likely major factors for tubal pathology. Additionally, IL-1 production triggers and 
primes superoxide production which lead to destruction of ciliated cells and 
subsequent scarring of the fallopian tubes [173]. C. trachomatis infection in 
epithelial cells is associated with high levels of IL-8 and TNF-D, triggering a pro-
inflammatory response could either resolve the infection or lead to tissue fibrosis and 
scarring [269]. The study identified significant up-regulation and production of pro-
inflammatory cytokines and chemokines, including a trending increase in IL-8 and
TNF-D in women with C. trachomatis-related TFI. This suggests that C. trachomatis
infection triggers pro-inflammatory cytokines that augment cellular inflammatory 
response resulting in tissue damage and subsequent tubal pathology [540]. The IgG 
and IgA antibodies that were identified in women with chlamydial infertility indicate 
that humoral immunity plays an active role in infection clearance. The B-
lymphocytes serve as antigen-presenting cells to T-lymphocytes, and the resolution 
of infection is facilitated by Th1 activation [541]. Since key Th1 (IFN-J, IL-12) and 
Th2 (IL-10, IL-4) were not upregulated in stimulated PBMCs from women with 
Chapter 7: General Discussion and Conclusions 194
chlamydial infertility, the exact role of Th1 and Th2 in chlamydial pathology cannot 
be elucidated. However, the study has identified markers that contribute to a better 
understanding of mechanisms that lead to C. trachomatis-related tubal factor 
infertility in women. 
This study also evaluated the sero-epidemiological prevalence of C. 
trachomatis-related infertility in Samoa, a developing country with high prevalence 
of C. trachomatis infections in the population. Using PCR, Sullivan et al. [506] and 
Cliff et al. [505] previously reported high prevalence rates of 30.9% and 26.8% in 
women attending antenatal clinics. Given that these prevalence rates have been 
estimated on a small cohort of women attending antenatal clinics, the prevalence in 
the population has the potential to be much higher. The study tested the sera of 239 
sexually active women between the ages of 18-29 from 41 villages for C. 
trachomatis infections. Walsh et al. [516] estimated the prevalence of C. trachomatis
in the population as 35.6% using PCR. 
MEDAC infertile, characterized by a combination of MEDAC MOMP and 
MEDAC cHSP60 was used to identify women with C. trachomatis-related infertility 
in the population. Additionally, the assay had the best diagnostic performance 
compared to other commercial serological assays in identifying women with tubal 
pathology and women with C. trachomatis-related infertility (as reported during the 
evaluation of QUT Chlamydia infertility assay). There was a high proportion of 
women with self-reported infertility (36.4%) based on their epidemiological 
questionnaire. In support of the high prevalence of self-reported infertility in the 
population, it was reported that women in low resource settings suffer from high 
rates of secondary infertility [395]. The WHO estimated the prevalence of secondary 
infertility caused by sexually transmitted infections to be higher in developing 
countries such as Sub-Saharan Africa (119/1000 population), Latin America/ 
Caribbean (71/1000) compared to developed countries such North America/ Western 
Europe (19/1000) [542]. 
The concordance between PCR (detects active C. trachomatis infection) and 
serological assays (MEDAC infertile, MEDAC MOMP, MEDAC cHSP60, MEDAC 
IgA and ANILabsystems) was evaluated and only 8% of samples showed 
concordance with all serological assays and PCR. Although the serological assays 
reported a high prevalence rate of C. trachomatis infections of 50% (MEDAC 
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Infertile 52.5%, MEDAC MOMP 55.3%, MEDAC cHSP60 42.02%, ANIlabsystems 
ELISA 50.9%) in infertile women in the Samoan populations, only MEDAC MOMP 
could significantly differentiate self-reported infertile women from fertile women
(Table 6.3).
This study found that younger women between the ages of 18-24 years were at 
a higher risk of developing infertility than women between the ages of 25-29 years.
Kennedy et al. [544] noted that based of DHS reports (Demographic health and 
survey reports, 2009), the median age for first marriages in women in Samoa were 
23.6 years, and while 2.7% of the women between the ages of 15-19 were currently 
married, 9.4% had commenced childbearing. Thus, high infertility rates reported 
amongst younger women in this population may be associated with early 
childbearing.
IgA antibodies in sera is an indication of current infection [165, 357], and in 
this study, the IgA levels in serum significantly associated with women with PCR 
positive C. trachomatis infection (p<0.001). However, contrary to results obtained in 
this study, C. trachomatis specific IgA levels have been reported by others to be 
higher in women with TFI and persistent chlamydial infection (83.3%), and were 
further able to discriminate between participants with TFI (n=33) from those with 
spontaneous miscarriage (n=54)[165]. Van den Broek et al. [357] reported that a 
higher proportion of women from the STI clinic (n=116) who were PCR positive had 
higher serum IgG (98%) than serum IgA (38%), and further concluded that serum 
IgG was a better predictor of current/past infection. Interestingly, the study also 
reported that mucosal IgA showed a high specificity for tubal pathology, comparable 
to that of serum IgG (Kappa IgA 0.41, P<0.001) (n=87). The low prevalence of IgA 
antibodies and a high prevalence of IgG antibodies in the population may reflect a 
high rate of repeat infections or past infections.
Antibodies to C. pneumoniae are highly prevalent in many populations with 
50–70% prevalence reported [531]. Gijsen et al. [373] reported that 87% of C. 
pneumoniae were found in 240 subfertile women, which suggests that the prevalence 
rate of C. pneumoniae in women with infertility. Interestingly, it was more prevalent 
in women without TFI and positive for C. trachomatis by MIF (84%) compared to 
without TFI and seronegative for C. trachomatis infections (69%) [373]. 
Additionally, the C. pneumoniae antibodies did not differ significantly between 
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women with tubal pathology and without tubal pathology [440]. In the Samoan 
population, antibodies to C. pneumoniae showed significant correlation with 
infertility, but it did correlate with acute C. trachomatis as determined by PCR. This 
reflects on the high prevalence of C. pneumoniae in this population, and possible 
cross-reactivity of chlamydial antibodies exhibited by commercial serological assays.
In this population we have limited knowledge of the other fertility factors, as 
this was a village based survey study in the absence of any gynecological 
investigations that would be conducted in a fertility clinic. This lack of gynecological 
data is a limitation of the study. The important observation is that by any of the 
assays it appears that approximately half of the women who are identified as infertile 
in this population have evidence of C. trachomatis-related infertility. This is higher 
than most studies report, even those conducted in fertility clinics, but is consistent 
with a fertility clinic study in India that found a similar prevalence of 55% in 96 
women with secondary infertility [406]. This is likely a reflection of the absence of 
routine screening and treatment for C. trachomatis infections in this population. This 
may support that the widespread implementation of screening programs in several 
developed countries is effectively reducing the sequelae such as infertility. 
7.1 CONCLUSION
Through this study, the QUT Chlamydia infertility test was designed, which is 
a peptide based diagnostic assay that showed superior sensitivity and specificity 
compared to all commercial serological assays in identifying women with C. 
trachomatis-related infertility. It is non-invasive, user-friendly, cost-effective and we 
found that women with predicted chlamydial infertility by QUT infertility test were 
as likely to conceive via IVF as women with other forms of infertility; thus, making 
it an ideal diagnostic for early infertility investigation that could recommend IVF 
without additional tests. The QUT Chlamydia infertility test would be an ideal 
diagnostic tool, particularly in routine testing for low resource settings like Samoa, 
where the prevalence of C. trachomatis-related infertility is very high. This study 
also estimated the prevalence of chlamydial infertility in a developing country,
Samoa, which has a high prevalence of C. trachomatis infections. The study also 
showed that one of the earliest immune response in women with C. trachomatis-
related infertility include a pro-inflammatory response to infection, which may be 
associated with tubal pathology an subsequent infertility. 
Chapter 7: General Discussion and Conclusions 197
7.2 FUTURE DIRECTIONS
The QUT Chlamydia infertility has higher sensitivity and specificity in 
identifying women with C. trachomatis-related infertility compared to other 
commercial assays. Its performance could be further validated in longitudinal studies 
that would assess the ability of QUT Chlamydia infertility test to predict the risk of 
women developing tubal pathology and subsequent infertility. QUT Chlamydia
infertility test could also be applied on the Samoa cohort to determine the risk of 
infertility in the population and compare its diagnostic performance with the 
commercial assays used in the study. The assay needs to be further tested for 
reproducibility and repeatability, an eventually developed for clinical purposes by 
improving its fitness of purpose by improving its performance costs, sample 
throughput, shelf-life, turn-around times for test results and quality control and 
assurance. 
The immunological aspect of the study identified the initial markers associated 
with C. trachomatis induced infertility. Further transcriptomic and translational 
studies on a larger cohort of samples could reveal a better understanding of the pro-
inflammatory cytokines in influencing the Th1/Th2 balance that induce pathology. 
Understanding the immune mechanisms associated with pathogenesis and protective 
immunity could be instrumental in the development of vaccines against C. 
trachomatis infection. The high prevalence of chlamydial infertility in the women of 
Samoa stresses the need for routine testing and increasing the awareness regarding 
STIs and their consequences. Since the mean likelihood of C. trachomatis - related 
infertility was higher in younger women, screening should be implemented for 
women starting from the age of 15 years. Steps must be taken to ensure that these 
women are checked for infertility and recommended treatment immediately. 
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Table 8.1: Demographic and gynaecological characteristics of participants from 
the infertile cohort recruited from an IVF clinic (development cohort)
Participa
nt ID
Average 
age 
(years) 
Gynaecological
history 
Average 
BMI
Parity Duration 
of 
infertility
Smokin
g status
Alcohol Average 
no. IVF 
cycles for 
successfu
l outcome 
Tubal 
factor 
infertilit
y (n=45)
36.88 History of fibroids 
(n=12)
History of 
endometriosis 
(n=14)
History of 
hydrosalpinx (n=9)
Polycystic ovaries 
(n=8)
Unilateral tubal 
blockage (n=16)
Bilateral tubal 
blockage (n=29)
History of PID 
(n=4)
Ectopic pregnancy 
(n=11)
23.75 No 
pregnancy 
(n=14)
Miscarriag
e (n=19)
<1year 
(n=5)
1-2 years 
(n=10)
2-4 years 
(n=14)
>4 years 
(n=14)
Past 
(n=17)
Never 
(n=27)
Current 
(n=1)
Never 
(n=27)
Yes 
(n=18)
3.55
Non-TFI 
associate
d 
infertilit
y (n=52) 
38.26 History of fibroids 
(n=10)
History of 
endometriosis 
(n=12)
Endometritis (n=3)
Polycystic ovaries 
(n=9)
Ectopic pregnancy 
(n=2)
25.01 No 
pregnancy 
(n=10)
Miscarriag
e (n=18)
<1year 
(n=4)
1-2 years 
(n=10)
2-4 years 
(n=22)
>4 years 
(n=14)
Past 
(n=12)
Never 
(n=37)
Current 
(n=1)
Never 
(n=31)
Yes 
(n=21)
4.34
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Table 8.2: Correlation between demographic and lifestyle factors to tubal 
infertility (development cohort)
Infertility Age 
[Correlation
coefficient (p 
value)]
BMI
[correlation 
coefficient (p 
value)]
Smoking 
[correlation 
coefficient (p 
value)]
Alcohol 
consumption
[correlation
coefficient 
(p value)]
Tubal pathology 0.136 (0.093) 0.052 (0.306) 0.179 (0.04)* 0.004 (0.485)
*Smoking showed significant correlation with tubal pathology (Spearman 
correlation coefficient)
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Table 8.2: Demographic and gynaecological characteristics of participants from 
the infertile cohort recruited from IVF clinic (Brisbane) (validation cohort)
Participant 
ID
Average 
age 
(years) 
Gynecological 
history 
Average 
BMI
Parity No. of sex 
partners 
Smoking 
status
Pregnancy 
outcome 
after IVF
Live 
birth 
oucome 
after 
IVF
Tubal 
factor 
infertility 
(n=19)
37.33 Tubal adhesion 
(n=4)
Tubal obstruction 
(n=7)
Ovarian cystecty 
(n=5)
PCOS (n=4)
Endometritis (n=5)
Fibroids (n=1)
Salpingitis (n= 6)
Ectopic pregnancy 
(n= 3)
PID (n=3)
23.2
No 
pregnancy 
(n=10)
<10 (n=2)
>10(n=6)
<5 (n=11)
Past 
(n=1)
Never 
(n=18)
No (n=12)
Yes (n=7)
No 
(n=13)
Yes 
(n=4)
Non-TFI 
associated 
infertility 
(n=54) 
37.10 History of fibroids 
(n=1)
Endometritis (n=13)
Polycystic ovaries 
(n=14)
Ectopic pregnancy 
(n=1)
PID (n=4)
Unknown etiology 
(n=23)
22.76 No 
pregnancy 
(n=40)
<10 (n=20)
>10(n=12)
<5 (n=20)
Past 
(n=12)
Never 
(n=40)
Current 
(n=2)
Yes (n=19)
No (n=35)
Yes 
(n=28)
No 
(n=26)
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Table 8.3: Demographic and epidemiological information of participants from 
Samoa
Demographic/ epidemiological variables Number of participants 
(N=239)
Employed
No
Yes 
196
43
Occupation
None
Clerical/ office work 
Hospitality
Retail/ sales 
Health care worker
Government worker
Police/ military 
Farmer
Street sales
Teacher
Other
196
12
8
6
1
2
1
3
1
3
6
Education qualifications 
University degree
Tertiary level diploma
Tertiary level certificate
High school
None
4
11
30
129
65
Fertility problem diagnosed
Blocked fallopian tubes
Unexplained infertility
Other
No diagnosis
1
3
1
234
Relationship status
Married
Living with partner 
Separated
Single 
102
43
19
75
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Age of first sex
19 or older 
18 or less
156
83
Number of sex partners in life
1 sex partner
2 sex partners
3 or more sex partners
127
72
40
Past pregnancy
No
Yes
88
151
Not intending to stop pregnancy
Yes, not preventing pregnancy now
Yes, in the future
No
Missing
13
42
8
176
Duration of preventing pregnancy
Less than 1 year
1-2 years
Over 2 years
Missing
2
10
5
222
Seek medical advice 
Upto 6 months
1 year
2 years
3 years
Over 3 years
Missing
25
14
15
1
23
165
Number of children
1 child
2 children
3 children
94
70
75
Time taken for first pregnancy
Less than 12 months 74
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12-24 months
Greater than 24 months
None
41
34
94
Trying for a child after last pregnancy
No
Yes
152
87
Time taken to get pregnant after last 
pregnancy
Less than a year
1-2 years
Over 2 years
Don’t know 
Missing 
12
10
26
12
179
Regard family complete
No
Yes
Unsure
Missing
61
33
57
88
Problems becoming pregnant 
No
Yes
Missing 
96
55
88
Age
18-24 years
25-29 years
145
94
BMI 
Underweight
Normal weight
Over weight
Obese
Missing
1
45
87
96
10
Smoking status
Current smoker
Ex-smoker
44
7
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Never smoked 188
Number of cigarettes per day
1
2
3
4
5
6
8
9
10
15
Missing
1
7
6
3
9
4
1
1
7
1
199
Frequency of drinking wine
Never
Less than once a week
Once or twice a week
229
9
1
Frequency of drinking beer
Never
Less than once a week
Once or twice a week
More than twice a week
210
23
4
2
Frequency of drinking spirits
Never
Less than once a week
Once or twice a week
219
17
3
Health problems
None
Tubal surgery
Pelvic surgery
Other pelvic infection
230
3
1
5
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